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SUMMARY 
1 
SUMMARY 
 
 Human chronic liver diseases continue to be a global burden in the European 
population, since approximately 29 million people still suffer from chronic liver diseases. In 
the past, a major progress has been made regarding the knowledge and management of 
liver diseases. The progression from early hepatic fibrosis to a chronic liver disease can 
probably result in the development of cirrhosis or hepatocellular carcinoma. Characteristic 
biological features of these disorders include inflammation, cell death, matrix deposition or 
angiogenesis and can lead to the progression of liver fibrosis. Some of these biological 
features also contribute to drug-induced liver injury (DILI), which is still the most common 
reason for drug withdrawal from the market. In the past, hepatotoxic effects were mostly 
associated with alterations in metabolism or redox state. Nowadays, it is well-known that 
complex signaling and transcriptional mechanisms are involved in the progression of hepatic 
injury as well as during the regenerative response.  
 Based on gene array analysis, WISP1 was identified as the strongest up-regulated 
member of the CCN family with regard to acute liver damage. Time-resolved analysis using 
qRT-PCR, confirmed the up-regulation of WISP1 expression in liver homogenates. 
Furthermore, the analysis of different cell populations revealed hepatocytes as the main 
source of WISP1 RNA upon CCl4 administration. Moreover, WISP1 was detected in human 
liver disease samples. Additionally, organ specific expression of WISP1 in mice, revealed the 
lung, brain and spleen as organs with the highest WISP1 RNA levels. 
 To assess the contribution of WISP1 to drug-induced liver injury, mice containing a 
genetic deletion of WISP1, as well as their corresponding wild type counterparts were used. 
This genetically modified mouse model was used in combination with two well-known 
models for hepatotoxicity, namely CCl4 and APAP. Surprisingly, time-resolved analysis of 
CCl4-induced liver damage revealed not only an enhanced susceptibility of WISP1 knockout 
mice, but also a time-shift in induction of liver damage in comparison to wild type mice. 
Moreover, APAP-induced liver damage also unveiled an enhanced susceptibility of WISP1 
knockout mice. This suggests that the protective effect of WISP1 is not a unique effect, but 
rather a general key mediator in response to hepatic injury. These pro-survival effects were 
neither mediated by alterations in cytochrome P450 metabolism, nor by alterations in redox 
state. Subsequently, qRT-PCR detected an up-regulation of WISP1 expression upon CCl4- and 
APAP-induced liver injury which peaked at 12h in wild type mice. Moreover, high levels of 
WISP1 protein were detected in the plasma samples of wild type mice, whereas among the 
same population protein levels in the liver tissue were found to be rather low.  
 Further analysis of signal transduction revealed alterations in MAPK-associated 
signaling pathways, such as early (2h) activation of stress-associated signaling (JNK) in WISP1 
knockout mice upon CCl4 administration, as well as enhanced inflammation associated 
signaling (STAT3). However, no alterations were observed for signal transduction after APAP 
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administration, suggesting that the protective phenotype is mediated through different 
pathways.  
 The enhanced liver damage of WISP1 knockout mice was associated with an 
increased inflammatory response, confirmed by increased pro-inflammatory cytokine and 
chemokine expression as well as by an enhanced amount of infiltrating immune cells. 
Moreover, in vitro stimulation of hepatocytes, using pro-inflammatory cytokines, resulted in 
a concentration-dependent increased susceptibility to cell death of WISP1 knockout 
hepatocytes. A similar effect was observed, when stimulating hepatocytes in vitro by using 
APAP.  
 Liver regeneration was investigated by histological analysis, qRT-PCR and western 
blot after CCl4 administration in a time-resolved manner up to D4. The capacity to recover 
from liver injury was comparable among both WISP1 knockout and wild type mice. However, 
liver damage of WISP1 knockout mice was not fully recovered at D4 which was associated 
with prolonged activation of proliferation markers and cell cycle dependent genes, such as 
PCNA and CycD1. These results suggest that WISP1 does not play a major role in liver 
regeneration after CCl4 administration. 
 Finally, a time-resolved gene array analysis of WISP1 knockout and wild type mice 
was performed in which both groups were treated with CCl4. Compared to wild type mice, 
genes associated with metabolism were down-regulated and genes associated with lipid 
metabolism showed an up-regulation in WISP1 knockout mice. Quantitative RT-PCR 
confirmed an up-regulation of cytochrome P450 enzymes, including Cyp4a10 and Cyp4A14, 
which were reported to be involved in ω-hydroxylation of saturated and unsaturated fatty 
acids. Moreover, two serine protease inhibitors showed a decreased expression in WISP1 
knockout mice at all time points. Additionally, CIDEC, which was reported to promote the 
development of alcoholic steatohepatitis, was stronger induced on D1 in mice lacking WISP1.  
 In conclusion, my study identified for the first time that mice lacking WISP1 show an 
enhanced susceptibility to CCl4- as well as to APAP-induced liver damage. These findings 
suggest that WISP1 might have a pro-survival and protective role with regard to acute liver 
injury. Time-resolved analysis detected alterations in signal transduction as well as changes 
in the inflammatory response. Furthermore, gene array data revealed changes regarding 
lipid metabolism in WISP1 knockout mice. Taken together, WISP1 seems to be an important 
protective mediator during acute liver injury and may be involved in the regulation of lipid 
metabolism as related to liver damage. The identification of a novel mediator during acute 
liver injury may also help to gain a deeper insight into the precise signal transduction and 
mechanisms in the progression of acute liver injury. Moreover, WISP1 seems to be an 
attractive potential target for therapeutic interventions, since human liver disease samples 
also showed an up-regulation of WISP1 expression.  
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ZUSAMMENFASSUNG 
 
 Chronische Lebererkrankungen des Menschen sind eine globale Belastung in der 
europäischen Bevölkerung, da schätzungsweise immer noch 29 Millionen Patienten davon 
betroffen sind. In der Vergangenheit gab es einen großen Fortschritt in Bezug auf das Wissen 
und den Umgang mit Leberkrankheiten. Der Verlauf einer frühen Leberfibrose hin zu einer 
chronischen Lebererkrankung kann unter anderem zu der Entwicklung einer Zirrhose oder 
eines hepatozellulärem Karzinoms führen. Entzündung, Zelltod, Ablagerung der Matrix oder 
Gefäßneubildungen sind charakteristische biologische Merkmale und können zur 
Entwicklung einer Leberfibrose beitragen. Einige dieser charakteristischen Merkmale sind 
auch bei einer Medikamenten-induzierten Lebertoxizität zu beobachten, welche immer noch 
eine der häufigsten Ursachen für den Rückzug eines Medikaments vom Markt ist. Früher 
wurden hepatotoxische Effekte meistens mit einer Veränderung des Metabolismus oder des 
Redoxzustandes assoziert. Allerdings ist es heutzutage bekannt, dass komplexe 
Signalübertragungen und transkriptionelle Mechanismen sowohl an der Entwicklung eines 
Leberschadens als auch bei der anschließenden Regeneration beteiligt sind.  
 Basierend auf Gene Array Analysen wurde WISP1 als das am stärksten hochregulierte 
Mitglied der CCN Familie bei einer Leberschädigung identifiziert. Zeitaufgelöste 
Genexpressionsanalysen mittels qRT-PCR bestätigten die Induktion von WISP1 in 
Leberhomogenaten. Weitere Analysen verschiedener Leberzellpopulationen zeigten, dass 
Hepatozyten die Hauptquelle der WISP1 RNA während einer CCl4 Intoxikation sind. Zudem 
wurde eine Expression von WISP1 in humanem Gewebe, welches verschiedene 
Leberkrankheiten aufwies, detektiert. Zusätzlich konnte eine organspezifische Analyse in 
Mäusen zeigen, dass Organe wie die Lunge, das Gehirn und die Milz eine hohe WISP1 
Expression aufweisen.  
 Um die Beteiligung von WISP1 an einer medikamenten-induzierten Leberschädigung 
zu untersuchen, wurden Mäuse mit einer genetischen Deletion des WISP1 Gens verwendet. 
Dieses genetisch veränderte Mausmodell wurde mit den gängigen Lebertoxizitätsmodellen 
Tetrachlorkohlenstoff (CCl4) und Paracetamol (APAP) kombiniert. In einer zeitaufgelösten 
Analysen einer CCl4-induzierten Leberschädigung konnte gezeigt werden, dass WISP1 
knockout Mäuse nicht nur eine höhere Sensitivität aufweisen als die Wildtyp-Mäuse, 
sondern auch eine Zeitverschiebung in der Entstehung des Leberschadens zeigen. Diese 
erhöhte Empfindlichkeit konnte auch bei einem Paracetamol-induziertem Leberschaden 
gezeigt werden. Dies deutet daraufhin, dass der schützende Effekt von WISP1 nicht 
spezifisch ist, sondern WISP1 als ein allgemeiner Schüsselfaktor in der Antwort auf eine 
Leberschädigung gesehen werden kann. Dieser protektive Effekt von WISP1 konnte nicht auf 
eine Veränderung der Cytochrom P450 Enzyme oder des Redoxzustandes zugeführt werden. 
Die Genexpression von WISP1 war während eines CCl4- und eines APAP-induzierten 
Leberschadens stark hoch reguliert, mit einem maximalen Wert nach 12h in den Wildtyp-
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Mäusen. Während WISP1 auf der Proteinebene in großen Mengen auch im Plasma 
nachgewiesen werden konnte, waren die Werte im Lebergewebe eher gering.  
Analysen der Signalübermittlung zeigten Änderungen im MAP-Kinase-Weg, wie zum Beispiel 
eine frühe Aktivierung der c-Jun N-terminale Kinasen (JNK) in CCl4 behandelten WISP1 
knockout Mäusen. Weiterhin konnte eine Aktivierung des JAK-STAT-Signalweges festgestellt 
werden, die mit einer erhöhten Entzündungsreaktion verbunden ist. Jedoch wurden keine 
Veränderungen in der Signalübermittlung nach Verabreichung von Paracetamol detektiert. 
Dies weist daraufhin, dass der protektive Phänotyp vermutlich durch andere Signalwege 
vermittelt wird.  
 Der vergrößerte Leberschaden in den WISP1 knockout Mäusen ist mit einer 
gesteigerten Immunantwort verbunden, welche durch eine erhöhte Expression an 
entzündungsfördernden Chemokinen und Zytokinen, sowie einer erhöhten Anzahl an 
infiltrierenden Immunzellen bestätigt werden konnte. In vitro Stimulationen von WISP1 
knockout Hepatozyten, mit entzündungsfördernden Zytokinen, wiesen einen 
konzentrationsabhängigen Anstieg der Empfindlichkeit in Hinblick auf den Zelltod auf. Ein 
ähnlicher Effekt konnte unter Stimulation der Hepatozyten mit Paracetamol gezeigt werden. 
 Die Leberregeneration wurde nach Behandlung mit Tetrachlorkohlenstoff 
zeitabhängig bis Tag vier, mithilfe von histologischen Analysen, qRT-PCR und Western blot 
Analysen, untersucht. Hierbei war die Fähigkeit zur Regeneration nach einem Leberschaden 
in Wildtyp und WISP1 knockout Mäusen vergleichbar. Jedoch war der Leberschaden in 
WISP1 knockout Mäusen an Tag vier nicht vollständig regeneriert, was sich unter anderem in 
einer verlängerten Aktivierung von Proliferationsmarkern und zellzyklusabhängigen Genen, 
wie zum Beispiel PCNA und CycD1, zeigte. Dies deutet daraufhin, dass WISP1 in der 
Leberregeneration, nach einer CCl4 Intoxikation, eine untergeordnete Rolle spielt.  
 Schließlich wurde eine zeitabhängige Gene Array Analyse von CCl4 behandelten 
Wildtyp und WISP1 knockout Mäusen durchgeführt. Verglichen mit den Wildtyp Mäusen, 
waren Gene in den WISP1 knockout Mäusen, welche mit dem Metabolismus assoziiert sind 
herunter reguliert, während Gene, die mit dem Lipidmetabolismus verbunden sind, induziert 
waren. Mithilfe einer quantitativen Echtzeit-PCR wurde bestätigt, dass Cytochrome P450 
Enzyme, wie Cyp4a10 und Cyp4a14, verstärkt exprimiert sind. Diese Enzyme sind an der ω-
Hydroxylierung von gesättigten und ungesättigten Fettsäuren beteiligt. Außerdem zeigten 
zwei Serin Protease Inhibitoren eine verminderte Expression in den WISP1 knockout Mäusen 
zu allen Zeitpunkten. Zusätzlich ist CIDEC, welches die Entwicklung einer alkoholischen 
Steatohepatitis fördern soll, an Tag eins in den WISP1 knockout Mäusen stärker induziert.  
 Abschließend kann festgestellt werden, dass meine Arbeit erstmalig zeigt, dass 
Mäuse die kein WISP1 besitzen, eine erhöhte Empfindlichkeit gegenüber einer 
Tetrachlorkohlenstoff- und einer Paracetamol-induzierter Leberschädigung aufweisen. Diese 
Ergebnisse zeigen, dass WISP1 einen schützenden und positiven Einfluss auf das Überleben 
der Leberzellen nach einer akuten Schädigung hat. Zeitaufgelöste Analysen haben 
Veränderungen in der Signalübermittlung, sowie in der Entzündungsreaktion ergeben. 
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Weiterhin zeigten Gene Array Daten, dass WISP1 knockout Mäuse Veränderungen in 
Hinblick auf den Lipid Metabolismus aufweisen. Zusammenfassend kann festgehalten 
werden, dass WISP1 ein wichtiger und protektiver Vermittler während einer akuten 
Leberschädigung zu sein scheint. Zudem könnte WISP1 in die Regulation des 
Lipidmetabolismus involviert sein. Die Identifizierung neuer Vermittler könnte helfen, ein 
tieferes Verständnis für die Signalübermittlung und die Mechanismen während einer akuten 
Lebertoxizität zu bekommen. Da auch menschliche Proben eine Induktion der Expression 
von WISP1 zeigten, scheint WISP1 außerdem ein attraktives Target für potentielle 
therapeutische Interventionen zu sein.  
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% Percent 
°C Celsius degree 
µg Microgram 
µl Microliter 
µm Micrometer 
ActD Actinomycin D 
AIF Apoptosis-inducing factor 
ALF Acute liver failure 
ALT Alanine aminotransferase 
Ap-1 Activator protein-1 
Apaf-1 Apoptotic protease activating factor-1 
APAP N-acetyl-p-aminophenol, Acetaminophen, paracetamol 
APC Adenomatous polyposis coli 
APS Ammonium persulphate 
ASK1 Apoptosis signal-related kinase 
AST Aspartate aminotransferase 
ATF Activating transcription factor 
ATP Adenosine triphosphate 
Axin Axis inhibitor 
Bax Bcl-2-associated X protein 
BCA Bicinchoninic acid 
Bcl-2 B-cell lymphoma-2 
BcL-XL B-cell lymphoma-extra large 
Bid BH3 interacting death domain 
Bik BCL-2 interacting killer 
Bim BCL-2-like-11 
BIP Binding immunoglobulin protein 
BKL Biobase Knowledge Library 
bp Base pair 
BP Biological process 
BSA Bovine Albumin Fraction V 
Ca Calcium 
CaCl2 Calcium chloride 
CC Cellular component 
CCC Cholangiocellular carcinoma 
CCl C-C motif chemokine 
CCl3* Trichloromethyl free radical 
CCl3COO* Trichloromethylperoxy radical 
CCl4 Carbon tetrachloride 
CD Cluster of differentiation 
cDNA Complementary DNA 
cFLIP Cellular fas-associated death domain-like interleukin-1-β-converting enzyme-inhibitory 
protein 
cFLIPL Full-length or long form of c-FLIP 
CHOP C/EBP homologous protein 
CHX Cycloheximide 
cIAP1/2 Cellular inhibitor of apoptosis-1/2 
CIDEC Cell death inducing DFFA like effector c 
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CK1 Casein kinase 1 
CM Collagen monolayer 
cm2 Square centimeter 
CO2 Carbon dioxide 
CRD Cysteine-rich domain 
CS Collagen sandwich 
CT Cysteine knot 
CTGF, CCN2 Connective tissue growth factor 
ctrl Control 
CXC C-X-C chemokine 
CXCL Chemokine (C-X-C motif) ligand 1 
CXCR C-X-C chemokine receptor 
Cyc Cyclin 
Cyp1a2 Cytochrome P450 enzyme 1a2 
Cyp2B1 Cytochrome P450 enzyme 2b1 
Cyp2E1 Cytochrome P450 enzyme 2e1  
Cyr61, CCN1 Cysteine-rich 61 
D Day 
DAB 3, 3 -diaminobenzidine 
DAMP Damage-associated molecular pattern 
Ddit3 DNA-damage inducible transcript 3 
DEG Differentially expressed gene 
DEPC Diethylpyrocarbonate 
D-Gal D-galactosamine 
DILI Drug-induced liver injury 
DISC Death-inducing signaling complex  
DMEM Dulbecco's Modified Eagle Medium 
DNA Deoxyribonucleic acid  
dNTP Deoxynucleotide triphosphate 
DTT DL-Dithiothreitol 
DVL Dishevelled 
ECL Enhanced Chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth-factor 
EGTA Ethylene glycol tetraacetic acid 
eIF-2α Eukaryotic translation Initiation Factor 2-α 
ELISA Enzyme-linked immunosorbent assay 
EndoG Endonuclease G 
ER Endoplasmic reticulum 
ERAD ER-associated degradation 
ERK Extracellular signal-regulated protein kinases 1 and 2 
Ero1l Endoplasmic oxidoreductin-1-like protein 
FADD Fas-associated death domain 
FBS Fetal bovine serum 
FDR False discovery rate 
FGF2 Fibroblast growth factor 2 
fz Frizzled 
g Gram  
GADD34 Growth arrest and DNA damage-inducible protein-34 
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Gadd45β Growth arrest and DNA damage-inducible 45 beta 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GO Gene ontology 
GOI Gene of interest 
gp Glycoprotein 
GPCR G-protein coupled receptors 
GRG Groucho-related gene 
GRP94 Glucose related protein 94 
GS Glutamine synthetase 
GSH Glutathione 
GSK3β Glycogen synthase kinase-3β 
h Hour 
H&E Hematoxylin and eosin staining 
H2O Water 
H2O2 Hydrogen peroxide 
HCC Hepatocellular carcinoma 
HCl Hydrogen chloride 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGF Hepatocyte growth-factor 
HKG House keeper gene 
HMGB1 High mobility group box 1 protein 
HRP Horseradish peroxidase 
HSC Hepatic stellate cells 
Hsd3b5 Hydroxyl-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 5 
HSGP Heparin sulfate proteoglycan 
Hsp Heat shock protein 
i.p. Intraperitoneal 
ICAM Intercellular Adhesion Molecule 
Ier3 Immediate early response 3 
IFNγ Interferon-γ  
IGFBP Insulin-like growth factor binding protein 
IKK Inhibitor of кB kinase 
IL Interleukin 
IRE1α Inositol-requiring enzyme 1α 
ITCH Itchy homolog 
IкBα Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
JAK Janus kinase 
JNK Jun NH2-terminal kinases 
KCl Potassium Chloride 
kDa Kilodalton 
KEGG Kyoto Encyclopedia of Genes and Genome 
kg Kilogram 
KH2PO4 Potassium dihydrogen phosphate 
L Liter 
Lcn2 Lipocalin 2 
LEF Lymphocyte enhancer-binding factor 
LGS Legless 
LRP Low-density lipoprotein receptor-related protein 
LRP5/6 Low-density-lipoprotein-receptor-related protein 5/6 
LSEC Liver sinusoidal endothelial cells 
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mA Milliampere 
MAP2K, MEK or MKK MAPK kinase 
MAPK Mitogen-activated protein kinase 
MAPKKK, MAP3K MAPK kinase kinase kinase 
MF Molecular function 
mg Milligram 
MgSO4 Magnesium sulfate 
min  Minutes 
ml Milliliter 
mM Millimolar 
MPT Mitochondrial membrane permeability transition 
mRNA Messenger RNA 
Mt Metallothionein 
mTNFα Membrane-bound TNFα 
mTOR2 Mechanistic target of rapamycin 
Na2HPO4 Di-Sodium Hydrogen Phosphat anhydrous 
NaCl Sodium chloride 
NAPQI N-acetyl-p-benzoquinone imine 
NEM N-Ethylmaleimide 
NF-кB Nuclear factor kappa-light-chain-enhancer of activated B cells 
ng Nanogram 
nm Nanometer 
Nov, CCN3 Nephroblastoma overexpressed 
NP-40 Nonidet P-40 
NPC Non-parenchymal cell 
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen-associated molecular patterns 
PBS Phosphate buffered saline solution 
PCA Principal component analyses 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PDK1 Phosphoinositide-dependent protein kinase 1 
PERK PKR-like ER kinase 
PFA Paraformaldehyde 
pg Picogram 
PI3,4,5-P3 Phosphatidylinositol-3,4,5-triphosphate 
PI3K Phosphatidylinositol 3-kinase 
PI-4,5-P2 Phosphorylates phosphatidylinositol-4,5-bisphosphate 
PKB Protein kinase B 
pmol Picomole 
PP1c Protein phosphatase 1 
PPAR Peroxisome proliferator-activated receptors 
PTEN Phosphatase and tensin homolog 
PVDF Polyvinylidene fluoride 
PYGO Pygopus 
qRT-PCR Real-time quantitative PCR 
RGD Arg-Gly-Asp 
RIP1 Receptor-interacting protein-1 
RIP3 Receptor interacting protein kinase 3 
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RNA Ribonucleic acid  
RNase Ribonuclease 
ROS Reactive oxygen species 
rpm Revolutions per minute 
RSK Ribosomal S6 kinase 
RT Reverse transcriptase 
RTK Receptor tyrosine kinase 
S.E. Standard error 
S1P Site 1 protease 
S2P Site 2 protease 
SAPK Stress-activated protein kinase 
SDS Sodium dodecyl sulfate 
sec Second 
Ser Serine 
siRNA Small interfering RNA 
STAT3 Signal transducer and activator of transcription 3 
sTNFα Soluble TNFα 
Sult2a8 Sulfotransferase family 2A, dehydroepiandrosterone (DHEA) – preferring, member 8 
TAK1 Transforming growth factor-β-activated kinase-1 
TBE  Tris/Borate/EDTA 
tBID Truncated BID 
TBS-T Tris Buffered Saline with Tween 20 
TCF1 T-cell factor1 
TEMED Tetramethylethylenediamine 
TGF-β Transforming growth factor-β 
TGFβR TGF-β receptors  
Thr Threonine 
TLR Toll-like receptors 
TNFR TNF receptor  
Tnfrsf12a Tumor necrosis factor receptor superfamily, member 12a 
TNFα Tumor necrosis factor alpha 
TRADD TNFR1-associated death domain protein 
TRAF2 TNF receptor-associated factor-2 
TRIS Tris(hydroxymethyl)aminomethane 
TSP-1 Thrombospondin type-1 
TUNEL Terminal transferase uridyl nick end labelling 
Tyr Tyrosine 
UNG Uracil-DNA glycosylase 
UPR Unfolded Protein Response 
V Volt 
VCAM-1 Vascular cell adhesion molecule 1 
VSMC Vascular smooth muscle cell 
VWC Von Willebrand factor type C 
WISP1, CCN4 Wnt-inducible signaling pathway protein-1 
XBP1 X-box binding protein 1 
XIAP X-linked inhibitor of apoptosis protein 
α-KG α-ketoglutarate 
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1 INTRODUCTION 
 
1.1 The global burden of liver disease 
 The past 30 years revealed a major progress in the knowledge and management of 
liver diseases, however, there are still approximately 29 million individuals who suffer from 
chronic liver disease in Europe. Cirrhosis of the liver and primary liver cancer are significant 
indicators in terms of liver transplantation in Europe (5,500 per year) and represent the end-
stage of liver pathology, thereby reflecting the associated mortality rate. Liver cancer is 
responsible for about 47,000 deaths per year in the EU, estimated by the World Health 
Organization (WHO). Furthermore, liver cirrhosis accounts for 1.8 % of all deaths in Europe 
(170,000 deaths per year). Harmful alcohol consumption, viral hepatitis B and C as well as 
metabolic syndromes related to obesity and being overweight are the four leading causes of 
chronic liver diseases. Each of these four causes is amenable to prevention and treatment, 
thereby leading to a potential reduction of liver diseases among the general population [1, 
2]. 
 The progression from chronic liver injury to cirrhosis often causes inflammatory 
damage, parenchymal cell death, matrix deposition and angiogenesis, all of which may lead 
to progressive fibrosis. Early hepatic fibrosis, the wound healing response of the liver, can be 
resolved if the underlying cause is eliminated. However, in the case of cirrhosis only 
regression but without resolution can be expected as an improved clinical outcome. 
Epigenetic marks, cofactors such as obesity and alcohol, as well as genetic polymorphisms 
can enhance the risk of fibrosis progression [3, 4]. Taken together, there is a strong need for 
prevention programs, novel treatments and early stage diagnosis to help preventing the 
progression to further clinical stages and complications [1, 2].  
 Moreover, another cause for liver disease in Europe is drug-induced liver injury (DILI). 
This is one of the most critical problems leading to the failure of many drugs during 
preclinical and clinical studies [5] and occurs in an incidence of 10 to 15 in 10,000 to 100,000 
in the United States [6]. Additionally, hepatotoxicity is the leading cause of drug withdrawal 
from the market [7]. DILI is multi-factorial and can mimic all forms of acute and chronic liver 
disease such as hepatitis or cholestasis, which shows the complexity of clinical scenarios [6]. 
Moreover, similar to chronic liver disease, there are various factors which can influence DILI, 
such as the adaptive immune system, infections, environment factors and genetics. 
Therefore, many drugs pass the animal toxicity tests, because they are performed in healthy 
animals [7].  
 Taken together, this highlights the need for a deeper understanding and further 
investigations into biological processes, for example, inflammation and cell death during 
acute and chronic liver injury, as a means of tackling the burden and problem of liver 
disease.  
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1.2 Liver 
 The liver is situated in the upper right area of the abdominal cavity, close to the 
diaphragm (Figure 1). It serves a central role in metabolic homeostasis and detoxification of 
the body. The liver is responsible for synthesis, storage, metabolism and redistribution of 
vitamins, fats, carbohydrates and nutrients. Moreover, production of albumin, acute-phase 
proteins and cofactors are important functions of the liver [8, 9]. Approximately 80 % of the 
blood supply comes from the portal vein, containing nutrient-rich blood from stomach and 
intestine. The remaining 20 % of blood supply comes from the hepatic artery, which provides 
oxygenated blood from the aorta [10, 11]. The blood exits the liver through the hepatic vein, 
which drains into the inferior vena cava.  
 
 
Figure 1: Liver enterohepatic circulation. Approximately 80 % of liver blood supply comes from the portal vein 
and 20 % from the hepatic artery. Blood derived from the portal vein is rich in nutrients and pathogen-derived 
molecules, since it is derived by the capillaries from gastrointestinal tract, pancreas and spleen. Therefore, 
xenobiotics will pass the liver through the portal vein for metabolization [12]. (Figure from 
http://www.Hopkins-gi.org) 
 
1.3 Structure (basic anatomy) 
  The classical structural unit of the liver is called hepatic lobule. It has a hexagonal 
shape and the central vein is localized in the middle of the hepatic lobule (Figure 2). At the 
edges of the lobule there are the portal triads, which are constituted by the portal vein, bile 
duct and the hepatic artery. Plates of hepatocytes (cords) radiate from the central vein to 
the borders of the lobule. The hepatic sinusoids, which separate the hepatic plates from one 
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another, are lined by liver sinusoidal endothelial cells. The blood flows through the sinusoids 
from the portal triad via the central vein and drains into the hepatic vein, which then leaves 
the liver and enters into the inferior vena cava [13, 14]. The plates of hepatocytes are joined 
by tight junctions, adherens junctions and the desmosomal belt. The apical pole is 
represented by the bile canaliculi, which are formed in the interface of the hepatocytes. The 
bile flows (as opposed to the blood flow) from the bile canaliculi into the bile ducts, which 
are localized at the portal triads. The basolateral site of hepatocytes are in contact with 
blood capillaries or sinusoids, where the secretion of various components and the uptake of 
recycled bile salts occur. To increase the surface for the exchange of substances, the 
hepatocytes have microvilli which extend in the space of Disse [15].  
 
 
Figure 2: Basic structure of a hepatic lobule. The diagram shows the classical structure unit of the liver: the 
hepatic lobule. At the edges, the portal triads are placed, consisting of the hepatic artery, the bile duct and the 
portal vein. From the central vein, plates of hepatocytes (cords) radiate to the perimeter of the lobule. The 
blood flows through hepatic sinusoids from the portal triad to the central vein (Figure from 
http://www.easynotecards.com). 
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1.4 Liver zonation 
 The liver acinus is the smallest functional unit of the liver and is characterized by the 
regional compartmentalization of metabolic capacities and can be divided into three zones: 
a periportal zone (1), a transitional zone (2) and a pericentral zone (3) (Figure 3). Within 
these zones, different metabolic pathways are described, which are regulated by chemical 
gradients of oxygen, hormones, growth factors and metabolites. There are two types of 
metabolic zonation in the liver: the gradient (dynamic) and the compartment (stable) 
zonation. The gradient-type zonation works dynamically in response to sinusoidal blood-flow 
derived gradients. All hepatocytes in this zonation express the gene, but in a gradient-
dependent manner. One example is the gluconeogenesis process, which exhibits a periportal 
to pericentral gradient of activity. In the compartment-like zonation, gene-products are 
expressed only in a restricted region, independent of the metabolic state of the liver. The 
best examples of compartment-like zonation are ammonia metabolism and glutamine 
synthetase (GS) [11, 16, 17].  
 
 
Figure 3: Structural and functional zonation of the liver. Discrete zones of the liver between the portal vein 
(PV) and the central vein (CV). The figure illustrates the difference in cell size, phenotype and gradients in the 
oxygen tension and metabolism. Figure adapted and modified from [15]. 
 
1.5 Liver cell types and function 
 Hepatocytes, also known as the parenchymal cells, account for about 80 % of liver 
mass. The remaining 20 % is comprised of non-parenchymal cells including Kupffer cells, 
stellate cells, liver sinusoidal endothelial cells, cholangiocytes, neutrophils and lymphocytes 
[8, 18].  
 The space of Disse is the perisinusoidal space between the basolateral surface of the 
hepatocytes and the anti-luminal side of sinusoidal endothelial cells (Figure 4). The hepatic 
stellate cells are localized in the space of Disse. The Kupffer cells are localized on the luminal 
side of the endothelial cells [18, 19]. 
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Figure 4: Major cell types in the liver. Several diverse cell types are located in the liver: hepatocytes, liver 
sinusoidal endothelial cells, Kupffer cells, hepatic stellate cells, cholangiocytes, hepatic progenitor cells, 
lymphocytes and neutrophils.  Kupffer cells are localized in the hepatic sinusoids, which separate hepatic cords 
from one another. Hepatic stellate cells are localized in the space of Disse. Figure adapted and modified from 
[20].  
 
1.5.1 Hepatocytes 
 Hepatocytes are highly differentiated epithelial cells that have primary roles in 
metabolism, protein production and biotransformation of xenobiotics. They make up about 
60 % of the total cell population in the liver and have an average diameter of about 25-30 
µm [21]. Hepatocytes have a cuboidal shape and possess one or more nuclei. They are rich in 
various cell organelles: mitochondria (about 1700 per cell on average), peroxisomes (about 
370 per cell), lysosomes (about 250 per cell), Golgi complexes (about 50 per cell) and rough 
and smooth endoplasmic reticulum (about 15% of cell volume) [22, 23].  
 
1.5.2 Liver sinusoidal endothelial cells (LSEC) 
 Liver sinusoidal endothelial cells (LSEC) comprise about 15-20 % of the liver cell 
population and about 50 % of the non-parenchymal cells in the liver [12, 23]. LSEC are 
elongated thin cells, which possess a large number of pinocytotic vesicles, representing a 
significant endocytotic activity. Moreover, a prominent feature of LSEC are multiple 
fenestrae throughout the cell, each with a diameter of 100 nm, which allow free diffusion of 
many substances between the blood and the hepatocyte basolateral surface. Additionally, 
they play an important role in hepatic immunity since they function as antigen-presenting 
cells and actively secrete cytokines, nitric oxide and some extracellular matrix (ECM) 
components [15, 21].  
 
1.5.3 Kupffer cells  
 The Kupffer cells are liver-resident macrophages, which comprise about 8-12 % of the 
liver cell population and about 35 % of the non-parenchymal cells in the liver [21, 23]. They 
reside in the lumen of the liver sinusoids, adherent to the endothelial cells and thus they are 
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directly exposed to the contents of blood. Kupffer cells are known to have the endocytic and 
phagocytic capacity of efficiently extracting cellular debris, soluble bacterial products and 
endotoxins from the blood via endosomal and lysosomal pathways. Upon activation, e.g. 
during chemical-induced liver injury, Kupffer cells are able to produce cytokines in order to 
induce the expression of acute phase proteins to stimulate liver regeneration [12, 15, 24].  
 
1.5.4 Hepatic stellate cells (HSC) 
 The hepatic stellate cells (HSC), also known as Ito cells, are located in the space of 
Disse. They are in close contact with both the sinusoidal endothelial cells and the 
hepatocytes. Making up about 3-8 % of the total number of liver cells, they present long 
extend dendrite-like processes that wrap around the sinusoids. During resting conditions 
hepatic stellate cells store vitamin A and lipids. However, upon chronic liver damage, they 
transdifferentiate to a fibrogenic, ECM-producing and proliferating cell phenotype. 
Moreover, HSC are considered to produce growth factors and cytokines, which play an 
important role in the regulation of hepatocyte growth and the development of inflammatory 
response [21, 23, 25]. 
 
1.5.5 Cholangiocytes 
 Cholangiocytes, also identified as intrahepatic bile duct cells, are biliary epithelial 
cells that line the bile ducts. They make up about 5 % of the total liver cell population and 
play an important role in regulating liver immune response through secretion of cytokines 
and mediators influencing the immune cell activity [15, 26]. 
 
1.6 Drug metabolism and hepatotoxicity 
 The liver is the main detoxifying organ of the human body. Drug and xenobiotics are 
taken up by the liver and converted into a water-soluble product, which can be easily 
excreted. These reactions are comprised of two steps: First Phase I, in which highly reactive 
functional groups are created by oxidation, reduction or hydrolysis; second Phase II, in which 
reactive products of phase I are conjugated into a highly polar (soluble) and inactive derivate 
that can be excreted [27]. 
 Most of phase I reactions are catalyzed by cytochrome P450 enzymes. These 
enzymes belong to the superfamily of heme enzymes, and about one quarter of the 57 
cytochromes P450s are considered to be involved in the metabolism of xenobiotics [28, 29]. 
Moreover, the metabolism of drugs and xenobiotics by cytochrome P450 enzymes exhibit a 
well-defined zonation occurring mostly in the pericentral region [30]. For example, Cyp2E1 is 
known to be involved in the metabolism of ethanol, carbon tetrachloride (CCl4) and 
acetaminophen (APAP), and its expression is restricted to the pericentral zone [31-33]. 
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 Conjugation reactions in phase II are catalyzed by glutathione S-transferase, N-
acetyltransferases, UDP- glucuronosyltransferase or sulfotransferases [34]. In the pericentral 
zone, glucuronidation takes place, whereas sulfation occurs predominantly in the periportal 
zone [11]. 
 
1.7 Animal models of hepatotoxicity 
 Acute liver failure, due to drug-induced hepatotoxicity, is the leading cause of acute 
liver failure in both the North American and European countries. Acetaminophen (APAP) 
accounts for nearly 50 % of all cases of acute liver injury. Additionally, 10 % of all cases are 
due to acute liver failure because of hepatitis A and B infections and nearly 5 % of all cases 
are associated to auto-immune hepatitis. Therefore, the availability of experimental models 
is needed to provide a better understanding of acute liver injury as well as to identify novel 
drug targets and assess the mechanisms of toxicity [33, 35]. One of the most popular models 
for investigating hepatotoxic effects in the liver, is APAP. However, models involving carbon 
tetrachloride (CCl4), ethanol, thioacetamide and endotoxin are also commonly used [36].  
 
1.7.1 Carbon tetrachloride  
Carbon tetrachloride (CCl4) is a well-known toxicant, which is widely used to induce liver 
injury in mice [37-39]. It has also been used as an organic solvent in industrial processes like 
spray painting, degreasing or metal processing [40]. CCl4 becomes activated through Cyp2e1 
enzymes and to a minor extend by Cyp2B1. Biotransformation of CCl4 leads to the 
production of highly reactive and hepatotoxic trichloromethyl free radical (CCl3*), which can 
covalently bind to lipids, proteins or DNA (Figure 5). CCl3* can further react with oxygen, 
leading to the conversion into an even more reactive trichloromethylperoxy radical 
(CCl3COO*). This free radical can cause hepatotoxic damage by lipid peroxidation reactions 
on the cell membranes. Finally, CCl4-metabolites cause covalent binding and lipid 
peroxidation, which influences the cellular homeostasis leading to the induction of oxidative 
stress and cellular damage [41, 42]. 
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Figure 5: Biotransformation and cell toxicity of CCl4. For the metabolic activation of CCl4, cytochrome P450 
enzymes (Cyp2E1) are necessary. Biotransformation generates highly reactive trichloromethyl free radical 
(CCl3*), which can react with various biological substances. Furthermore, CCl3* can react with oxygen, forming 
a more reactive metabolite trichloromethylperoxy radical (CCl3OO*). As a consequence, covalent binding and 
lipid peroxidation affects liver cell homeostasis leading to the induction of oxidative stress and severe cell 
damage. Figure adapted and modified from [41]. 
 
1.7.2 Acetaminophen (APAP) 
 Acetaminophen (APAP, paracetamol, N-acetyl-p-aminophenol) is an analgesic and 
antipyretic drug which is currently being used worldwide. Moreover, in therapeutic doses it 
is well accepted as an effective and safe drug [43, 44]. However, an overdose of 
acetaminophen can cause centrilobular hepatic necrosis and even acute liver failure (ALF) in 
humans and experimental animals [45]. Similar to CCl4, the toxicity of APAP is strongly 
dependent on the metabolism by cytochrome P450 enzymes, such as Cyp2E1 [46, 47]. Once 
APAP is metabolized by Cyp2E1, reactive intermediate N-acetyl-p-benzoquinone imine 
(NAPQI) is generated, which is rapidly conjugated to glutathione (GSH) for detoxification 
(Figure 6). However, toxic doses cause cellular and mitochondrial GSH depletion, which leads 
to excessive reactive metabolite formation that causes protein adduct formation. 
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Modification of mitochondrial proteins causes mitochondrial damage, ATP depletion and 
oxidative stress, which leads to the activation of JNK pathway. Activated JNK translocates to 
the mitochondria and further increases reactive oxygen species (ROS) formation, leading to 
mitochondrial membrane permeability transition (MPT). Lysis and matrix swelling of the 
outer mitochondrial membrane lead to the release of endonucleases apoptosis-inducing 
factor (AIF) and endonuclease G (EndoG) from the mitochondria. Endonucleases translocate 
to the nucleus and cause nuclear DNA fragmentation, finally leading to oncotic necrosis [7, 
48-51].  
 
 
Figure 6: Mechanism of acetaminophen toxicity. Under therapeutic conditions, acetaminophen (APAP) is 
conjugated and excreted. A small amount is converted into the reactive metabolite N-acetyl-p-benzoquinone 
(NAPQI). Small amounts of NAPQI can be detoxified by glutathione (GSH), however, an overdose of NAPQI 
leads to covalent binding to proteins which in turn lead to mitochondrial protein alkylation and the induction of 
oxidative stress. Therefore, JNK pathway is activated and p-JNK translocate to the mitochondria and further 
increases the oxidative stress. Mitochondrial membrane permeability transition (MPT) occurs, resulting in the 
release of endonucleases apoptosis-inducing factor (AIF) and endonuclease G (EndoG) from the 
intermembrane space. Endonucleases translocate to the nucleus and lead to nuclear DNA fragmentation. 
Figure adapted and modified from [48, 49]. 
 
1.8 Sterile inflammation during acute liver injury 
 Hepatic inflammation is a common feature of various liver diseases, such as alcohol 
steatohepatitis, nonalcoholic steatohepatitis, ischemia/reperfusion and drug-induced liver 
injury. This sterile inflammatory response occurs without involvement of pathogens and is 
required for wound repair and restoration of homeostasis. However, dysregulated sterile 
inflammation can lead to various acute and chronic inflammatory diseases [52, 53]. 
 Figure 7 represents the mechanism of drug-induced sterile inflammation, which is 
well described for APAP and CCl4 toxicity [25, 54-56]. Drugs or chemicals can be metabolized 
by hepatocytes, leading to the formation of reactive metabolites. Such metabolites can 
cause cell injury and necrosis. Thereby, cellular components such as DNA, RNA and proteins 
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are released. These cellular components are also called damage-associated molecular 
patterns (DAMPs) and are known to trigger inflammation via binding to toll-like receptors 
(TLR) on macrophages and neutrophils. DAMPs, such as DNA, bind to TLR9 whereas HMGB1 
acts through TLR4 [53, 56-60]. Engagement of TLR on Kupffer cells activates NF-кB pathway, 
resulting in the production of pro-inflammatory cytokines (TNF-α, IL-6, TGF-β, IL-10, IL-1), 
chemokines (CXCL2, CXCL8) and reactive nitrogen and oxygen species. Elevated levels of 
TNF-α mainly cause activation of death receptor signaling in hepatocytes, leading to an 
amplification of hepatocyte cell death [61-63]. However, IL-6 is known to activate STAT3 
signaling in hepatocytes leading to the transcription of anti-apoptotic and anti-oxidative 
genes [55]. Secretion of IL-1β and chemokines by Kupffer cells trigger neutrophil 
extravasation through expression of adhesion molecules, such as ICAM-1 or VCAM-1, on 
endothelial cells [25, 64]. However, accumulation of neutrophils cause release of ROS and 
proteases, evoking further hepatocyte necrosis [61], as well as phagocytosis of cell debris for 
contribution to wound healing [65, 66].  
 
 
Figure 7: Mechanism of drug-induced sterile inflammation. Drugs or chemicals can induce cell necrosis and 
injury via reactive metabolites, resulting in the release of cellular components like DNA, RNA and proteins 
(HMGB1, HSPs). These damage-associated molecular patterns (DAMPs) bind to toll-like receptors on 
macrophages and neutrophils, triggering cytokine and chemokine secretion. Thereby, monocytes and 
neutrophils in the blood can be activated and recruited to the liver. Subsequently, they extravasate into the 
parenchyma and adhere to the target cells. By generating reactive oxygen species (ROS), neutrophils can 
trigger cell toxicity. However, both neutrophils and macrophages can phagocytose cell debris. Figure adapted 
and modified from [64]. 
 
1 INTRODUCTION 
21 
 Various studies showed that there are still controversies concerning the contribution 
of inflammation to acute liver injury. For example, Liu et al [67] investigated the role of 
neutrophils in the progression of APAP toxicity. In this case, neutrophils were depleted using 
anti-Gr-1 antibody before the administration of APAP, resulting in reduced APAP-induced 
toxicity. However, Jaeschke et al [68] suggested that the protective effect of depleting 
neutrophils is mediated through the induction of metallothionein 1 (MT-1) and MT-2, which 
were reported to protect the organism against liver injury [69]. Furthermore, antagonism of 
TLR or inhibition of DAMP receptors were shown to protect against hepatic ischemia-
reperfusion injury [70, 71] and deletion of interferon-γ (IFNγ) reduced liver injury upon APAP 
overdose in mice [72]. Taken together, these studies suggest a pro-damaging influence of 
inflammation upon liver injury. In contrast, several studies showed a pro-regenerative 
contribution of inflammation. For example, depletion of Kupffer cells (CD68+) using 
clodronate liposomes resulted in an enhanced hepatic injury combined with an increase of 
TNF levels in serum [73, 74]. Moreover, genetic deletion of STAT3 in myeloid cells reduced 
liver damage upon administration of CCl4, which was found to be associated with enhanced 
immune cell infiltration, cytokine and chemokine formation and elevated hepatic STAT3 
activation [55]. 
 In conclusion, these studies highlight the complexity of inflammation during acute 
liver injury. There is a strong need for further investigations regarding the impact of 
inflammation, in particular homeostatic processes versus pathological processes. 
 
1.9 Signaling pathways involved during hepatotoxicity/regeneration 
1.9.1 Canonical Wnt/β-catenin pathway 
 Currently, the Wnt/β-catenin pathway is the best understood pathway controlling 
liver zonation. Drug metabolism is strongly dependent on Wnt pathway, since the expression 
of two major cytochrome P450 enzymes (Cyp2e1, Cyp1a2) is controlled by Wnt signaling 
[30]. Sekine et al showed that mice with a specific deletion of β-catenin were insensitive to 
CCl4 administration [75]. Out of 19 Wnt factors identified in mice, 11 are known to be 
expressed in the liver [76, 77]. Moreover, WISP1 was reported to be a Wnt/β-catenin-
induced protein [78]. 
 Periportal hepatocytes are rich in APC (adenomatous polyposis coli), the inhibitor of 
β-catenin, allowing accumulation of active unphosphorylated β-catenin in perivenous 
hepatocytes (Figure 8). Deletion of APC leads to a perivenous-like liver, whereas deletion of 
β-catenin leads to a periportal-like liver [30].  
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Figure 8: Wnt/β-catenin pathway in liver zonation. APC is enriched in periportal hepatocytes, leading to the 
accumulation of unphosphorylated β-catenin in the perivenous region. Deletion of β-catenin in mice leads to a 
periportal-like liver, whereas an APC knockout leads to a perivenous-like liver. Adapted from Colnot et al. 
Figure adapted and modified from [30]. 
 
 In the absence of Wnt, β-catenin is kept at low levels by association to a degradation 
complex. This complex is formed by the active serine-threonine kinase glycogen synthase 
kinase-3β (GSK3β), two tumor suppressor proteins called APC (Adenomatous Polyposis coli) 
and Axin (Axis inhibitor) as well as the serine/threonine kinases CK1 (casein kinase 1) (Figure 
9a). Whereby, GSK3β and CK1 phosphorylate β-catenin, which results in the ubiquitination of 
β-catenin by β-TRCP. This leads further to the proteasomal degradation of β-catenin. TCF1 
(T-cell factor)/LEF (lymphocyte enhancer-binding factor) is bound to the nucleus and 
inactivated by repressors belonging to members of the GRG (groucho-related gene) family. 
Activation of Wnt signaling starts by binding of Wnt to its receptor Frizzled (fz) through the 
cysteine-rich domain (CRD), together with its co-receptor low-density-lipoprotein-receptor-
related protein 5/6 (LRP5/6) (Figure 9b). Binding of Wnt to its receptor leads to the 
inactivation of GSK3β by dishevelled (DVL; the mammalian homologue of the Drosophila 
melanogaster protein DSH) resulting in the dissociation of β-catenin degradation complex. 
Therefore, unphosphorylated β-catenin translocates to the nucleus and associated with TCF1 
leading to the activation of transcription of target genes. The transcription activity depends 
on pygopus homologue (PYGO) and legless homologue (LGS), two nuclear proteins [30, 79, 
80].  
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Figure 9: Wnt/β-catenin pathway. a) Non-activated Wnt signaling.In the absence of Wnt, β-catenin is kept at 
low levels in the cytoplasma through phosphorylation of CK1 and GSK3β, within the degradation complex. 
Phosphorylated β-catenin is ubiquitinylated by β-TRCP, resulting in the degradation by the proteasome. b) 
Activated Wnt signaling. Wnt binding to its receptor Frizzled (fz), together with the co-receptor LRP5 or LRP6, 
causes dissociation of the degradation complex. Unphosphorylated β-catenin translocates to the nucleus and 
binds to TCF, which leads to the transcription of target genes. Figure adapted and modified from [79]. 
 
1.9.2 Janus kinase (JAK) - signal transducer and activator of transcription 
(STAT) pathway 
 As described above, inflammation is a major feature of drug-induced liver injury. 
Thereby, activated Kupffer cells produce pro-inflammatory cytokines, such as TNFα or IL-6, 
which influence further immune cell infiltration during the progress of liver injury. One of 
the best known signaling pathways, induced during liver inflammation and regeneration, is 
the JAK-STAT-pathway. Hepatoprotective cytokine IL-6 can bind to its receptor gp80 located 
on hepatocytes, leading to the dimerization of gp130 signal chain (Figure 10). The JAK kinase 
is associated with gp130 chains where it undergoes dimerization and autophosphorylation. 
Subsequently, activated JAK phosphorylates gp130, which further activates STAT3 
monomers. Once STAT3 is phosphorylated, it forms dimers and translocates to the nucleus, 
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inducing the expression of various genes including anti-oxidative and anti-apoptotic genes, 
thereby protecting the hepatocytes from damage [8, 21, 55, 81, 82].  
 
 
Figure 10: Schematic representation of JAK-STAT-pathway. Binding of cytokines to the receptor results in the 
dimerization of the receptor. Subsequently, activated JAK tyrosine kinases lead to the phosphorylation of 
cytoplasmic transcription factors STAT. Phosphorylation allows dimerization of STATs leading to the 
translocation into the nucleus, which results in the activation of transcription of various target genes. Figure 
adapted and modified from [83]. 
 
1.9.3 Mitogen-activated protein kinase (MAPK) 
 Several studies of downstream targets of MAPK signaling revealed an important 
contribution to drug-induced liver injury such as JNK. Already a decade ago, Gunawan et al 
reported that JNK is critical for APAP toxicity since JNK inhibitor (SP600125) was shown to 
reduce APAP-induced liver injury in mice. This was demonstrated in reduced serum 
transaminases values and smaller dead cell areas. However, a protective effect was not 
observed when using ERK (PD98059) or p38 (SB203589) inhibitors. In the same study, the 
usage of JNK inhibitor did not protect against liver injury upon CCl4 intoxication [84]. 
Recently, Cubero et al demostrated that combined activity of JNK1 and JNK2 protects against 
APAP-induced liver injury by controlling the oxidative stress response. Moreover, deletion of 
JNK 1 and 2 in hepatocytes (JNKΔhepa) led to a sustained JNK1 activation of infiltrating cells 
and NPCs upon APAP administration, which correlates with increased transaminases and 
enlarged dead cell areas [85]. Furthermore, activation of ERK1/2 was associated with DNA 
replication of hepatocytes in vivo and proliferation of hepatocytes in vitro [82]. On the top of 
that, Bhushan et al showed a dose-dependent increase of phosphorylated ERK as well as p38 
after APAP intoxication [86]. Preclinical studies, which investigated p38 inhibitors, showed a 
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reduced inflammatory response in animal models suggesting a pivotal role in the regulation 
of inflammation [87-89].   
 Mitogen-activated protein kinase (MAPK) signal transduction pathway is a highly 
conserved eukaryotic mechanism of cells known to regulate important cellular functions, 
such as proliferation, differentiation or apoptosis [88]. Upon activation through hormones, 
growth factors, cytokines, DAMPs, PAMPs or environmental stress, a kinase cascade 
consisting of various MAPKs is activated (Figure 11). First, MAPK kinase kinase (MAP3K or 
MAPKKK) phosphorylates and thereby activates MAPK kinase (MAP2K; MAPKK; MKK or 
MEK), leading to the activation of one or more MAPKs. Specific MAP2K are known to activate 
their downstream MEKs, for example, MEK1/2 activates the MAPK ERK1/2, whereas MKK4/7 
lead to the activation of MAPK JNK1/2/3 and MKK3/6 activates p38 isoforms respectively. 
Those MAPK can further phosphorylate various targets such as transcription factors, 
membrane transporters, nuclear pore proteins or other kinases [88, 90]. More importantly, 
there is dynamic balance among the three MAPKs ERK1/2, JNK1/2/3 and p38, which is 
fundamental for the fate of the cell [91].  
 
 
Figure 11: The MAPK signaling cascade. Extracellular stimuli can activate a kinase cascade, which starts with 
the MAPK kinase kinase (MAP3K or MAPKKK). MAP3K phosphorylates MAPK kinase (MAP2K, MAPKK or MEK), 
which in turn phosphorylates one or more MAPKs (ERK, JNK, p38). These three MAPKs can further 
phosphorylate various targets, such as transcription factors or other kinases (MAPKAPK2 or MK2). Downstream 
targets of the transcription factors can further influence cell growth, differentiation, matrix regulation and 
inflammation or cytokine production. There is a dynamic balance among ERK, JNK and p38. Furthermore, the 
responses are overlapping, which is important to determine the fate of the cell. Figure adapted and modified 
from [87]. 
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 Jun NH2-terminal kinases (JNKs), also known as stress-activated protein kinases or 
SAPKs, can be activated by various environmental stresses (heat shock, oxidants, ionizing 
radiation), genotoxins, inflammatory cytokines such as TNFα or IL-1β, ischemic reperfusion 
injury or DAMPs/PAMPs [88, 92]. MEK4 and MEK7 catalyze the dual phosphorylation of 
Thr183 and Thr185 leading to the activation of JNK1-3, whereas JNK3 is exclusively 
expressed in the central nervous system, testis and heart. In contrast to JNK3, JNK1 and 2 
are expressed in hepatocytes [85, 88]. Activated JNK phosphorylates c-Jun at serine residues 
Ser63 and Ser73 in the NH2-terminal region of c-Jun leading to the activation of activator 
protein-1 (Ap-1), as well as various transcription factors, such as ATF-2, Elk1 and JunD [88] 
leading to the regulation of apoptosis and inflammation [91, 93].  
 The extracellular signal-regulated kinases (ERK1 and ERK2) can be activated by 
growth factors, such as TGFβ or HGF, as well as pro-inflammatory cytokines including TNFα 
[82]. Dual phosphorylation of tyrosine and threonine (Tyr185, Thr187) by MEK1 and MEK2 is 
required to activate ERK1/2. This leads to the phosphorylation of numerous substrates, such 
as transcription factor c-Myc and protein kinases, such as ribosomal S6 kinase (RSK) [93]. The 
transcription factor c-Myc is known to be an early transcription factor associated to 
hepatocyte proliferation, cell growth and loss of differentiation [94-96]. Moreover, 
overexpression of c-Myc was associated with promoting progressive of liver fibrosis by the 
activation of HSC [97].  
 The four isoforms of p38 α, β, γ, δ are activated by environmental stress, 
inflammatory cytokines, such as IL-1 and TNF, as well as DAMPs and PAMPs. Similarly to JNK 
and ERK, p38 requires dual phosphorylation of Thr180 and Tyr182 by MEK3 and MEK6 to be 
activated. Phosphorylated p38 in turn activates transcription factors such as ATF2, 
MAPKAPK2, Elk1 and CHOP. P38 was associated with cytokine production and inflammation, 
since blockage of p38 decreases synovial inflammation, cartilage damage and bone 
destruction in animal models of arthritis [87, 88]. Moreover, similar to JNK, p38 was 
associated with the induction of apoptosis [91]. 
 
1.9.4 The Unfolded Protein Response (UPR) 
 The endoplasmic reticulum (ER) is responsible for protein folding, biosynthesis, 
translocation and post-translational modifications [98]. However, the biotransformation of 
CCl4 leads to the production of highly reactive metabolites, which can bind to lipids, proteins 
or DNA [41]. These alterations of macromolecules can cause membrane dysfunction, 
including loss of Ca2+ from the ER membrane. This process leads to the accumulation of 
unfolded proteins in the ER lumen (ER stress) triggering an unfolded protein response (UPR) 
[98-100]. The UPR is sensed by three transmembrane ER stress sensors: inositol-requiring 
enzyme 1α (IRE1α; also known as ERN1), PKR-like ER kinase (PERK; also known as EIF2AK3), 
and activating transcription factor 6α (ATF6α) (Figure 12). However, prolonged or enhanced 
ER stress can induce apoptosis by the activation of transcription factor C/EBP homologous 
protein (CHOP) [101, 102]. CHOP was reported to induce the expression of pro-apoptotic 
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genes, including BCL-2-like-11 (Bim) as well as endoplasmic oxidoreductin-1-like protein 
(Ero1l) and the repression of anti-apoptotic genes like B-cell lymphoma-2 (Bcl-2) [99]. 
Moreover, CHOP knockout mice were reported to show reduced liver necrosis and increased 
survival upon APAP intoxication [103]. 
 
 
Figure 12: The unfolded protein response sensors. The three ER stress sensors ATF6α, IRE1α and PERK can 
mediate the ER stress response. Accumulation of misfolded proteins leads to the dissociation of chaperone 
protein BIP from the sensors, resulting in their activation. UPR activation results in the activation of pathways 
to restore homeostasis by translation attenuation to reduce the number of proteins entering the ER. 
Furthermore, UPR induces the transcription of proteins, which increases the folding capacity. Figure adapted 
and modified from [101]. 
 
 IRE1α possess two enzymatic activities: a serine/threonine kinase domain and an 
endoribonuclease (RNase) domain. Once binding immunoglobulin protein (BIP) is 
dissociated, IRE1α is activated by dimerization and transautophosphorylation, leading to the 
activation of the endoribonuclease. RNase activity initiates splicing of X-box binding protein 
1 (XBP1), thus producing a translational frameshift that results in an enhanced translation of 
Xbp1 protein. The spliced form of Xbp1 (Xbp1s) translocates to the nucleus, leading to the 
transcription of protein-folding enzymes. Chaperons, such as ER-associated degradation (ERAD) 
components and CHOP lead to an increased ER function and size [100, 101].  
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 Similar to IRE1α, PERK dimerizes and autophosphorylates by the dissociation of BIP 
from the ER luminal domain. Activated PERK phosphorylates eukaryotic translation initiation 
factor 2-α (eIF-2α) leading to a transiently global translation attenuation [100, 104]. 
However, translation of some species of mRNA is selectively enhanced upon activation of 
eIF-2α, such as activating transcription factor 4 (ATF4). This leads to the transcription of 
genes associated with oxidative stress resistance, amino acid metabolism and apoptosis 
including expression of the transcription factor CHOP. Expression of growth arrest and DNA 
damage-inducible protein-34 (GADD34) is induced by CHOP and ATF4 leading to the 
formation of a complex with the protein phosphatase 1 (PP1c) to target dephosphorylation 
of eIF-2α. This negative feedback loop results in restoration of mRNA translation [100, 101, 
104]. 
 The third ER-stress sensor, ATF6α, is activated as well via the dissociation of BIP. 
Upon its activation, ATF6 translocates to the Golgi compartment, following a proteolytic 
cleavage by Golgi enzymes site 1 protease (S1P) and S2P leading to the production of a 
cytosolic fragment that migrates to the nucleus. Finally, the fragment induces the 
transcription of certain ER chaperone genes such as BIP, GRP94 (glucose related protein 94), 
Xbp1 and ERAD together with the transcription factor CHOP [100-102, 104].  
 
1.9.5 Phosphatidylinositol 3-kinase (PI3K)/Akt signaling cascade 
 The phosphatidylinositol 3-kinase (PI3K)/Akt signaling cascade is known to play an 
important role during cell cycle progression, differentiation, apoptosis, transcription and 
metabolism [21, 105]. Moreover, Akt is activated during APAP-induced liver injury [86] and it 
was shown to take on a protective role by decreasing p53 mediated apoptosis [106]. 
 Activation of receptor tyrosine kinases (RTKs), Ras or G-protein coupled receptors 
(GPCRs) through binding of various signaling molecules, such as epidermal growth-factor 
(EGF), TNF-α, IL-6, platelet-derived growth factor (PDGF) or hepatocyte growth-factor (HGF) 
[81, 105, 106] results in autophosphorylation of tyrosine residues. Subsequently, 
phosphatidyl-inositol-3-kinases (PI3Ks) is recruited to the membrane and phosphorylates 
phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) to generate second messenger 
phosphatidylinositol-3,4,5-triphosphate (PI3,4,5-P3). PI3K phosphorylation capacity can be 
reversed by phosphatase and tensin homolog (PTEN), which degrade PI3,4,5-P3 to PI-4,5-P2. 
PI3,4,5-P3 provides phospholipid binding sites for phosphoinositide-dependent protein 
kinase 1 (PDK1) and Akt/protein kinase B (PKB), which leads them to be recruited to the 
plasma membrane. Once Akt is recruited to the plasma membrane, phosphorylation on 
threonine residue (Thr308) takes place by means PDK1. Phosphorylation of serine residue 
(Ser473) in the Akt COOH-terminus, requires mTor complex 2 (mTOR2). Although 
phosphorylation of Thr308 is sufficient for the activation of Akt, full activation requires 
phosphorylation of both residues. Activated Akt migrates through the cytosol leading to the 
translocation into the nucleus followed by modulation of cell survival and cell cycle 
progression [81, 105-107].  
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1.9.6 Death receptor signaling via TNFa or TGFβ 
 Tumor necrosis factor alpha (TNFα) is a pro-inflammatory cytokine, which is a key 
mediator in a variety of diseases including ischemia/reperfusion injuries, as well as upon 
drug-induced liver injury (DILI) [6, 7, 108]. Activated Kupffer cells, along with leukocytes, 
release TNFα which can bind to its receptors TNF receptor 1 (TNFR1) and TNF receptor 2 
(TNFR2) [109]. However, with regard to liver physiology, TNFR1 has a predominant role [63]. 
Upon binding of TNFα to its receptor, either hepatocyte death or survival pathways may be 
activated. Moreover, TNFα is commonly used in combination with D-galactosamine (D-Gal) 
as an experimental model in vivo of induced hepatitis. Thereby, D-Gal blocks transcription 
specifically in hepatocytes leading to the inhibition of mRNA synthesis of anti-apoptotic 
genes, ultimately resulting in the activation of caspase cascade and DNA fragmentation [35, 
110]. In vitro, the same effect can be provoked by adding the transcription inhibitor 
actinomycin D (ActD) or the translation inhibitor cycloheximide (CHX) in combination with 
TNFα [24].  
 Soluble TNFα (sTNFα) and membrane-bound TNFα (mTNFα) can bind to its receptor 
TNFR1 and TNFR2. However, only TNFR1 is involved in the apoptotic signaling since TNFR2 
lacks a functional death domain. After binding of TNFα to its receptor, trimerization of the 
receptor occurs (Figure 13). TNFR1-associated death domain protein (TRADD) binds to the 
trimeric death domain, further recruiting receptor-interacting protein-1 (RIP1), cellular 
inhibitor of apoptosis-1/2 (cIAP1/2) and TNF receptor-associated factor-2 (TRAF2) leading to 
the formation of complex I. This complex induces the activation of the inhibitor of кB kinase 
(IKK) complex, which includes IKKα, IKKβ, and IKKγ/NEMO. The IKK complex further induces 
phosphorylation and proteasomal degradation of the NF-кB regulatory subunit IкBα leading 
to the activation of NF-кB. Translocation of NF-кB to the nucleus leads to the activation of 
transcription of anti-apoptotic genes such as cFLIPL, TRAF1/2, cIAP-1/2, XIAP and Gadd45β to 
regulate cell survival and proliferation [108, 111].  
 Additionally, complex I can also lead to the activation of MAPK cascade including JNK, 
p38 and ERK. Oligomerization of TRAF2/5 results in the binding of transforming growth 
factor-β-activated kinase-1 (TAK1) to TRAF2/5. TAK1 itself is a MAPKKK, which further 
phosphorylates MAPKK, such as MEK4/7, leading to the activation of MAPK including JNK. 
Moreover, apoptosis signal-related kinase (ASK1) was reported to activate JNK leading to the 
transcription of pro-apoptotic and proliferation-dependent genes [108, 109]. Upon normal 
conditions transient JNK activation promotes proliferation and is rapidly inactivated by 
phosphatases. However, upon prolonged and sustained activation of JNK, ubiquitin ligase 
ITCH is phosphorylated and cFLIP is targeted for degradation resulting in the activation of 
caspase cascade, thus leading to the induction of apoptosis. Therefore, JNK antagonizes NF-
кB during TNFα mediated signal transduction [108, 112].  
 Finally, internalization of complex I leads to the degradation of cIAP1/2 and the 
dissociation of TRAF2, TRADD and RIP1 from complex. Association with FADD and caspase 8 
and 10 results in the formation of complex 2 or so called death-inducing signaling complex 
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(DISC). Initiator caspases 8/10 are further activated by an autoproteolytic process leading to 
the activation of effector caspase 3/6/7. Apoptosis can be triggered by two different 
pathways: either caspase 8 directly cleaves caspase 3, thereby promoting apoptosis; or 
caspase 8 initiates signal amplification to induce mitochondrial death pathway. In the latter 
case, cytosolic Bid is cleaved by caspase 8 resulting in the active form tBID, which 
translocates to the mitochondrial membrane and contributes to mitochondrial permeability 
(mitochondrial permeability transition, MPT). Subsequently, cytochrome C is released from 
the mitochondria, triggering the formation of the apoptosome; a complex consisting of 
cytochrome C, Apaf-1 and caspase 9. The apoptosome processes and activates effector 
caspase 3 resulting in apoptosis-induced cell death through the cleavage of cytoplasmic and 
nuclear substrates [108, 109, 113].  
 
 
Figure 13: TNFα signaling. Upon binding of TNFα to its receptor TNFR1, receptor trimerization occurs and NF-
кB pathway is activated through IKK complex. Nuclear translocation of NF-кB activates transcription of pro-
inflammatory and anti-apoptotic genes. Additionally, TNFα induces pro-apoptotic pathway via association of 
TRADD and FADD leading to the activation of caspase-dependent apoptosis through initiator caspase 8 and 
effector caspase 3. Finally, TNFα can induce MAPK-associated pathways, such as JNK, leading to the 
transcription of pro-apoptotic and proliferation-dependent genes. However, upon sustained activation of JNK, 
c-FLIP is degraded resulting in the induction of caspase cascade. Figure adapted and modified from [109]. 
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 Transforming growth factor-β (TGFβ) is a pleiotropic cytokine, which has various 
functions including cell cycle control, regulation of early development, differentiation, 
hematopoiesis, angiogenesis, chemotaxis and immune functions [114]. However, its pivotal 
role in the liver and other organs, such as lung and kidney, is the development of fibrosis 
[115]. TGFβ expression is markedly enhanced in patients with chronic liver disease and in 
animal models of liver fibrosis as well as after partial hepatectomy and CCl4/APAP-induced 
liver injury [24, 116]. Overexpression of TGFβ is associated with increased matrix deposition. 
Furthermore, neutralization of the activity results in attenuation of liver fibrosis. Upon 
stimulation, TGFβ can be released by hepatocytes, Kupffer cells and hepatic stellate cells 
(HSC). This leads to the activation of HSC and the production of extracellular matrix proteins, 
resulting in the resolution of inflammation and wound closure [20, 24]. However, TGFβ was 
also associated to apoptosis in vitro via Smad proteins and AP-1 [117] or by GADD45β 
through p38 activation [118, 119]. Furthermore, in vivo studies also revealed an apoptosis 
induction in transgenic mice that overexpress TGFβ [120, 121].  
 TGFβ acts through its membrane-bound receptors type I and type II (TGFβRI and 
TGFβRII) leading to the formation of a heterotetrameric complex. Thereby, TGFβRI is 
phosphorylated by TGFβRII and subsequently the receptor activated Smad proteins, Smad2 
and Smad3, are activated. Phosphorylation of Smad2 and Smad3 leads to the formation of a 
heteromeric complex including Smad4 (co-Smad). This complex translocates to the nucleus 
to regulate gene transcription, including pro- and anti-apoptotic genes, such as p53, Bax, 
BcL-2, BcL-XL or Bik [114, 118, 122] . Furthermore, TGFβ can act through the TGFβ activated 
kinase 1 (TAK1), which was reported to belong to the MAP kinase family. TAK1 kinase is 
reported to activate p38 mitogen-activated protein kinase (p38 MAPK), as well as c-Jun N-
terminal kinase (JNK), which were associated with stress and inflammation as well as to 
apoptosis [122, 123]. Moreover, TGFβ can induce apoptosis through pro-apoptotic events, 
such as oxidative stress, down-regulation of Bcl-2 family members, up-regulation of pro-
apoptotic factor Bax and the initiation of caspase cascades [118].  
 
1.10 The CCN family 
 The CCN family was already first described more than a quarter of a century ago 
[124-126]. Thereby, the first three members were cysteine-rich 61 (Cyr61; CCN1), connective 
tissue growth factor (CTGF; CCN2) and nephroblastoma overexpressed (Nov, CCN3), which 
provide the acronym for the CCN family [127]. A few years later, Pennica et al identified 
three additional members: WNT1-inducible signaling pathway protein-1 (WISP1 or CCN4), 
WISP2 (CCN5) and WISP3 (CCN6), which were reported as Wnt-inducible secreted proteins 
[128]. This group of six highly conserved secreted proteins share a modular structure 
containing an N-terminal secretory peptide followed by four different domains (Figure 14): 
an insulin-like growth factor binding protein-like domain (IGFBP; module I), a von Willebrand 
factor type C repeat module (VWC), a thrombospondin type-1 repeat module (TSP-1) and a 
cysteine knot-containing module (CT) (Figure 14). Moreover, module II and III are connected 
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by a hinge region, which is susceptible for proteolytic cleavage [129-132]. Besides CCN5, 
which lacks the cysteine knot, all modules are encoded by a separate conserved exon, 
suggesting that the CCN genes are evolved through exon shuffling [133]. CCN proteins 
contain 349 up to 381 amino acids with the exception of CCN5 [134]. 
 
 
Figure 14: Structure of the CCN family members. The CCN family consists of 6 members: CCN1 (Cyr61), CCN2 
(CTGF), CCN3 (Nov) and CCN 4-6 (WISP-1 – 3). They share a similar structure containing a secretory signal 
peptide (SP), an IGF-binding domain (Module I), a von Willebrand type C domain (VWC, Module II), a 
thrombospondin-1 domain (TSP-1, Module III) and a cysteine knot (Module IV) domain. Only CCN5 is lacking 
the cysteine knot at the end. The domains are linked by a hinge region, which is susceptible to protease 
cleavage. Figure adapted and modified from [129]. 
 
 This family of secreted extracellular matrix (ECM)-associated proteins belong to the 
group of matricellular proteins, including thrombospondin-1 (TSP1), SPARC (secreted 
protein, acidic and rich in cysteine), hevin, osteopontin and tenascin C and X. Matricellular 
proteins are known to be dynamically expressed rather than serving structural roles in the 
matrix [131, 135].  
 CCN proteins are expressed in many organs during embryonic development and their 
biological relevance was shown via embryonic or perinatal lethality of knockout mice 
regarding CCN1, CCN2 and CCN5 [136-141]. The expression of CCN proteins is 
downregulated during adulthood in various tissues. However, the transcription of genes 
encoding CCN proteins can be upregulated by various mitogenic signals and environmental 
disorders, such as exposure of growth factors (PDGF, FGF2), inflammatory cytokines (TNF, IL-
1β, TGFβ), oxygen deprivation, steroid hormones, ultraviolet radiation and mechanical 
forces. Therefore, it is not surprising that CCN proteins are involved in various important 
functional pathways including mitogenesis, migration, adhesion, cell survival, differentiation, 
angiogenesis, tumorigenesis, inflammation and wound healing, as reviewed in [130, 132]. 
These biological processes are mediated mainly through binding of CCN proteins to integrin 
receptors, including co-factors in some contexts. CCN proteins do not contain the canonical 
RGD sequence. Therefore, they interact with integrins through their non-canonical binding 
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sites, which are shown in figure 15. Up to now, eight integrin receptors have been identified 
to mediate interactions with CCN1-3 proteins as well as co-receptors, such as heparin sulfate 
proteoglycans (HSGPs) and low-density lipoprotein receptor-related proteins (LRPs) [131, 
132, 142]. 
 
 
Figure 15: CCN protein structure and the localization of integrin-binding sites. Eight integrins were reported to 
bind CCN proteins, as well as co-receptors such as HSPGs and LRPs. CCN proteins do not contain the canonical 
RGD sequence. Therefore, non-canonical binding sites are essential for interaction of CCN proteins with 
integrins. Figure adapted and modified from [132].  
 
 Although the CCN proteins share a similar structure, they were reported to play 
divergent roles in liver pathophysiology. For example, CCN1 was shown to be induced upon 
hepatic injury in mouse models. Furthermore, it was shown to act as a key regulator of liver 
fibrosis through triggering cellular senescence in hepatic stellate cells and portal fibroblasts 
leading to limited fibrogenesis and the regression of liver fibrosis [143, 144]. Moreover, 
CCN1 was reported to mediate opposing biological activities just by interacting with different 
integrins on various cell types, as reviewed in [145]. Furthermore, Chen et al unveiled an 
apoptotic synergistic effect of CCN1 and TNFα. In cases of liver injury, TNFα is one of the 
most prominent pro-inflammatory cytokines leading to the expression of anti-apoptotic 
proteins [111]. The binding of CCN1 and TNFα to their receptors, results in the production of 
reactive oxygen species by CCN1 and leads to the sustained activation of JNK and a blockage 
of NF-кB. Thus, cytotoxicity effect of TNFα is induced and activation of caspase cascade 
proceeds, leading to apoptosis in the affected cells [144-146]. In contrast to CCN1, CCN2 was 
shown to act synergistically with TGFβ1 in order to promote matrix deposition and 
fibrogenesis [147]. Moreover, knockdown of CCN2 by usage of small interfering RNA (siRNA) 
or oligonucleotides reduced CCl4-induced liver fibrosis [148, 149], suggesting that CCN2 
acted as a pro-fibrotic regulator [132, 134].  
 A recent study by Perbal revealed an increasing interest in CCN proteins, since the 
number of publications raised from 18 between 1996-1998 up to 3,335 in 2015-2016 [150]. 
Moreover, CCN proteins have been taken to account for potential therapeutic approaches 
since they are secreted proteins, which could be tackled by humanized monoclonal 
antibodies to block their activity. For example, FG-3019, a humanized antibody against 
CCN2, was shown to be safe and well tolerated in patients with idiopathic pulmonary fibrosis 
[151-153]. Another Phase II study using the same antibody revealed efficiency to reverse 
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liver fibrosis in patients, which was caused by chronic hepatitis B infection (ClinicalTrials.gov 
identifier: NCT01217632). However, up to now clinical trials were only planned for the 
investigation of efficacy to target CCN2. Taken together, this highlights the impact of CCN 
proteins to a broad spectrum of diseases making this protein family even more important 
and attractive for further investigations [132].  
 
1.10.1 WNT1-inducible signaling pathway protein-1 (WISP1) 
 WNT1-inducible signaling pathway protein-1 (WISP1), a member of the CCN family, 
was first identified as a target of β-catenin Wnt-transformed cells and in colon cancer cells. 
Additionally, it was shown to induce dedifferentiation and tumorigenic features in 
fibroblasts [128, 154]. The murine WISP1 is located on chromosome 15 and the human 
WISP1 gene is located on chromosome 8q24.1–q24.3 [128, 134]. The murine cDNA length is 
about 1,766 and the human is about 2,830 bp. Furthermore, WISP1 is expressed as a protein 
of 367 amino acids and it can be glycosylated at several residues resulting in an apparent 
molecular weight of 60 kDa. WISP1 gene expression can be mainly detected in adult lung, 
heart, kidney, pancreas, ovary, placenta, spleen and small intestine. However, the 
expression levels in brain, liver, skeletal muscle, thymus, colon and peripheral blood 
leukocytes are either low or absent [128].  
 Most of the studies regarding the potential effect of WISP1 are associated with 
proliferation, migration and survival. For example, WISP1 was reported to attenuate p53 
mediated apoptosis by the activation of antiapoptotic Akt pathway leading to inhibition of 
cytochrome C release and up-regulation of antiapoptotic Bcl-XL [106]. In line with this, 
Venkatachalam et al showed that WISP1 antagonizes TNF-α mediated cardiomyocyte death, 
suggesting that WISP1 act in a pro-mitogenic and pro-survival manner in myocardial 
constituent cells [155]. Overexpression of WISP1 in vascular smooth muscle cells (VSMCs) led 
to enhanced migration and proliferation through the activation of Akt signaling [156]. In 
opposition to claims pertaining to the pro-survival role of WISP1, Tong et al reported that 
WISP1 expression was enhanced 6h after ischemia-reperfusion. The usage of anti-WISP1 led 
to decreased ALT and AST values as well as to decreased pro-inflammatory cytokine levels 
[157]. 
 Moreover, WISP1 was reported to be induced upon various cytokines, for example, 
Dooley et al showed in a gene array study that WISP1 is induced in primary mouse 
hepatocytes stimulated with TGFβ, which is a profibrogenic cytokine. Furthermore, several 
studies suggested that WISP1 is induced by various cytokines such as IL-1β, TNFα in cardiac 
myocytes or TGFβ in osteoblasts [158-161].  
 Since most of the studies in the past were focused on investigating effects of CCN1-3, 
there are only 114 research articles published to date regarding WISP1 [150]. Moreover, 
there is no known publication, which describes the precise role of WISP1 in liver 
pathophysiology. Just recently, Murahovschi showed that WISP1 can induce cytokine and 
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chemokine expression as well as secretion in human monocyte-derived macrophages [162]. 
This suggests that WISP1 is a potent regulator during immune response with a yet undefined 
role in terms of acute liver injury.  
 
1.11. Aim of this work  
 The aim of this study was to investigate the potential influence of WNT1-inducible 
signaling pathway protein-1 (WISP1, CCN4) during acute liver injury. For this purpose, a 
WISP1 knockout mouse line was established and confirmed for the absence of WISP1 by 
immunohistochemical staining as well as by qRT-PCR in different organs.  
 In order to study the potential influence of WISP1 during acute liver injury, two well-
known liver toxicant models were applied in vivo, including CCl4 and paracetamol. Potential 
effects were studied in a dose and time-dependent manner. Therefore, I used histological as 
well as molecular biology techniques, such as western blot and qRT-PCR analysis. The results 
revealed a significant enhanced liver injury in WISP1 knockout mice, which was associated 
with an increase inflammatory response as well as stronger induced stress signaling. Since 
first results revealed differences regarding inflammation, I further implemented in vitro 
studies to investigate the effects on wild type and WISP1 knockout hepatocytes to 
inflammatory cytokines as well as paracetamol. These analyses also revealed an enhanced 
susceptibility of WISP1 knockout hepatocytes to cell death. Finally, a time resolved global 
gene expression profile of wild type and WISP1 knockout mice was carried out using 
Affymetrix microarrays. To identify mechanisms responsible for transcriptional alterations, I 
used a combination of gene array analysis, bioinformatics and knowledge-based 
interpretation of the identified deregulated genes. Finally, I validated the identified 
biological motifs by using qRT-PCR. 
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2 MATERIALS AND METHODS 
 
2.1 Materials  
2.1.1 Technical equipment 
 
Table 1: Equipment 
Equipment  Company  
Autoclave 5075 ELV, Tuttenauer 
Balance  EW, Kern  
Benches HERA-Safe, Heraeus 
Bright Field Microscope  Primo Vert, Zeiss, Software ZEN from Zeiss  
Bunsen Burner  IBS Fireboy Plus, Integra Bioscences  
Centrifuge  Megafuge 1.0R, Thermo Scientific  
Centrifuge  Centrifuge 5415 R, Eppendorf  
Centrifuge with cooling function  5424R, Eppendorf  
EC 350 – Modular tissue embedding center Microm, Walldorf, Germany 
Electrophoresis Chamber Sub-Cell® Model 192 Cell, BioRad 
Electrophoresis Chamber (western blot) Mini-PROTEAN® Tetra Cell Systems, BioRad 
HM 450 Sliding Microtome  Microm, Walldorf, Germany 
Ice machine AF 100, Scotsman 
Image acquisition system E-BOX CX5, Vilber Lourmat 
Image acquisition system 
 
Fusion Fx7, Vilber Lourmat 
Incubators  CO2 Incubator C150 R Hinge 230, Binder  
Infinite M200 Pro Plate reader  Tecan  
Laminar Flow Hood  Electronics FAZ 2, Waldner  
Magnetic stirrer  IKAMAG RCT, IKA  
Mercury Lamp Nikon Insilight C-HGFI 
Microcentrifuge  Mini Spin Plus, Eppendorf  
Microscope Olympus BX61 microscope 
Microscope CCD-Camera  AxioCam ICm 1  
Minicentrifuge  FVL-2400N Combi-Spin, Biosan  
Minishaker MS 2, IKA 
pH meter  CG 842, Schott  
Pipetteboy  Integra  
Pipettes  Research and Reference, Eppendorf  
Power Supplies Standard Power Pack 25, Biometra 
Power Pack 300, BIO RAD 
Precision balance  EW 150-3M, Kern  
Real Time PCR System  7500 Real-Time PCR System, Applied Biosystems  
Shaker KS 260 basic, IKA 
Software Olympus Fluoview Ver. 4.O 
Sonicator  Bandelin, SONOPLUS  
Spectrometer  NanoDrop 2000, Thermo Scientific  
Spin Tissue Processor STP 120  Microm, Walldorf, Germany 
Sub-Cell Model 192, BIO RAD 
TaqMan 7500 Real-Time PCR Applied Biosystems 
Thermocycler  TGRADIENT, Biometra 
Thermoshaker HTM 130, HLC 
PHMT Grant-bio, Keison 
Transfer chamber  Trans-Blot® SD Semi-Dry Transfer Cell, BioRad   
UV/Vis Spectrometer V-530,  Jasco 
Vacuum pump  Diaphragm Vacuum Pump, Vacuumbrand  
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Vortex  Vortex-Genie 2, Bender&Hobein  
Water purification system  Maxima Ultra-Pure Water, ELGA  
Waterbath  GFL 1083, Gesellschaft für Labortechnik  
 
2.1.2 Consumables 
 
Table 2: Consumables 
Consumable  Company  Catalog No  
Biosphere Filtered Tip, 1000uL  Sarstedt, Numbrecht, Germany  70.762.211  
Biosphere Filtered Tip, 100uL  Sarstedt, Numbrecht, Germany  70.760.212  
Biosphere Filtered Tip, 200uL  Sarstedt, Numbrecht, Germany  70.760.211  
Biosphere Filtered Tip, 20uL  Sarstedt, Numbrecht, Germany  70.1116.210  
Blotting Paper Grade 703, 46x57cm  VWR international, Darmstadt, Germany  732-0591  
Cell culture microtiter plate, 96 well  Greiner bio-one  655986  
Cell Scraper, 25cm  Sarstedt, Numbrecht, Germany  83.183  
Corning™ 96-Well Clear Bottom Black or 
White Polystyrene Microplates 
Costar 3610, Thermo Scientific, Braunschweig, 
Germany 
07-200-566 
Cover glass, 24 x 32 mm  VWR International (Argos Technologies) 631-0711 
Falcon tube, 15mL  Sarstedt, Numbrecht, Germany  62.554.512  
Falcon tube, 50mL  Sarstedt, Numbrecht, Germany  62.547.254  
Gentle Skin Classic Laboratory Gloves  Meditrade, Kiefersfelden, Germany  1221R  
Hypodermic Needle, 26G x 5/8  BD Bioscience, San Jose, USA  304300  
Inject F, 1ml   B Braun, Germany 9166017V   
Kimtech Science Delicate Task Wipes  Kimberly-Clark Professionals, Roswell, USA  7216  
MicroAmp Optical 96-well Reaction 
Plate  
Applied Biosystems, California, USA  N801-0560  
MicroAmp Optical Adhesion Film Applied Biosystems, California, USA 4311971 
Parafilm Wrap  Cole-Parmer, Kehl/Rhein, Germany  PM-992  
PCR SingleCap 8er-SoftStrips 0.2ml Biozym Scientific GmbH, Germany 710988 
Pestle & microtube 1,5 ml VWR International (Argos Technologies) 431-0098 
Pipette Tips, 1000uL  Sarstedt, Numbrecht, Germany  70.762  
Pipette Tips, 200uL  Sarstedt, Numbrecht, Germany  70.760.002  
Pipette Tips, 20uL  Sarstedt, Numbrecht, Germany  70.1116  
Polyscreen PVDF Transfer Membrane  Perkin-Elmer, Massachusetts, USA  NEF1002001PK  
RNase-free Microfuge Tubes 1.5 mL  Ambion, Thermo Fischer Scientific, Waltham, USA  AM12400  
RNaseZap® RNase Decontamination 
Solution  
Ambion, Thermo Fischer Scientific, Waltham, USA  AM9780/AM97
82  
SafeSeal 0.5mL microtube  Sarstedt, Numbrecht, Germany  72.699  
SafeSeal 1.5mL micotube  Sarstedt, Numbrecht, Germany  72.706  
SafeSeal 2.0mL microtube  Sarstedt, Numbrecht, Germany  72.695.500  
Serological Pipette, 10mL  Sarstedt, Numbrecht, Germany  86.1254.001  
Serological Pipette, 25mL  Sarstedt, Numbrecht, Germany  86.1685.001  
Serological Pipette, 5mL  Sarstedt, Numbrecht, Germany  86.1253.001  
Sterile filter, Filtrapur S0.2 Sarstedt, Numbrecht, Germany 83.1826.001   
SuperFrost Plus® microscopic slides  Thermo Scientific, Braunschweig, Germany J1800AMNZ  
Surgipath Paraplast Leica, Germany  39601006 
Tissue Culture Plate Flat-Bottom 6-Well 
Plate  
Sarstedt, Numbrecht, Germany  83.1839  
Tissue-Loc™ HistoScreen™ Cassette Thermo Scientific, Braunschweig, Germany C-1000 
Vacuum Filtration Unit, 0.22um, 250mL  Sarstedt, Numbrecht, Germany  83.1822.001  
WypAll L30 wipes  Kimberly-Clark Professionals, Roswell, USA  7301  
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2.1.3 Chemicals and kits 
 
Table 3: Chemicals and kits 
Chemical  Company  Catalog No 
2-propanol  Carl Roth, Karlsruhe, Germany  AE73.1 
Acetic acid Carl Roth, Karlsruhe, Germany 3738.5 
Actinomycin D, from Streptomyces species Sigma-Aldrich Corp., St. Louis, MO, USA  A9415 
Agarose Biozym Scientific GmbH, Hessisch Oldendorf, 
Germany  
840004 
Alanine Aminotransferase Activity Assay Kit Sigma-Aldrich Corp., St. Louis, MO, USA MAK052 
Amino acid solution (Costumer 
formulation)  
PAN Biotech GmbH, Aidenbach, Germany  SO-33100 
APS  Sigma-Aldrich Corp., St. Louis, MO, USA  3678-25g 
Aspartate Aminotransferase (AST) Activity 
Assay Kit 
Sigma-Aldrich Corp., St. Louis, MO, USA MAK055 
Avidin/Biotin Blocking Kit Vector Laboratories, Lörrach, Germany SP-2001 
Boric acid  Carl Roth, Karlsruhe, Germany 5935.1 
Bovine Albumin Fraction V (BSA)  Carl Roth, Karlsruhe, Germany  8076.4 
Bromophenol Blue  Merck, Darmstadt, Germany  108122 
Buffer concentrate A  Carl Roth, Karlsruhe, Germany  L510.1 
Buffer concentrate K  Carl Roth, Karlsruhe, Germany  L511.1 
Calcium chloride (CaCl2) Sigma-Aldrich Corp., St. Louis, MO, USA 5239.1 
CCl4  Sigma-Aldrich Corp., St. Louis, MO, USA 7345.1 
Cell Lysis Buffer 2  R&D Systems, Minneapolis, USA #895347 
Cell Titer Blue Assay  Promega, Wisconsin, USA G8081 
Chloroform Carl Roth, Karlsruhe, Germany 7331.2 
Citric acid monohydrate Carl Roth, Karlsruhe, Germany 3958.2 
Collagenase from Clostridium hystolyticum  Sigma-Aldrich Corp., St. Louis, MO, USA  C2674 
Complete feed for Rats&Mice - 
Maintenance  
Ssniff Spezialdiaeten, Soest, Germany  V1534-000 
D-(+)- Glucose monohydrate Sigma-Aldrich Corp., St. Louis, MO, USA 49159 
DAB Peroxidase substrate kit Vector Laboratories, Lörrach, Germany SK 4100 
Dako Pen Dako, Hamburg, Germany REF S2002 
DeadEnd™ Colorimetric TUNEL System Promega, Wisconsin, USA G7130 
DEPC Treated Water  Invitrogen GmbH, Darmstadt, Germany  750024 
di-Sodium Hydrogen Phosphate anhydrous 
(Na2HPO4)  
Carl Roth, Karlsruhe, Germany  P030.2 
DMSO Sigma-Aldrich Corp., St. Louis, MO, USA 34869 
DNA ladder, 100 bp  Invitrogen GmbH, Darmstadt, Germany  15628-050 
DTT (DL-Dithiothreitol)  Sigma-Aldrich Corp., St. Louis, MO, USA  D9779 
EDTA  Carl Roth, Karlsruhe, Germany  8040.3 
EGTA  Carl Roth, Karlsruhe, Germany  3054.2 
Eosin Y disodium salt  Sigma-Aldrich Corp., St. Louis, MO, USA  E4382 
Ethanol  Merk, Darmstadt, Germany  100983 
Ethanol, 70%  Walter CMP, Kiel, Germany  WAL10506 
Ethidium Bromide  Invitrogen GmbH, Darmstadt, Germany 15585-011 
Ficoll  Sigma-Aldrich Corp., St. Louis, MO, USA F4375 
FluorPreserve™ Reagent  Calbiochem, Darmstadt, Germany.  345787 
Glycerin  Carl Roth, Karlsruhe, Germany  3783.2 
Glycine  Carl Roth, Karlsruhe, Germany  HN07.3 
HEPES Carl Roth, Karlsruhe, Germany  9105.4 
High Capacity cDNA Reverse Transcription 
Kit  
Applied Biosystems, Karlsruhe, Germany  4368813 
Hydrochloric Acid, 32%  Carl Roth, Karlsruhe, Germany  P074.4 
Hydrogen peroxide 30% (H2O2) Sigma-Aldrich Corp., St. Louis, MO, USA H1009 
Isopropyl Carl Roth, Karlsruhe, Germany 6752.2 
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Ketamin-ratiopharm® 50 mg O.K. Injection 
Solution  
Ratio pharm, Ulm, Germany  N64477.04 
L- Glutamine Sigma-Aldrich Corp., St. Louis, MO, USA G3126 
Luminol Sigma-Aldrich Corp., St. Louis, MO, USA A8511 
Magic Mark XP Western Protein Standard  Invitrogen GmbH, Darmstadt, Germany  LC5602 
Magnesium sulfate (MgSO4) Carl Roth, Karlsruhe, Germany  P027.2 
Mayer´s Hemalum solution  Merck, Darmstadt, Germany  1.09249.0500 
Methanol  Sigma-Aldrich Corp., St. Louis, MO, USA  322415 
Microscopy Entellan  Merck, Darmstadt, Germany  1.07960.0500 
Mouse/Rat WISP-1/CCN4 Quantikine ELISA 
Kit 
R&D Systems, Minneapolis, USA MWSP10 
Nonidet P-40 (NP-40) Roche Diagnostics GmbH, Manheim 11754599001 
Olive oil  Sigma-Aldrich Corp., St. Louis, MO, USA 75343-1L 
Paracetamol (4-Acetamidophenol 98 %)  Sigma-Aldrich Corp., St. Louis, MO, USA  A 7302 
Paraffin Histowax Surgipath paraplast Leica Microsystems, Wetzlar, Germany 3901006 
p-Coumaric acid Sigma-Aldrich Corp., St. Louis, MO, USA C9008 
Phire Animal Tissue Direct PCR Kit Thermo Scientific, Braunschweig, Germany F-140WH 
Phosphatase Inhibitor Cocktail II  Sigma-Aldrich Corp., St. Louis, MO, USA  P5726 
Phosphatase Inhibitor Cocktail III  Sigma-Aldrich Corp., St. Louis, MO, USA  P0044 
Pierce BCA Protein Assay Kit  Thermo Scientific, Braunschweig, Germany  23225 
Ponseau S  Carl Roth, Karlsruhe, Germany  5938.1 
Potassium Chloride (KCl)  Carl Roth, Karlsruhe, Germany  6781 .1 
Potassium dihydrogen phosphate (KH2PO4)  Carl Roth, Karlsruhe, Germany  3904.1 
Precision Plus Protein standard Bio-Rad Laboratories, Munich, Germany  161-0374 
Propidium Iodide Sigma-Aldrich Corp., St. Louis, MO, USA P4170 
Protease Inhibitor Cocktail  Sigma-Aldrich Corp., St. Louis, MO, USA  P8340 
Qiazol Lysis Reagent  Qiagen, Hilden, Germany  79306 
Recombinant Human TGF-beta 1 Protein 
(TGFβ)  
R&D Systems, Minneapolis, USA 240-B 
Recombinant Human TNF-alpha Protein 
(TNFα) 
R&D Systems, Minneapolis, USA 210-TA 
Rompun 2% Bayer Health Care, Leverkusen, Germany - 
Roti Histofix 4%  Carl Roth, Karlsruhe, Germany  P087.5 
Roti-Histol  Carl Roth, Karlsruhe, Germany  6640.1 
Rotiphorese® Gel 30 (37,5:1)  Carl Roth, Karlsruhe, Germany  3029.1 
SDS pellets  Carl Roth, Karlsruhe, Germany  CN30.1 
Sera Plus (Special Processed FBS)  PAN Biotech GmbH, Aidenbach, Germany  3702-P103009 
Sodium chloride (NaCl) Carl Roth, Karlsruhe, Germany  3957.2 
Sodium deoxycholate  Sigma-Aldrich Corp., St. Louis, MO, USA  D6750 
Sodium hydroxide pellets  Merck, Darmstadt, Germany  1.06482 
Taq DNA Polymerase kit 5-Prime, Hamburg, Germany 2900169 
TaqMan® Universal Master Mix II, with 
UNG  
Applied Biosystems, Karlsruhe, Germany  4440038 
TEMED  Carl Roth, Karlsruhe, Germany  2367.1 
Trichloroacetic Acid  Carl Roth, Karlsruhe, Germany  8789.2 
Trichloromethane/Chloroform  Carl Roth, Karlsruhe, Germany  7331.2 
TRIS  Carl Roth, Karlsruhe, Germany  4855.2 
Tris-HCl  Sigma-Aldrich Corp., St. Louis, MO, USA  T3253 
Triton X-100  Carl Roth, Karlsruhe, Germany  3051 
Trizma base  Sigma-Aldrich Corp., St. Louis, MO, USA  33742 
Trypan Blue  Sigma-Aldrich Corp., St. Louis, MO, USA  T6146 
Tween 20  Sigma-Aldrich Corp., St. Louis, MO, USA  P7949 
Tween 80 Sigma-Aldrich Corp., St. Louis, MO, USA  P8074 
VECTASTAIN Elite ABC Kit (Rat IgG) Vector Laboratories, Lörrach, Germany PK-4004 
Whatman paper  VWR, Langenfeld, Germany 28298 
Xylol AnalaR Norampur VWR, Langenfeld, Germany UN1307 
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2.1.4 Buffers for liver perfusion and in vivo collection 
 
Table 4: Buffers for liver perfusion and in vivo collection 
Buffer Chemical Amount 
Collagenase buffer Amino acid solution 
CaCl2 solution (19 g/L CaCl2* 2 H2O) 
Collagenase Type 1 
Glucose solution (9 g/L) 
Glutamine (7 g/ml) 
HEPES (60 g/L) (pH 8.5) 
KH buffer 
 
30 ml 
10 ml 
100 mg 
155 ml 
2.5 ml 
25 ml 
25 ml 
 
EGTA buffer Amino acid solution 
EGTA solution (47.5 g/L) 
Glucose solution (9 g/L) 
Glutamine (7 g/L) 
KH buffer 
HEPES (60 g/L) (pH 8.5) 
 
60 ml 
1.6 ml 
248 ml 
4 ml 
30 ml 
30 ml 
 
KH buffer Potassium chloride (KCl)  
Potassium dihydrogen phosphate (KH2PO4)  
Sodium chloride (NaCl)  
filled to 1 L with H2O, set pH to 7.4 
 
1.75 g 
1.6 g 
60 g 
 
PBS (10x) Potassium chloride (KCl) 
Potassium dihydrogen phosphate (KH2PO4) 
Sodium chloride (NaCl) 
di-Sodium Hydrogen Phosphat anhydrous (Na2HPO4) 
set pH to 7.4, filled up to 5 L with distilled water 
 
10 g 
10 g 
400 g 
46 g 
 
Suspensions buffer Albumin Fraction V 
Amino acid solution 
CaCl2 solution (19 g/L CaCl2* 2 H2O) 
Glucose solution (9 g/L) 
Glutamine (7 g/ml) 
HEPES (60 g/L) (pH 7.6) 
KH buffer 
MgSO4 solution (24,6 g/L MgSO4 * 7H2O) 
 
400 mg 
30 ml 
1.6 ml 
124 ml 
2 ml 
20 ml 
20 ml 
0.8 ml 
 
 
2.1.5 Cell culture 
2.1.5.1 Cell culture chemicals 
 
Table 5: Cell culture chemicals 
Other Chemicals  Company  Catalog No  
Acetic acid glacial  Carl Roth, Karlsruhe, Germany  3738.5  
Rat tail collagen  Roche Diagnostics GmbH, Manheim,  11171179001  
DMEM low glucose 1.0 g/L 10x  BioConcept, Allschwil, Switzerland  1-25K03-I  
Gentamycin  PAN Biotech GmbH, Aidenbach, Germany  P06-13001  
Insulin (ITS) 100x  Sigma-Aldrich Corp., St. Louis, MO, USA  I3146  
Penicillin/Streptomycin  PAN Biotech GmbH, Aidenbach, Germany  P06-07100  
Sera Plus (Special Processed FBS)  PAN Biotech GmbH, Aidenbach, Germany  3702-P103009  
Stable L- Glutamine  PAN Biotech GmbH, Aidenbach, Germany  P04-82100  
William’s Medium E  PAN Biotech GmbH, Aidenbach, Germany  P04-29510  
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2.1.5.2 Cell culture medium  
 
Table 6: Cell culture medium  
Additives for cell 
culture medium Final Concentration For 500 ml Medium Company 
Catalog 
No 
William’s Medium E - - PAN Biotech GmbH, 
Aidenbach, Germany 
P04-29510 
Dexamethasone 100 nM 20 μl from 2.5 mM 
stock in EtOH 
Sigma-Aldrich Corp., 
St. Louis, MO, USA 
D4902-
25MG 
Gentamycin 10 μg/ml 500uL PAN Biotech GmbH, 
Aidenbach, Germany 
P06-13001 
Insulin (ITS) 100x 2 ng/ml 5 µl Sigma-Aldrich Corp., 
St. Louis, MO, USA 
I3146 
Penicillin/Streptomycin 100 U/ml Pen; 
100 U/ml Strep 
5 ml PAN Biotech GmbH, 
Aidenbach, Germany 
P06-07100 
Stable L- Glutamine 2 mM 5 ml PAN Biotech GmbH, 
Aidenbach, Germany 
P04-82100 
Sera Plus (Special 
Processed FBS) 
10 % (Full Media only) PAN Biotech GmbH, 
Aidenbach, Germany 
3702-
P103009 
 
 
2.1.6 Protein lysate buffer 
 
Table 7: RIPA buffer for western blot 
RIPA buffer  
50 mM Tris-Cl (pH 7,5)  
150 mM NaCl  
1 % Nonidet P-40 (NP-40)  
0,5 % sodium deoxycholate  
0,1 % SDS  
Added prior to use:  
Protease inhibitor 1:100 
Phosphatase inhibitor 2 1:100 
Phosphatase inhibitor 3 1:100 
 
  
2 MATERIALS AND METHODS 
43 
2.1.7 Buffers for SDS electrophoresis and western blot 
 
Table 8: Buffers for SDS electrophoresis and western blot 
Buffer Chemical and amount 
10 % APS (Ammonium persulphate): 0.5 g APS in 5 ml dist. water 
10 % SDS (Sodium dodecyl sulphate): 0.5 g SDS in 5 ml dist. water 
5 % BSA solution: 5 g Albumin in 100 ml TBS-T 
Anode buffer: Buffer concentrate A (Roth) 40 ml 
Methanol 80 ml 
Dist. water 280 ml 
Cathode buffer: Buffer concentrate K (Roth) 40 ml 
Methanol 80 ml 
Dist. water 280 ml 
Loading buffer (5 x): Bromophenol blue 5 mg 
DTT 1 M 2.5 ml 
Glycerol 5 ml 
SDS 10 %  0.5 g 
Tris-HCl 1 M 2.25 ml 
Ponseau S: 1 g Ponseau S in 500 ml 3 % trichloride acetic acid  
Running buffer (10 x): Glycine 144.0 g 
SDS 10.0 g 
Tris base 30.3 g 
Separation buffer: (3 M Tris-HCl) Tris 36.34 g in 100 ml dist. water 
pH set to 8.8 
Stacking buffer: (0.47 M Tris-HCl) Tris 5.69 g in 100 ml dist. water  
pH set to 6.7  
Stripping buffer: Glycine 15 g 
SDS 1 g 
Tween 20 10 ml 
pH set to 2.2  
1 L total volume (dist. water) 
TBS (10 x)  
 
NaCl 265 g 
TRIS 60 g  
filled up to 5 L with distilled water 
set pH to 7.4 
TBS-T: TBS 250 ml 
Tween-20 2.5 ml 
Dist. water 250 ml 
filled up to 2.5 L with distilled water  
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2.1.8 List of primary antibodies 
 
Table 9: Primary antibodies for western blot analyses 
Antigen Origin Company Catalog No Dilution 
p-STAT3 XP® Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
9145 1:1000 (WB) 
STAT3 XP® Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
8768 1:1000 (WB) 
pAkt  XP® Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
4060 1:2000 (WB) 
Akt  Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
4691 1:1000 (WB) 
PCNA XP® Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
13110 1:2000 (WB) 
p-p44/42 (p-ERK1/2)  Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
9101 1:1000 (WB) 
p-SAPK/JNK  Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
4668 1:1000 (WB) 
p-p38 XP® Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
4511 1:1000 (WB) 
p38 XP® Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
8690 1:1000 (WB) 
SAPK/JNK  Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
9252 1:1000 (WB) 
RIP3 Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
14401 1:1000 (WB) 
CYP2E1 Rabbit LSBio, LifeSpan BioSciences Inc., 
Seattle, Washington, USA 
LS-C313045 1:1000 (WB) 
Cleaved Caspase 3 Rabbit  Cell Signaling New England Biolabs 
GmbH, Frankfurt am Main, Germany  
9664 1:1000 (WB) 
 
2.1.9 List of secondary antibodies  
 
Table 10: Secondary antibodies for western blot analyses 
Antigen  Origin  Company  Catalog No Dilution 
GAPDH  Rabbit  Cell Signaling New England Biolabs GmbH, 
Frankfurt am Main, Germany  
2118 1:1000 (WB) 
β-actin  Mouse Sigma-Aldrich Corp., St. Louis, MO, USA  A5316 1:10000 
 
2.1.10 ECL solution 
 
Table 11: ECL solution 
Chemical  Amount 
Luminol (250 mM in DMSO)  2.5 ml 
p-coumaric acid (90 mM in DMSO) 0.55 ml 
Fill it up with 0.1 M TRIS to 250 ml, protect from light, store at 4°C 
Mix 5 ml ECL solution with 3 µl H2O2 prior to use 
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2.1.11 Buffers for PCR 
 
Table 12: TBE-buffer  
Buffer Amount 
TBE-buffer (10 x) Boric acid 55 g 
 TRIS 108 g 
 40 ml EDTA (0.5 M pH 8) 
Fill up to 2 L with distilled water 
 
Table 13: Ficoll loading buffer 
Buffer Amount 
Ficoll loading buffer Bromophenol blue 125 mg  
 Ficoll 7.5 g  
 Add 50 ml dist. water 
 
2.1.11.1 Primers for PCR 
All primers were purchased from Eurofins, Ebersberg, Germany. 
 
Table 14: Primers for genotyping  
Primer  Sequence 5´ 3´ 
alt Puro3a forward AATTGCATCGCATTGTCTGAGTAGG 
Wisp-alt6 forward TACGCAATAGGAGTGTGTGCACG 
Wisp-alt9 reverse GGCAGTGTCTCCATATCATTTGATAGG 
 
Table 15: PCR primers 
Primer  Sequence 5´ 3´ 
XBP1 forward GAACCAGGAGTTAAGAACACG 
XBP1 reverse AGGCAACAGTGTCAGAGTCC 
 
2.1.12 Taqman assay  
 
Table 16: Taqman assays (Thermo Scientific, Braunschweig, Germany) 
Target gene Gene name Assay Catalog No. 
Atf3 activating transcription factor 3 Mm00476032_m1 
Ccl2  chemokine (C-C motif) ligand 2 Mm00441242_m1  
Ccl3 chemokine (C-C motif) ligand 3 Mm00441259_g1 
Ccl4 chemokine (C-C motif) ligand 4 Mm00443111_m1 
Ccl5 chemokine (C-C motif) ligand 5 Mm01302427_m1 
CCnd1 cyclin D1 Mm00432359_m1 
CCne2 cyclin E2 Mm00438077_m1 
CHOP  DNA-damage inducible transcript 3 (Ddit3) Mm01135937_g1 
Cidec cell death-inducing DFFA-like effector c Mm00617672_m1 
Ctgf connective tissue growth factor Mm01192933_g1 
Cxcl1 chemokine (C-X-C motif) ligand 1 Mm04207460_m1 
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Cxcl2 chemokine (C-X-C motif) ligand 2 Mm00436450_m1 
Cxcl5 chemokine (C-X-C motif) ligand 5 Mm00436451_g1  
Cyca2 cyclin A2 Mm00438063_m1 
Cycg2 cyclin G2 Mm00432394_m1 
Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 Mm00491127_m1 
Cyp4a10 cytochrome P450, family 4, subfamily a, polypeptide 10 Mm02601690_gH 
Cyp4a14 cytochrome P450, family 4, subfamily a, polypeptide 14 Mm00484135_m1 
Cyr61 cysteine rich protein 61 Mm00487499_g1 
Gadd45ß growth arrest and DNA-damage-inducible 45 beta Mm00435121_g1 
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase 4352932E  
Ifng interferon gamma Mm01168134_m1 
Il6 interleukin 6 Mm00446190_m1 
Lcn2  lipocalin 2 Mm01324470_m1  
Myc myelocytomatosis oncogene Mm00487804_m1 
Nov nephroblastoma overexpressed gene Mm00456855_m1 
Pcna proliferating cell nuclear antigen Mm00448100_g1 
PCNA proliferating cell nuclear antigen Mm00448100_g1 
Serpina12 serine (or cysteine) peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 12 
Mm01337213_m1 
Sperina1d serine (or cysteine) peptidase inhibitor, clade A, member 1D Mm00842094_mH 
TNF tumor necrosis factor Mm00443260_g1 
WISP1  WNT1 inducible signaling pathway protein 1 Mm00457574_m1 
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2.2 Methods 
2.2.1 Animal models 
 All experiments involving animals were carried out in accordance with the European 
Union Community Council guidelines. Experiments were either performed with C57BL/6NRj 
(Janvier Labs, France) or WISP1 knockout and wild type mice. Mice were fed ad libitum with 
Ssniff R/M-H, 10 mm standard diet (Ssniff, Soest, Germany). Experiments were approved by 
the German authorities. 
 
2.2.1.1 WISP1 knockout mice 
 Heterozygous WISP1 mice (B6;129S5-Wisp1tm1Lex/Orl) were purchased from 
Lexikon Pharmaceuticals (Lexko-1174). Heterozygous mice were bred in our animal facility to 
obtain homozygous WISP1 knockout and wild type mice. The gene knock down is 
accomplished by replacing Exon 2 of WISP1 by a construct containing a puromycin resistance 
cassette for clone selection, and a stop codon at its 3’ end to inhibit transcription of WISP1 
(Figure 16). The company reported no differences in bone marrow or blood leucocyte 
content in the WISP1 knockout mice. Therefore, the WISP1 knockout model can be used to 
assess the role of WISP1 in acute liver injury.  
 
 
Figure 16: Generation of WISP1 knockout mice. Exon 2 of WISP1 was replaced by a construct containing a 
puromycin resistant cassette and a stop codon at its 3` end region resulting in the inhibition of the transcription 
of WISP1. 
 
2.2.1.2 Genotyping of WISP1 mice 
 For the genotyping of WISP1 mice, Phire Animal Tissue Direct PCR Kit (Thermo 
Scientific) was used. Ear punch tissue from mice was collected in a microtube containing 
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25 µl Dilution buffer. To release the DNA from the tissue, 1.5 µl of DNARelease Additive were 
added and microtube was shortly flicked to ensure proper mixing. Afterwards, the samples 
were heated in a thermo shaker to 98°C for 25 min with gentle agitation followed by a short 
centrifugation step. To verify that the DNA release was successful, the DNA concentration 
was assessed using a spectrometer (NanoDrop2000). The reaction mixture for one PCR 
reaction is listed in table 17, and the PCR primers are specified in table 14. For the wild type 
mice, the PCR primers Alt6 and Alt9 were used; whereas, for the mutant samples Alt9 and 
Puro3A primer pairs were used at a concentration of 10 pmol/µl (Table 18). Finally, 1 µl of 
DNA was added to each wild type and mutant PCR. The reaction steps for PCR reaction are 
listed in table 19.  
 
Table 17: Master mix conditions for PCR reaction  
Phire Animal Tissue Direct PCR Kit  Volume per reaction [µl] 
Phire Animal Tissue PCR Buffer 10 
Primer forward 5 
Primer reverse 5 
Phire Hot Start II DNA Polymerase 0.4 
Final volume  20.4 + 1 µl of DNA 
 
Table 18: PCR primer set up for WT and mutant PCR reaction 
 Wild type PCR Mutant PCR 
Primers Alt6 + Alt9 Alt Puro3A + Alt9 
PCR product 363 bp 459 bp 
 
Table 19: Thermocycler program for PCR reaction (genotyping) 
Step Temperature [°C] Time [min] Note 
1 94 3  
2 94 0.5  
3 58 1  
4 72 1 Go to step 2, repeat 39 cycles 
5 72 10  
6 Pause at 4   
 
 Thereafter, the PCR product was mixed with 5 µl of Gel loading dye and shortly 
centrifuged before loading onto a 1.5 % Agarose gels (250 ml) containing 18 µl ethidium 
bromide. Gel electrophoresis was performed at 150 V for approximately 2h in 1 x TBE buffer 
(Table 12) using the BioRad Sub-Cell Model 192 system (BioRad). The PCR product in the 
agarose gel was detected using E-BOX C5 (Vilber Lourmat, Germany).  
 
2.2.2 CCl4-induced acute liver damage 
 To study the possible influence of WISP1 in acute liver damage, the model compound 
CCl4 was used. CCl4 was dissolved according to table 20 with olive oil and injected 
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intraperitoneally (i.p.) as described previously [14]. To induce different degrees of liver 
damage, various concentrations from a mild dose to a maximum dose of CCl4 were chosen. 
The control group received olive oil only as the vehicle control. All solutions were freshly 
prepared and mixed before injections.  
 
Table 20: Overview for preparation of different CCl4 solutions 
Dose [mg/kg] CCl4 [µl] Olive oil [µl] 
0 0 4000 
76 47.5 3952.5 
132.4 82.75 3917.25 
460 287.5 3712.5 
920 575 3425 
1600 1000 3000 
 
2.2.3 Paracetamol 
 For the second model of acute liver damage, the hepatotoxic compound paracetamol 
was selected. Mice were starved overnight and a single dose of 300 mg/kg paracetamol, 
dissolved in sterile PBS, was administered intraperitoneally. Therefore, a solution containing 
14.9 g/L paracetamol was first heated in a water bath at 60°C for 5-10 min to ensure 
solubilization. Thereafter, the solution was cooled to room temperature and sterile filtered. 
The final volume injected into the mice was 20.12 µl/g. The control mice were injected with 
sterile PBS as the vehicle control [49]. All solutions were prepared freshly before the 
injection.  
 
2.2.4 Collection of liver tissue and blood sampling  
 At the indicated time points, mice were anesthetized using a mixture of sedative 
Rompun 2 % (20 mg/kg) and anesthetic Ketamine (120 mg/kg) that was administered via i.p. 
The abdominal wall was opened carefully after checking that all reflexes were lost. 
Therefore, mice were fixed in a dorsal position on a grid. 
 
2.2.4.1 Blood sampling and plasma separation 
 To analyze the activity of liver enzymes, immunoassays for ALT and ELISA were 
performed using approximately 400 µl of blood that was collected by heart puncture with a 
26G cannula containing 25 µl EDTA (32 mg/ml). The blood was carefully transferred into a 
precooled sterile 1.5 ml tube and centrifuged for 10 min at 4°C and 13,000 rpm. Thereafter, 
the supernatant (about 200 µl plasma), was separated into two precooled and sterile 0.5 ml 
tubes. Plasma was stored at -80°C for further analyses.  
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2.2.4.1.1 Alanine Aminotransferase (ALT) Activity Assay Kit 
 Alanine transferase (ALT), also known as serum glutamic-pyruvic transaminase (SGPT) 
was measured colorimetrically using the Alanine Aminotransferase Activity Assay Kit (Sigma). 
The transfer of an amino group from alanine to α-ketoglutarate (α-KG) results in the 
generation of pyruvate, leading to a colorimetric product, which is proportional to the ALT 
enzymatic activity. One unit of ALT is defined as the amount of enzyme that generates 
1.0 µmole of pyruvate per min at 37°C. The assay was performed as described by 
manufacturer’s instructions. Plasma samples from the control mice were measured without 
dilution prior to assay. Samples with expected high values of ALT were diluted prior to 
performing the assay (1:100, 1:200, 1:400).  
 
2.2.4.1.2 ELISA  
 To determine the concentration of WISP1 in blood plasma and liver tissue samples, 
Quantikine® ELISA Mouse/Rat WISP-1/CCN4 immunoassay was used. Therefore, all plasma 
samples were diluted 1:10 with Calibrator Diluent RD6-31 (1:2) prior to measurement. Liver 
tissue samples were prepared from snap frozen tissue. First, the samples were transferred 
into a new 1.5 ml microtube to measure the weight of liver piece followed by homogenizing 
in 150 µl sterile PBS with a pestle. An equal volume of Cell lysis Buffer 2 was added and 
samples were shortly mixed to obtain a homogenous lysate. Afterwards, the samples were 
lysed at room temperature for 30 min with gentle agitation in a thermo shaker followed by a 
centrifugation step at 13.000 rpm at 4°C for 10 min. Supernatants were transferred into a 
new microtube and stored at -80°C for analysis. The assay was performed according to the 
manufacturer`s protocol. The concentration of WISP1 was calculated according to the 
standard curve and the dilution of the sample. For liver tissue samples the concentration 
was calculated for pg/mg of liver tissue.  
 
2.2.4.2 Collection of liver tissue samples 
 Directly after blood collection, the whole liver was carefully excised without 
destroying the liver capsule and briefly rinsed with sterile PBS. The left liver lobe was divided 
into two halves. One half was collected in Tissue-Loc™ HistoScreen™ Cassettes for paraffin 
embedding and the other half was cut into small pieces (0.5 cm2) and snap-frozen in liquid 
nitrogen (Figure 17). Snap frozen samples were stored at -80°C for further analyses. The 
right segment of median liver lobe was also collected for paraffin embedding. All other 
lobules were cut into smaller pieces and transferred into a 1.5 ml tube and snap-frozen.  
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Figure 17: Collection of liver tissue samples. The left liver lobe was divided into two halves. One half was 
collected for paraffin embedding and the other half was cut into pieces and snap frozen in liquid nitrogen. The 
median lobe was collected also for paraffin embedding. 
 
2.2.4 2.1 GSH measurement 
 For GSH measurement, about 20 mg of snap frozen tissue was weighed out directly in 
100 µl NEM buffer. The tissue was homogenized with a pestle and the resulting lysate was 
snap frozen in liquid nitrogen. Further analyses were done as previously described [163].  
 
2.2.4.3 Paraffin embedding of mouse liver tissue 
 For paraffin embedding, tissue samples were fixed in 4 % PFA for 2 days at 4°C. 
Afterwards, the samples were washed with sterile PBS for 2 days at 4°C followed by 
embedding in paraffin using Microm STP120 embedding automate (Microm, Walldorf, 
Germany). The program for embedding is listed in table 21. Thereafter, the tissue samples 
were submerged in paraffin using EC 350 – Modular tissue embedding center.  
 
Table 21: Embedding program for mouse liver tissue 
Step Treatment Time [min] 
1 70 % ethanol 30 
2 70 % ethanol 60 
3 90 % ethanol 30 
4 90 % ethanol 30 
5 99 % ethanol 30 
6 99 % ethanol 35 
7 99 % ethanol 60 
8 xylol 30 
9 xylol 35 
10 xylol 60 
11 Paraffin Histowax 80 
12 Paraffin Histowax 105 
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2.2.5 Liver slices for histological analyses 
 For histological analyses, the liver tissue was sliced in 5 µm sections using the HM 450 
Sliding Microtome followed by a fixation on glass microscopy slides at 60°C for 20 min. All 
tissue slides were stored at 4°C until further usage.  
 
2.2.5.1 Hematoxylin and eosin staining  
 For the first step, the tissue slides were incubated three times in Roti-Histol for tissue 
deparaffinization. Afterwards, the tissue on the slides were rehydrated in an ethanol 
gradient (95 %, 90 %, 80 %, 70 %) for 5 min each, followed by washing in distilled water for 5 
min. After rehydration, the tissue slides were incubated in Mayer´s Hemalum solution (1:5 
diluted with distilled water, filtered before use) for 5 min. Subsequently, the slides were 
washed for 15 min under running tap water followed by an incubation in 1 % Eosin solution 
for 3 min (1 % Eosin Y with 1 drop of acetic acid, filtered before use). Thereafter, the slides 
were washed in distilled water for 10 s and dehydrated in ethanol gradient for 5 s each (70 
%, 80 %, 90 %). Finally, the sections were incubated two times for 5 min in 100 % ethanol 
followed by 3 min incubation in Roti-Histol. Subsequently, the stained tissue was preserved 
with Entellan, allowed to dry overnight, and analyzed the next day using bright-field 
microscopy to quantify the dead cell areas. 
 
2.2.5.1.1 Quantification of dead cell areas 
 In order to quantify the dead cell areas of the H&E stained liver sections, 5 or 10 
images per mice (biological replicate) were acquired using Cell^M software. First, to 
precisely quantify the necrotic lesions, the entire area of the image was quantified. Then, the 
areas showing no hepatocyte nuclei were determined as dead cell areas (Figure 18). The % 
of the dead cell area was calculated according to the formula shown below. 
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𝐃𝐞𝐚𝐝 𝐜𝐞𝐥𝐥 𝐚𝐫𝐞𝐚 (%)  =  
𝐚𝐫𝐞𝐚 𝐨𝐟 𝐥𝐞𝐬𝐢𝐨𝐧 − 𝐜𝐞𝐧𝐭𝐫𝐚𝐥 𝐯𝐞𝐢𝐧
𝐭𝐨𝐭𝐚𝐥 𝐢𝐦𝐚𝐠𝐞 𝐚𝐫𝐞𝐚 − 𝐩𝐨𝐫𝐭𝐚𝐥 𝐯𝐞𝐢𝐧
 𝐱 𝟏𝟎𝟎 
 
Figure 18: Quantification of H&E staining. The dead cell areas were defined as areas where no hepatocyte 
nuclei are visible (red area). To precisely determine the dead cell areas, empty areas of the central veins (blue) 
and portal veins (yellow) were subtracted from the total area. 10 images from each biological replicate were 
quantified and calculated for the % of dead cell area as shown in the formula above. Scale bar 100 µm.  
 
2.2.5.2 Immunohistochemistry (Cyp2e1, Ly6G, CD45, F4/80) 
 For immunohistochemical staining, paraffin slides of 5 µm thickness were used. For 
deparaffinization, the slides were incubated four times in Roti-Histol for 5 min each. 
Afterwards, rehydration was performed using a descending ethanol gradient (100 %, 95 %, 
90 %, 80 %, 70 %) for 5 min each followed by an incubation in distilled water for 5 min. For 
antigen retrieval, the slides were boiled with citrate buffer (2.1 g/L in distilled water, pH 6.0) 
for 15 min followed by a cool down with fresh citrate buffer for 30 min. Afterwards, the 
slides were washed in distilled water for 5 min and blocked for endogenous peroxidase 
activity in 3 % H2O2 for 10 min at room temperature followed by another washing step in 
PBS for 3 min (three times). Thereafter, unspecific binding sites were blocked by incubation 
in 3 % BSA/1 % Tween80 in PBS for 1 hour at room temperature in a humidified chamber. 
Moreover, endogenous avidin and biotin were blocked using Avidin/Biotin blocking kit 
(Vector Laboratories) each for 15 min at room temperature. Next, the slides were incubated 
overnight with primary antibodies in 0.3 % BSA/ 1 % Tween80 according to table 22 in a 
humid chamber at 4°C.  
 
Table 22: Conditions for primary antibodies 
Antigen Origin Dilution DAB substrate Company Catalog No. 
Ly6G rat 1:250 4 min R&D Systems MAB1037 
CD45 rat 1:100 5 min BD Pharmingen 550539 
F4/80 rat 1:50 15 min BioRad MCA497 
Cyp2E1 rabbit 1:50 4 min LSBio LS-C313045 
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 After overnight incubation with the primary antibody, the slides were washed three 
times in PBS for 3 min followed by incubation with the secondary antibody as listed in table 
23. Antibody solution contained 30 µl serum and 15 µl secondary antibody in 2 ml PBS. After 
30 min incubation at room temperature, the slides were washed three times in PBS for 3 min 
each. In the next step, tissues were incubated in a mixture of 40 µl of reagent A and 40 µl of 
reagent B in 2 ml PBS for another 30 min incubation at room temperature. Afterwards, the 
slides were washed again as previously described and incubated in the dark with the DAB 
substrate (2 drops buffer stock solution, 2 drops hydrogen peroxidase, 4 drops DAB 
substrate in 5 ml PBS). DAB substrate incubation times are listed in table 22. Next, the slides 
were shortly washed under running tap water followed by incubation with Mayer´s 
Hemalum solution (1:5 diluted with distilled water, filtered before use) for 2 min. 
Subsequently, the slides were washed with running tap water for 6 min and rehydrated in an 
ethanol gradient for 1 min each (30 %, 50 %, 70 %, 80 %, 90 %, 95 %, 100 %), followed by an 
incubation in Roti-Histol for 3 min. Finally, the slides were fixed with Entellan and covered 
with a glass slide. 
 
Table 23: Kits for secondary antibodies 
Antibody Kit Enzyme Company Catalog No. 
Anti-Rat Vectastain ABC - HRP Vector PK4004 
Anti-Rabbit Vectastain ABC - HRP Vector PK6101 
     
 
2.2.5.3 Immunohistochemistry (WISP1) 
 For immunohistochemical staining, paraffin embedded liver sections of 5 µm 
thickness were used. After deparaffinization, for four times 5 min each using Roti-Histol, 
slides were rehydrated using a descending ethanol gradient (100 %, 95 %, 90 %, 80 %, 70 %, 
50 %, 30 %) for 5 min each. Afterwards, the slides were washed for 5 min in distilled water, 
followed by antigen retrieval with citrate buffer (2.1 g/L, pH 6.0) for 15 min. Subsequently, 
the slides were cooled down for 30 min using fresh citrate buffer. Thereafter, the slides were 
washed two times for 5 min in PBS, followed by H2O2 (3 %) blocking for 15 min at room 
temperature. Next, the slides were washed three times for 5 min each in PBS, followed by 
blocking of unspecific binding sites using 3 % BSA/ 0.1 % Tween20 for 2h. Moreover, 
endogenous avidin and biotin were blocked using Avidin/Biotin blocking kit (Vector 
Laboratories) each for 15 min at room temperature. Afterwards, the slides were incubated 
overnight with a primary antibody diluted in 0.3 % BSA/ 0.1 % Tween20 (Table 24). On the 
next day, the slides were washed in PBS three times for 5 min each, followed by the 
incubation step with the secondary antibody as listed in table 25. The antibody solution 
contained 30 µl serum and 15 µl secondary antibody in 2 ml PBS. After 1h incubation at 
room temperature, the slides were washed three times in PBS for 5 min each. In the next 
step, 40 µl of reagent A and 40 µl of reagent B were mixed in 2 ml PBS and used for another 
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30 min incubation at room temperature. Afterwards, the slides were washed again as 
previously described and incubated in the dark with DAB substrate (2 drops buffer stock 
solution, 2 drops hydrogen peroxidase, 4 drops DAB substrate in 5 ml PBS). DAB substrate 
incubation times are listed in table 24. Subsequently, the slides were washed using running 
tap water for 10 min, followed by incubation with Mayer´s Hemalum solution (1:5 diluted 
with distilled water, filtered before use) for 90 sec. The slides were then washed using 
running tap water for 10 min, followed by rehydration in an ethanol gradient (70 %, 90 %, 95 
%, 100 %) for 5 min each. Finally, the slides were incubated in Roti-Histol for 3 min and fixed 
with Entellan and covered with a glass slide. 
 
Table 24: Conditions for primary antibody 
Organ DAB substrate Dilution Antigen origin Company Catalog No. 
Brain 1 min 1:100 WISP1/ CCN4 sheep R&D Systems AF1680 
Kidney 1 min 1:100 WISP1/ CCN4 sheep R&D Systems AF1680 
Spleen 1 min 1:100 WISP1/ CCN4 sheep R&D Systems AF1680 
Lung 1 min 1:100 WISP1/ CCN4 sheep R&D Systems AF1680 
Heart 2 min 1:100 WISP1/ CCN4 sheep R&D Systems AF1680 
Intestine 1 min 1:100 WISP1/ CCN4 sheep R&D Systems AF1680 
Muscle 2 min 1:100 WISP1/ CCN4 sheep R&D Systems AF1680 
Liver 1 min 1:100 WISP1/ CCN4 sheep R&D Systems AF1680 
 
Table 25: Kits for secondary antibody 
Antibody Kit Enzym Company Catalog No. 
Anti-Sheep Vectastain ABC - HRP Vector PK4006 
 
2.2.5.4 TUNEL staining 
 TUNEL staining was performed using the DeadEnd™ Colorimetric TUNEL System 
(Promega). The assay was conducted following the manufacturer’s instructions with the 
exception of using 3 % H2O2 instead of 0.3 %. After DAB incubation, the slides were rinsed 
several times with water followed by an incubation with Mayer´s Hemalum solution (1:5 
diluted with distilled water, filtered before use) for 90 sec. Afterwards, the slides were 
washed under running tap water for 10 min and rehydrated in ethanol gradient for 1 min 
each (30 %, 50 %, 70 %, 80 %, 90 %, 100 %). Finally, the slides were incubated in Roti-Histol 
for 5 min and mounted with Entellan.  
 
2.2.5.5 High mobility group box 1 protein staining (HMGB1) 
 High mobility group box 1 protein staining was performed at the university hospital 
Jena (Prof. Dr. Uta Dahmen, University hospital Jena). 
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2.2.6 RNA isolation from liver tissue and primary mouse hepatocytes 
 RNA was isolated from mouse liver tissue, primary mouse hepatocytes and NPCs 
using QIAzol Lysis Reagent and phenol/chloroform method according to the manufacturer´s 
description.  
a) Snap frozen liver tissue: Sections of about 0.5 cm2 were homogenized with a plastic 
pestle in a 1.5 ml tube using 1 ml of QIAzol while kept on ice. 
b) Freshly isolated hepatocytes/ NPCs: Volume needed for 1 million cells was 
calculated, transferred into a new 1.5 ml tube and centrifuged at 13,000 rpm for 10 
min at 4°C. Subsequently, the supernatant was removed and cells were lysed using 
1ml QIAzol.  
 After the homogenization step, the samples were sonicated on ice for 30 sec (5 sec 
pulse, 2 sec break). Thereafter, 200 µl of chloroform was added and samples were strongly 
shaken for 15 sec. After 2-3 min incubation at room temperature, a first phase separation 
was seen. After the first centrifugation step at 4°C for 15 min at 12,000 rpm, the upper 
aqueous phase was transferred into a new RNase free 1.5 ml tube and RNA was precipitated 
using 500 µl of isopropanol. Samples were incubated at room temperature for 10 min, 
followed by a centrifugation step at 4°C for 15 min at 12,000 rpm. Afterwards, the 
supernatant was removed and RNA pellet was resuspended in 1 ml of 100 % ethanol and 
centrifuged at 7,500 rpm at 4°C for 5 min. The supernatant was discarded and RNA pellet 
was resuspended with 1 ml of 75 % ethanol and centrifuged for 5min at 4°C and 7,500 rpm. 
Thereafter, the supernatant was removed and RNA pellet was air-dried under fume hood for 
30 min. Finally, the RNA pellet was dissolved in RNase-free water depending on the pellet 
size (liver tissue: 100-150 µl, hepatocytes: 10-30 µl). RNA concentration and integrity was 
determined spectrophotometrically using the NanoDrop 2000. Extracted RNA was stored at -
80°C until further usage. 
 
2.2.6.1 cDNA synthesis 
 For complementary cDNA synthesis, 2 µg of RNA were transcribed using High 
Capacity cDNA reverse transcription kit. The reaction mixture for cDNA synthesis is listed in 
table 26.  
 
Table 26: Composition of master mix for cDNA synthesis 
Compound Volume per reaction 
10x RT-Buffer  2 μl 
25x dNTP  0.8 μl 
Random primer  2 μl 
Reverse transcriptase  1 μl 
H2O  4.2 μl 
Total volume 1  10 μl 
RNA  2 μg 
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DEPC water up to  10 μl 
Total volume 2  10 μl 
Final total volume  20 μl 
 PCR conditions were programmed as follows: 
Table 27: Program for RT-PCR 
Step Temperature Time 
Incubation 25°C 10 min 
Reverse Transcription 37°C 120 min 
Inactivation 85°C 5 sec 
 4°C hold 
 
 The resulting cDNA was dissolved to a final concentration of 10 ng/µl with DEPC 
treated water and stored at -20°C.  
 
2.2.6.2 Quantitative Real Time PCR (qRT-PCR) 
 The quantitative real time PCR was performed by using Taq-Man-PCR technology 
with a 7500 Real-Time PCR System using TaqMan® Universal Master Mix II, with UNG. 
Reagents were purchased from Applied Biosystems and Taqman probes are listed in table 
16. The composition of master mix reaction for qRT-PCR is shown in table 28.  
 
Table 28: Master mix composition for qRT-PCR 
Compound Volume per sample 
Universal PCR Master Mix  10 μl 
DEPC treated H2O  6.5 μl 
Taqman probe  1 μl 
25 ng cDNA  2.5 μl 
Final volume  20 μl 
 
 Samples were measured in technical duplicates. For negative control, DEPC water 
instead of cDNA was used. The conditions for qRT-PCR are shown in table 29. 
 
Table 29: Conditions for qRT-PCR  
Stage  Temperature Time Repetitions 
1 50 °C 2 min 1 
2 95 °C 10 min 1 
3 
94 °C 
60 °C 
72 °C 
15 sec 
30 sec 
35 sec 
40 
4 
95 °C 
60 °C 
95 °C 
60 °C 
15 sec 
20 sec 
15 sec 
15 sec 
1 
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PCR products were analyzed using the 7500 Real-Time PCR System software. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was used as the 
endogenous control for each sample. The expression levels in treated mouse liver were 
normalized to mouse control liver tissue. For calculation the comparative threshold method 
(ΔΔCt method) was used [164]. The relative expression was calculated according to the 
following steps. 
1. ΔCt1 = Ct Gene of interest (GOI) – Ct House keeper gene (HKG) 
2. ΔCt2 = Ct GOI of control samples – Ct HKG of control samples  
3. ΔΔCt = ΔCt1 – ΔCt2  
4. Calculation of 2-ΔΔCt 
 
2.2.7 Analysis of Xbp1 splicing by PCR 
 Taq DNA Polymerase kit of 5-Prime (Hamburg, Germany) with primers from Eurofins 
(Ebersberg, Germany) were used to perform PCR reaction in a T-gradient thermocycler from 
Biometra. The reaction was conducted as depicted in the table 30 below. The final PCR 
product was mixed with 5 µl Ficoll loading buffer (Table 13), shortly spun down and loaded 
onto a 1.5 % Agarose gel. Gel electrophoresis was performed at 150 V for approximately 2h 
in 1 x TBE buffer (Table 12). The electrophoresis results were detected using E-BOX CX5 
(Vilber Lourmat, Eberhardzell, Germany). 
 
Table 30: Thermocycler program for Xbp1 PCR reaction  
Step Temperature Time Go back to step Number of cycle repetitions 
1 94 2 min   
2 94 30 s   
3 58 1 min   
4 72 1 min   
5 72 10 min 2 39 
6 4  -  
 
2.2.8 Affymetrix gene array analysis 
 Whole genome gene array analysis from WISP1 knockout and wild type mice was 
performed using Affymetrix GenChip® Mouse Genome 430 2.0 arrays. The following time 
points from 460 mg/kg CCl4 treated WISP1 knockout and wild type mice were chosen: 
control (olive oil), 8h, 12h, D1 and D3. RNA from 5 mice per condition was isolated as 
described above. RNA concentration and integrity were determined spectrophotometrically 
using Nanodrop 2000.  
 To analyze the RNA expression, 5 µg of RNA were transcribed into cDNA by oligo dT 
primers, and reverse transcribed to biotinylated cRNA with the GeneChip 3’ IVT Express Kit. 
IVT product was cleaned up using CHROMA SPIN-100 columns and quantified 
spectrophometrically. Subsequently, cRNA was fragmented using Affymetrix’s protocol. 
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Labeled and fragmented cRNA was hybridized to Mouse Genome 430 2.0 Affymetrix 
GeneChips for 16h at 45°C according to the manufacturer’s instructions. Afterwards, the 
microarrays were washed using an Affymetrix fluidics station 450 and stained initially with 
streptavidin-phycoerytherin. For each sample, the signal was further enhanced by incubation 
with biotinylated goat anti-streptavidin followed by a second incubation with streptavidin-
phycoerytherin, and a second round of intensities were measured. Microarrays were 
scanned using Affymetrix Gene-Chip Scanner-3000-7G controlled by GCOS software.  
 
2.2.8.1 Microarray processing and statistical analysis 
 Biostatistical analysis was performed at Leibniz Institute for Natural Product Research 
and Infection Biology Hans-Knöll-Institute (HKI) in Jena, Germany. Affymetrix gene array data 
were pre-processed using ‘affyPLM’ packages [165] of the Bioconductor Software [166]. To 
obtain genes with the most evidence of differential expression, the pre-processed dataset 
was analyzed using linear models with least squares regression and empirical Bayes 
moderated t-statistics of the LIMMA (Linear Models for Microarray Data) package [167] of 
Bioconductor software [166]. Benjamini Hochberg false discovery rate correction (FDR) was 
used to adjust the obtain p-values for multiple comparisons [168]. Data obtained from 
healthy control liver tissue were used as a reference. The custom chip definition file from 
Brainarray [169] based on Unigene ID’s was used to annotate the microarrays. Two selection 
criteria were chosen as significance level to detect differentially expressed genes (DEGs): 
first was p-value < 0.05 and second was an absolute fold change > 2. Processing and 
visualization (Principal Component Analysis) of data were performed using MATLAB tools 
(The MathWorks Inc., Natick, MA). 
 
2.2.8.2 Fuzzy clustering of gene expression profiles 
 The time-profiles of differentially expressed genes in wild type and WISP1 knockout 
mice were scaled between their respective absolute temporal extreme values to focus on 
subsequent cluster analysis on the qualitative behavior of the expression profiles. The time 
series were clustered using fuzzy c-means [170] (fuzzy exponent = 1.5; maximum number of 
iteration = 200; minimum cost function improvement = 10-10). The optimum number N of 
cluster was estimated by repeated calculation (number of iterations = 100) of the fuzzy 
cluster index ‘Separation Index’. 
 
2.2.8.3 Gene ontology (GO) and KEGG Pathway analyses 
 Genes which show change ratios greater (or less) than 2-fold in the triplicate arrays at 
any one of the timepoints have been considered as up or down-regulated and subjected to 
gene ontology (GO) and pathway analysis. Differentially regulated genes were categorized 
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using the manually curated Gene Ontology of the Biobase Knowledge Library (BKL) of the 
ExPlain™ webservice (BioBase GmbH, Wolfenbüttel, Germany). 
 
2.2.9 Protein extraction and western blot analyses 
2.2.9.1 Protein isolation from liver tissue and cell culture 
 Protein extraction was performed as follows: 
a) Snap frozen liver tissue: Sections of about 0.5 cm2 were homogenized with a plastic 
pestle in a 1.5 ml tube using 0.5 ml of ice cold RIPA while kept on ice. 
b) Primary hepatocytes in vitro culture: Culture plate was placed on ice and culture 
medium was removed. Subsequently, the cells were lysed with 250 µl of RIPA buffer 
using a cell scraper and transferred into a pre-cooled 1.5 ml tube. 
 Thereafter, the samples were sonicated for 30 sec (5 sec pulse, 2 sec break) while 
kept on ice. The homogenates were incubated for 20 min on ice at 4°C and centrifuged for 
10 min at 13,000 rpm at 4°C. Solubilized proteins in the supernatant were transferred into a 
pre-cooled 1.5 ml tube and stored at -80°C for further analyses. 
 
2.2.9.2 Protein quantification (BCA) 
 For protein quantification, bicinchoninic acid (BCA) assay was used. Depending on the 
estimated protein concentration 2.5 µl up to 10 µl of the sample were used together with 
appropriate amount of reagents recommended by the manufacturer`s protocol. The samples 
were heated to 60°C for 30 min and afterwards measured to determine the absorbance. The 
mean value of three independent measurements was used to determine the protein 
concentration related to protein standard curve and used dilution of the samples.  
 
2.2.9.3 SDS-page and western blot  
 For SDS-PAGE, 30 to 50 µg of protein lysate were adjusted to the volume of 30 µl 
with distilled water including 6 µl of loading buffer (5x). The Samples were denatured at 95°C 
for 5 min and shortly centrifuged at 13,000 rpm. 10 % SDS-PAGE gel with 1.5 mm x 10 wells 
or 1.5 mm x 15 wells were used. All components for a 10 % SDS-PAGE gel are listed in table 
31. In the first two lanes, Precision Plus protein standard (4 µl) and MagicMark TM XP 
Western Protein Standard (2 µl) were loaded onto the gel to estimate the molecular weight 
of separated proteins in the samples. After loading of the samples, the gel was run using the 
Bio-Rad Mini PROTEAN Tetra System. Biometra Standard Power Pack P25 was used to 
perform the gel electrophoresis for 3h at constant voltage of 25 mA. 
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Table 31: Components of 10 % SDS gel 
Separation gel (10 %) Stacking gel 
1 Gel  1 Gel  
H2O  3.2 ml H2O  2.4 ml  
Acrylamide  2.64 ml Acrylamide  0.5 ml  
Separation buffer  2 ml Stacking buffer  0.4 ml  
10 % SDS  80 μl 10 % SDS  32.5 μl  
TEMED  3.2 μl TEMED  2.5 μl  
10 % APS  80 μl 10 % APS  50 μl  
 
2.2.9.4 Semi-dry blotting 
 For semi-dry protein transfer, Fastblot B44 blotting system with a 5 x 8 cm size gel-
membrane sandwich was used. The PVDF membrane was activated in methanol, 4 Whatman 
paper were saturated with cathode buffer and 12 Whatman papers were saturated with 
anode buffer. The correct buildup can be seen in table 32. Semi-dry blotting was performed 
for 40 min at a constant current of 250 mA/gel- membrane sandwich. Thereafter, the 
membranes were washed with distilled water and stained with Ponseau S for a few seconds 
to verify that the transfer was successful. Finally, Ponseau S was removed by washing the 
membranes in TBS-T solution for 5 min.  
 
Table 32: Western blot set up for semi-dry blotting 
Top: cathode 
4 Whatman papers 
Gel 
PVDF membrane 
12 Whatman papers 
Bottom: anode 
 
2.2.9.5 Protein immunodetection and chemiluminescence  
 For immunodetection of proteins, membranes were blocked with 5 % BSA or 5 % milk 
in TBS-T buffer for 1h at room temperature, followed by an overnight incubation at 4°C with 
primary antibody (Table 9) diluted either in 5 % BSA or 5 % milk solution. The next day, the 
membranes were washed three times for 10 min in TBS-T at room temperature. Afterwards, 
horseradish peroxidase-labeled secondary antibody was added in a 5 % TBS-T or 5 % milk 
solution for appropriate time and concentration at room temperature as listed in table 9. 
Thereafter, the membranes are washed again in TBS-T three times for 10 min at room 
temperature. Protein detection was performed by chemiluminescence using 5 ml ECL 
solution (Table 11) in a Fusion-FX7 imager (Vilber Lourmat) equipped with a CCD camera. 
Next, the membranes were incubated for 30 min with stripping buffer at room temperature 
to remove the probed antibodies off the membrane followed by a washing step with TBS-T 
for 5 min. For detection of further proteins, membranes were blocked again for 30 min with 
5 % BSA or 5 % milk in TBS-T at room temperature, followed by incubation with a second 
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primary antibody or loading control as described in table 10. Quantification was performed 
using the Bio-1D (Vilber Lourmat, Germany) software.  
 
2.2.10 Isolation of primary mouse hepatocytes and culturing method 
 To obtain primary mouse hepatocytes, a two-step perfusion from WISP1 knockout 
and wild type mice (8-12 weeks old) was performed as previously described [24]. For 
anesthesia, the mice received i.p. injection containing 2 % Rompun (20 mg/kg) and Ketamine 
(120 mg/kg). The abdominal wall was opened carefully after checking that all reflexes were 
lost. Therefore, mice were fixed in a dorsal position on a grid under a heating lamp. The 
inferior vena cava was carefully exposed followed by inserting a 24G cannula for perfusion 
with EDTA buffer at 37°C for 15 min with a rate flow of 15 ml/min. At this step, the liver 
colour immediately became pale, blood volume and Ca2+-dependent adhesion factors were 
removed. Afterwards, the perfusion was continued with collagenase buffer, warmed up to 
37°C, for an additional 15 min at the same rate flow. During this step of perfusion, the 
extracellular matrix is digested and depending on the collagenase activity this step can last 5-
15 min. Thereafter, the liver was excised completely and transferred onto a petri dish 
containing suspension buffer. The liver capsule was carefully opened under a sterile hood 
using a forceps to release the liver cells in the suspension buffer. The cell suspension was 
filtered through a 100 µm cell strainer and centrifuged for 5 min at 4°C and 50 rpm. The 
supernatant contained the non-parenchymal cells and the pellet contained the larger and 
heavier hepatocytes. The pellet was resuspended with 10 ml of suspension buffer. An aliquot 
of the cell suspension was diluted 1:5 with suspension buffer and further mixed with 0.4 % 
trypan blue solution at a ratio of 1:1 for cell counting in a Neubauer chamber 
hemocytometer. Dead cells, which stained blue were counted together with unstained living 
cells in all four corner squares. The average of viable cells was multiplied by 1x105 to achieve 
the cell number per milliliter of cell suspension. The viability varied from 90-95 % with total 
cell yield of 5-7 x 106 cells per ml. 
 For collection of fresh NPCs, the supernatant was transferred to a new 50 ml falcon 
tube. After centrifugation at 400 rpm for 10 min at 4°C, the supernatant was discarded and 
cells were washed using 25 ml of suspension buffer. After a second centrifugation step at 
400 rpm for 10 min at 4°C, cells were resuspended using 1 ml suspension buffer and counted 
to assess the viability as described above.  
 
2.2.11 In vitro culture of hepatocytes 
 Primary mouse hepatocytes were cultured in 6-well pates from Sarstedt. During all 
experiments, cells were maintained at 37°C and 5% CO2.  
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2.2.11.1 Collagen monolayer confluent (CM) 
 For the cultivation of primary mouse hepatocytes on collagen monolayer, 10 mg of 
rat-tail collagen was dissolved in 40 ml of 0.2 % acetic acid resulting in a stock solution of 
250 µg/ml. The 6-well plates were coated with the stock solution and allowed to dry 
overnight under the sterile bench. On the next day, the plates were shortly washed twice 
with sterile PBS, and Williams E medium with 10 % Sera Plus was added to the wells (Table 
6). Thereafter, the appropriate cell number (Table 33) was seeded and plates were 
incubated for 3h in the incubator. The plates were then washed for three times with 
medium to remove unattached cells followed by the addition of a final volume of 2 ml 
Williams E medium.  
 
Table 33: Conditions for collagen monolayer and collagen sandwich culture system 
Culture system Amount of cells [x106] Medium [ml/well] 
Collagen monolayer (CM) 1 2 
Collagen sandwich (CS) 0.85 2 
 
2.2.11.2 Collagen sandwich (CS) 
 For cultivation of primary mouse hepatocytes in collagen sandwich system, 10 mg of 
rat-tail collagen was dissolved in 9 ml of 0.2 % acetic acid for at least 3h to obtain a final 
concentration of 1.1 mg/ml. Afterwards, the collagen was mixed with 10x DMEM (ratio 9:1) 
resulting in a yellow solution (pH indicator): By slowly adding 1 M NaOH on ice, the solution 
was neutralized until the colour changed from yellow to fuchsia. Finally, 350 µl of collagen 
solution was added to each well and properly distributed to obtain an even first layer 
followed by an incubation for 45 min at 37°C to allow polymerization. Next, full media (Table 
6) was added to wells and an appropriate cell amount was seeded (Table 33). Cells were 
allowed to attach for 3h in an incubator. Subsequently, the unattached cells were removed 
by washing the plates three times with cell culture media and the second collagen layer was 
added to the cells, as described above. After 45 min polymerization, Williams E medium with 
all additives (Table 6) was added.  
 
2.2.11.3 Stimulation of primary hepatocytes with TNFα or TGFβ 
 Stimulation of primary WISP1 knockout and wild type hepatoyctes was performed on 
D1 in culture using collagen monolayer (CM) configuration. Recombinant human TNFα 
protein (10 µg) was reconstituted in sterile PBS containing 0.1 % bovine serum albumin to a 
final concentration of 10 ng/µl. Recombinant human TGFβ protein (2 µg) was reconstituted 
in sterile 4 mM HCl containing 0.1 % bovine serum albumin to a final concentration of 10 
ng/µl. Reconstituted proteins were stored in 20-50 µl aliquots at -20°C. On the day of 
stimulation, a stock solution (10 ng/ml) in Williams E medium plus additives (Table 6) was 
prepared for each cytokine containing 0.1 µg/ml Actinomycin D. The stock solution was used 
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to prepare further dilutions of 1 ng/ml, 2.5 ng/ml, 5 ng/ml and 7.5 ng/ml of the cytokines. 
Williams E medium was used as the control condition. Before stimulation, cells were washed 
with Williams E medium three times to remove dead cells followed by adding 2 ml per well 
of prepared cytokine solutions. TNFα stimulated cells were incubated for 8h and TGFβ 
stimulated hepatocytes were incubated for 24h at 37°C. Subsequently, representative 
images were taken from each condition and protein samples were collected as described 
previously (Chapter 2.2.9.1). In order to study time resolved effects, the highest TNFα 
concentration (10 ng/ml) was chosen to stimulate primary hepatocytes for 30 min, 1h, 2h, 
4h, 6h, 8h, 10h and 24h. At the indicated time points, representative images were taken and 
protein samples were collected as described above.  
 
2.2.11.3.1 Quantification of apoptotic hepatocytes 
 To quantify apoptotic hepatocytes after cytokine stimulation, images were taken 
using a 20x magnification with bright field microscope. Five images per condition were 
counted for apoptotic and vital hepatocytes using ImageJ Cell Counter (Figure 19).  
 
 
Figure 19: Example for counting vital and apoptotic primary hepatocytes in collagen monolayer 
configuration. On the left side, representative picture of cytokine-stimulated primary hepatocytes is shown. 
Vital hepatocytes were clearly distinguished from apoptotic cells by showing typical cuboidal morphology and 
multiple nuclei. Apoptotic cells a showed different morphology caused by blebbing and no nuclei were visible. 
On the right side, marker 1 in red depicted all vital hepatocytes and marker 2 in white identified cells, which 
were counted as apoptotic hepatocytes.  
 
 The % of apoptotic cells was calculated as shown below:  
 
% 𝐨𝐟 𝐚𝐩𝐨𝐩𝐭𝐨𝐭𝐢𝐜 𝐜𝐞𝐥𝐥𝐬 =  
𝐧𝐮𝐦𝐛𝐞𝐫 𝐨𝐟 𝐚𝐩𝐨𝐩𝐭𝐨𝐭𝐢𝐜 𝐜𝐞𝐥𝐥𝐬
𝐭𝐨𝐭𝐚𝐥 𝐚𝐦𝐨𝐮𝐧𝐭 𝐨𝐟 𝐜𝐞𝐥𝐥𝐬
 𝐱 𝟏𝟎𝟎 
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2.2.11.4 Stimulation of primary hepatocytes with paracetamol 
 The first step was to prepare a stock solution of 10 mM paracetamol dissolved in 
Williams E medium (Table 6). The solution was incubated for approximately 15 min in a 
water bath to ensure proper solubilization. Afterwards, the stock solution was sterile filtered 
and used to prepare further solutions containing 7.5 mM, 5 mM, 2.5 mM and 1 mM 
paracetamol in Williams E medium. For stimulation with paracetamol, the collagen sandwich 
(CS) configuration was used. For the first approach, hepatocytes were stimulated after 3h of 
attachment and incubated for 24h. For the second approach, hepatocytes were stimulated 
at D1 in culture and incubated for 24h.  
 
2.2.11.4.1 Propidium idodide staining 
 In order to quantify dead cells after paracetamol treatment, propidium iodide 
staining was performed. The propidium iodide was diluted 1:500 in Williams E medium 
directly before usage. Medium was removed and 2 ml of propidium iodide solution was 
added to the cells in the dark. After incubation for 15 min at 37°C, cells were washed three 
times with sterile PBS followed by adding Williams E medium. Finally images were acquired 
using Nikon Eclipse TS100 microscope. 
 
2.2.11.4.2 Quantification of propidium iodide staining 
 To quantify the propidium iodide staining, 10 images were taken per condition. 
Propidium iodide stained cells were counted as dead and cells without a fluorescence signal 
as living cells (Figure 20) using ImageJ Cell Counter.  
 
 
Figure 20: Example for counting dead cells after paracetamol stimulation using collagen sandwich 
configuration. On the left side, representative image of hepatocytes stained with propidium iodide is shown. 
Dead cells showed red stained nuclei and can be clearly distinguished from living cells. On the right side, orange 
marker number 1 shows counted cells as alive and green marker number 2 exhibits counted cells as dead. 
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 The % of dead cells was calculated as shown below:  
 
% 𝐨𝐟 𝐝𝐞𝐚𝐝 𝐜𝐞𝐥𝐥𝐬 =  
𝐍𝐮𝐦𝐛𝐞𝐫 𝐨𝐟 𝐝𝐞𝐚𝐝 𝐜𝐞𝐥𝐥𝐬
𝐓𝐨𝐭𝐚𝐥 𝐚𝐦𝐨𝐮𝐧𝐭 𝐨𝐟 𝐜𝐞𝐥𝐥𝐬
 𝐱 𝟏𝟎𝟎 
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3 RESULTS 
 
3.1 WISP1 expression increases after induction of liver damage in 
C57Bl/6N mice 
 In a previous transcriptomic study of acute liver injury with CCl4 in C57Bl/6N mice 
[171], we observed an induction of Wnt-induced secreted protein-1 (WISP1) expression 
during the first 24h after CCl4 administration. To validate this result and to obtain a more 
precise overview of the time course of WISP1 induction, levels of WISP1 RNA were 
quantified by qRT-PCR. Therefore, livers from 3 independent C57Bl/6N mice treated with 1.6 
g/kg CCl4 intraperitoneally for 8h, 12h, D1, D2 and D4 were used. The results confirmed gene 
array data showing an increase in WISP1 expression after 8h, which was further increased 
until D1 and returned back to control levels again at D2 (Figure 21).  
 
 
Figure 21: Real time qPCR analysis of WISP1 mRNA in mouse liver tissue at the indicated time points after 
1.6 g/kg CCl4 administration intraperitoneal. The results show an increase of WISP1 expression with a 
maximum of about 40-fold at D1 after CCl4 administration. WISP1 RNA turned back to control levels at D2. Data 
represent mean values and standard deviations of three independent biological replicates per time point. 
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3.2 WISP1 expression in control (healthy liver tissue) is mainly derived 
by non-parenchymal cells 
 The previous qRT-PCR result showed an increase in WISP1 expression after 
administration of CCl4 in liver tissue homogenates. To determine the cellular source of 
WISP1 expression (i.e. hepatocytes or non-parenchymal cells (NPCs)) in a normal liver, 
C57Bl/6N mice were treated intraperitoneally with oil as the control vehicle (healthy liver 
tissue). After 24h, the livers were perfused and RNA from freshly isolated hepatocytes and 
non-parenchymal cells was isolated. WISP1 expression levels were determined in each cell 
population using healthy liver tissue extracts as the reference. Quantitative RT-PCR analysis 
revealed low WISP1 expression in primary hepatocytes, whereas WISP1 expression was 
approximately 20-fold higher in NPCs compared to liver homogenates (Figure 22).  
 
 
Figure 22: Quantitative RT-PCR of WISP1 expression show highest levels in non-parenchymal cells. WISP1 
expression is higher in NPCs (20-fold) compared to hepatocytes (0.05-fold) in healthy livers. Liver homogenates 
(vehicle control) were used as the reference. Data represent mean of three biological replicates ± S.E.  
 
 The results revealed that under control conditions, WISP1 expression is higher in 
NPCs compared to hepatocytes. However, the absolute contribution to WISP expression is 
rather low, because NPCs comprise only 20% of the liver mass compared to 80% by the 
hepatocytes.  
 
3.2.1 WISP1 expression is induced in hepatocytes and NPCs upon CCl4 
administration 
 To investigate WISP1 expression in hepatocytes and NPCs after administration of 
CCl4, C57Bl/6N mice were treated intraperitoneally with either olive oil as control vehicle or 
1.6 g/kg CCl4. After 24h, hepatocytes and non-parenchymal cells were isolated and WISP1 
RNA was quantified by qRT-PCR. The corresponding control cell populations were used as 
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references. The results showed approximately 40-fold induction of WISP1 RNA in 
hepatocytes compared to a 3-fold induction in non-parenchymal cells (Figure 23). 
 
 
 
Figure 23: Real time qPCR analysis of WISP1 expression in isolated primary mouse hepatocytes versus non-
parenchymal cells. Mice were pretreated with either oilve oil as control vehicle or 1.6 g/kg CCl4. The results 
indicate stronger induction of WISP1 RNA in hepatocytes compared to in NPCs. Data represent mean values ± 
S.E. of three independent biological replicates per time point. 
 
 The results indicated an induction of WISP1 in both hepatocytes and NPCs. However, 
the induction was much stronger in hepatocytes compared to NPCs after administration of 
1.6 g/kg CCl4. This suggests that WISP1 expression is mainly derived from hepatocytes after 
administration of CCl4. Moreover, hepatocytes make up the main cell type (about 80%) in 
the liver and the NPCs compose only 20% of liver mass, which further supports our 
hypothesis.  
 
3.3 WISP1 expression is induced in human liver diseases 
 The previous results showed a strong induction of WISP1 in a mouse model of acute 
liver injury. In a next step, an analysis of WISP1 mRNA was performed in liver biopsies from 
human donors to establish whether WISP1 expression is also altered in the course of human 
liver disease. RNA was received from human liver tissue of 132 patients (kindly donated by 
Prof. Dr. Thomas Weiß, University hospital Regensburg). Quantitative RT-PCR was performed 
to analyse WISP1 expression. The expression of WISP1 was compared to control (healthy) 
samples and further clustered into three groups according to the type of liver injury - from 
fibrosis to hepatocellular carcinoma (HCC). The analysis revealed a significant induction of 
            ctrl                                 1.6 g/kg CCl4 
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WISP1 expression in the group of cirrhosis and HCC in comparison to the control group 
(Figure 24).  
 
 
Figure 24: Quantitative RT-PCR of WISP1 expression in human liver disease tissue. Results revealed a 
significant induction of WISP1 expression in the group of cirrhosis and HCC. The data include 24 samples in the 
control group; 24 samples in the group of fibrosis; 53 samples in the group of cirrhosis and 30 samples in the 
group of HCC. Error bars indicate mean ± S.E., ns not significant, ****P<0.0001, **P<0.01 to control group, 
unpaired t-test. 
 
Taken together, the increased expression in the different disease conditions suggests that 
WISP1 may be also important in human liver disease.  
 
3.4 Establishment of a WISP1 knockout mouse line  
 The previous results showed an upregulation of WISP1 during acute liver injury 
induced by CCl4 as well as in human liver disease tissue. To investigate whether WISP1 has 
an influence during acute liver injury, a knockout mouse line was established.  
 All WISP1 knockout and wild type mice were examined for the correct genotype using 
Phire Animal Tissue Direct PCR Kit (Thermo Scientific), as described in the material and 
methods section (Chapter 2.2.1.1). Gel electrophoresis showed clear bands for both PCR 
products. The first lane shows a PCR product at 459 bp in the mutant PCR, which indicates 
that this mouse was a homozygous WISP1 knockout (Figure 25 b). A 363 bp PCR product 
indicative of the wild type mouse is observed in the second lane of the wild type PCR blot. 
Finally, the third lane showed both PCR products, concluding that this mouse was a 
heterozygote carrying the wild type allele and the mutant allele, which contains the 
puromycin cassette and a stop codon to inhibit the transcription of WISP1.  
3 RESULTS 
71 
 
Figure 25: Establishment of WISP1 knockout mouse line a) Generation of WISP1 knockout mice. Exon 2 of 
WISP1 was replaced by a construct containing a puromycin resistant cassette and a stop codon in its 3` end 
region resulting in the inhibition of the transcription of WISP1. b) Genotyping of WISP1 mice. The first lane 
corresponds to knockout, second to wild type and third to heterozygous genotypes respectively. The mutant 
PCR product can be detected at 459 bp and the wild type PCR product at 363 bp. Images are representative for 
all PCR analyses done.  
 
3.4.1 Validation of WISP1 expression in different organs of mice confirmed 
successful knockout of WISP1 
 The next step was to investigate WISP1 expression in various organs in both the wild 
type and WISP1 knockout mice. For this reason, RNA was isolated from liver, brain, kidney, 
spleen, heart, lung, and intestine as well as muscle tissue. WISP1 expression was found to be 
highest in lung tissue (about 12-fold) followed by brain (about 4-fold), spleen (about 3-fold) 
and intestine (2-fold). WISP1 RNA was comparable in heart (about 1-fold), kidney (about 1.5-
fold) and liver (1-fold). Almost no expression was detected in muscles (about 0.08-fold) 
(Figure 26). All WISP1 knockout organs were undetermined for WISP1 expression, confirming 
the efficient deletion of WISP1. Taken together, WISP1 was expressed in the wild type mice 
with different levels in almost all tissues tested. 
 
3 RESULTS 
72 
 
Figure 26: Organ specific quantitative RT-PCR of WISP1 mRNA of untreated wild type mice and WISP1 
knockout mice. The highest expression level of WISP1 was found in lung, followed by brain, spleen and 
intestine. WISP1 expression was comparable in the heart, kidney and liver. Liver tissue was used as a reference 
for all organs. Data represent mean of three biological replicates ± S.E. (-) No expression was detectable in the 
WISP1 knockout mice. 
 
 The qRT-PCR did not provide any information about the possible zonation and 
localization of WISP1 expression in the different tissues. Therefore, immunohistochemical 
staining of WISP1 in different organs was performed (Figure 27). Unfortunately, IHC staining 
detected comparable signals in WISP1 knockout and wild type mice, revealing unspecific 
signals in all organs.  
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Figure 27: Immunohistochemical staining of WISP1 in various tissues of wild type mice and WISP1 knockout 
mice. The results show no difference in the wild type mice compared to WISP1 knockout mice, revealing that 
the staining was not successful. WISP1 knockout mice were used as negative control. Representative images of 
three mice per organ, scale bars represent 100 µm. 
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 In conclusion, qRT-PCR detected different levels of WISP1 RNA in various organs of 
wild type mice. However, localization of WISP1 was not possible to determine, because IHC 
staining was not successful, due to antibody unspecificity. Nevertheless, the results revealed 
the successful establishment of WISP1 knockout mouse model which could be used for 
further investigation of WISP1 phenotype. For example, in vivo studies to examine the 
potential role of WISP1 during acute liver injury by administration of CCl4 or APAP in a time- 
and concentration-dependent manner. Moreover, the WISP1 knockout mice also allow the 
investigation of WISP1 in the context of liver regeneration after administration of 
hepatotoxic compounds. Furthermore, in vitro experiments using isolated hepatocytes and 
NPCs could be used to study the influence of WISP1 in liver cell subpopulations. 
 
3.5 WISP1 knockout mice exhibit higher susceptibility to CCl4-induced 
liver damage 
 The previous validation of WISP1 deletion in knockout mice provided a good 
precondition for assessing the potential role of WISP1 in acute liver injury. 
 First, a titration of CCl4 was performed to investigate the potential effects of WISP1 
deletion in knockout mice compared to wild type mice during acute liver damage in a dose-
dependent manner. Therefore, the mice were challenged with different concentrations of 
CCl4 (1.6 g/kg, 920 mg/kg, 460 mg/kg, 132.4 mg/kg, 0.076 mg/kg) or control vehicle (olive 
oil). Blood and liver tissue samples were collected after 24h. For each time point, 3 mice 
were used. The genotype was confirmed by Phire Animal Tissue Direct PCR Kit as described 
in the method section.  
 CCl4 intoxication caused macroscopically-visible hepatic alterations in forms of white 
spots in all concentrations in both mice. However, more extensive white puncta were 
observed in the WISP1 knockout mice afteronly mild concentrations of CCl4 compared to 
wild type mice (Figure 28). 
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Figure 28: Concentration-dependent analysis of gross appearance of WISP1 knockout and wild type mouse 
liver after administration of CCl4 for 24h. Both control livers show a smooth appearance and intense red color. 
At lower concentrations of CCl4 (76 mg/kg up to 460 mg/kg), an enhanced characteristic white spotted pattern 
was observed in WISP1 knockout mice compared to wild type mice, indicating a more advanced stage of liver 
injury. Representative images of three mice per concentration.  
 
 In order to assess the microscopic hepatic lesions induced by CCl4, paraffin 
embedded liver sections were stained with hematoxylin and eosin. WISP1 knockout and wild 
type mice showed a concentration-dependent increase in the dead cell areas around the 
central veins up to a concentration of 460 mg/kg. However, at lower concentrations of CCl4 
(76 mg/kg, 132.4 mg/kg, 460 mg/kg), the WISP1 knockout mice displayed an enlarged dead 
cell area compared to wild type mice (Figure 29). Moreover, qualitative differences were 
observed in the dead cell area of wild type mice treated with 920 mg/kg CCl4. The yellow 
3 RESULTS 
76 
arrow indicates still visible nuclei of hepatocytes in the dead cell area, which were not visible 
in the dead cell areas of WISP1 knockout mice. 
 
 
Figure 29: H&E staining of WISP1 knockout and wild type mouse liver after administration of various 
concentrations of CCl4 for 24h. The area of centrilobular liver damage (black arrows) was identified in a 
concentration-dependent manner in WISP1 knockout and wild type mice. Enlarged dead cell areas were 
observed at lower concentrations in the WISP1 knockout mice compared to wild type mice. At a concentration 
of 920 mg/kg of CCl4, hepatocyte nuclei were still visible in the wild type mice (yellow arrow), whereas WISP1 
knockout mice displayed a clear dead cell area. Representative images of three mice per condition, scale bars 
represent 100 µm. 
 
 In order to obtain quantitative measurements of liver injury in the WISP1 knockout 
and wild type mice, the dead cell areas were quantified using image analysis software. The 
quantification indicated a concentration-dependent increase in the dead cell areas in both 
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WISP1 knockout and wild type mice (Figure 30). However, the WISP1 knockout mice showed 
a significant increase in the dead cell areas at lower concentrations of CCl4 (76 mg/kg up to 
460 mg/kg) compared to wild type mice. Moreover, WISP1 knockout mice showed a maximal 
dead cell area of about 50 % already at a dose of 460 mg/kg CCl4; whereas, the wild type 
mice displayed a dead cell of about 25 %. 
 
 
Figure 30: Concentration-dependent quantification of the dead cell areas of WISP1 knockout and wild type 
mice after administration of CCl4 for 24h. The extent of the dead cell areas was quantified as described in the 
method section. The quantification revealed a concentration-dependent increase in the dead cell areas in wild 
type and WISP1 knockout mice. At lower concentrations of CCl4 enlarged dead cell areas were observed in the 
WISP1 knockout mice compared to wild type mice. The data represent at least three mice per concentration. 
Error bars indicate mean values ± S.E. ***P<0.001 to wild type condition, **P<0.01 to wild type condition, 
*P<0.05 to wild type condition, unpaired t-test. 
 
The extent of liver damage was also assessed by measuring the plasma concentrations of 
hepatic damage marker alanine transaminase (ALT). Consistent with the quantification of the 
dead cell areas, the liver enzymes were elevated with increased CCl4 concentrations in both 
wild type and WISP1 knockout mice. Importantly, this analysis was more sensitive than the 
quantification of dead cell areas, showing higher ALT values in WISP1 knockout mice at all 
concentrations (Figure 31). A significant difference compared to the wild type mice was 
observed at 920 mg/kg of CCl4. 
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Figure 31: Plasma transaminase activity after different doses of CCl4 in WISP1 knockout and wild type mice. 
Increased ALT activity was observed for the wild type and WISP1 knockout mice in a concentration-dependent 
manner. However, the WISP1 knockout mice showed higher ALT values compared to wild type mice at all 
concentrations. Data obtained from at least three mice per condition. Error bars indicate mean values ± S.E. 
**P<0.01 to wild type condition, unpaired t-test. 
 
 In conclusion, the histological features of liver injury (i.e. dead cell areas) and the 
increased activity of liver enzymes in wild type and WISP1 knockout mice indicated that a 
robust and reproducible experimental setup was achieved, similar to what has been 
reported in previous studies [14]. Moreover, the titration of CCl4 was a useful tool to deliver 
a first robust and reproducible insight into the effect of the absence WISP1 upon liver injury. 
It was beneficial to establish an optimal concentration for further time-dependent and 
kinetic analysis of WISP1 knockout mice. Interestingly, the WISP1 knockout mice exhibited 
an enhanced liver damage at all concentrations of CCl4 compared to wild type mice. This led 
to the hypothesis that WISP1 is a protective mediator during acute liver injury in mice. 
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3.6 Time-resolved challenge using CCl4 revealed different kinetics of liver 
damage in WISP1 knockout mice 
 The previous concentration-dependent analysis of WISP1 knockout and wild type 
mice challenged with CCl4 suggested that WISP1 may play a protective role in the acute liver 
injury model. Titration of CCl4 revealed that a dose of 460 mg/kg CCl4 leads to the most 
robust phenotype with the highest quantitative differences between WISP1 knockout mice 
and wild type mice. Therefore, to further investigate kinetic and molecular events leading to 
an advanced liver damage, WISP1 knockout mice and wild type mice were treated with 
460mg/kg CCl4 for 30min, 2h, 8h, 12h, 18h and D1. For the vehicle control, mice were 
treated with olive oil for 24h.  
 WISP1 knockout and wild type livers both showed the typical intense red coloration 
in the control situation, which did not change until 8h after CCl4 treatment (Figure 32). After 
12h of 460 mg/kg CCl4 WISP1 knockout livers exhibited small white spots, which became 
more prominent after 18h and 24h of treatment. In contrast, the wild type mice displayed 
initial white spots after 18h of treatment, which became more prominent after 24h. 
However, WISP1 knockout mice showed more extensive white spots at 18h and D1 
compared to wild type mice, indicating a more advanced stage of liver damage.  
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Figure 32: Time-dependent analysis of gross pathology appearance of WISP1 knockout and wild type mouse 
liver after administration of 460 mg/kg CCl4 for the indicated time points. Both wild type and WISP1 knockout 
control livers showed a smooth appearance and an intense red coloration. An enhanced characteristic white 
spotted pattern was observed in the WISP1 knockout mice compared to wild type mice, indicating a more 
severe liver injury already at 18h after administration of CCl4. Representative images of three mice per 
concentration. 
 
 In order to microscopically assess the pericentral necrotic lesions, H&E staining was 
performed from paraffin embedded liver tissue. According to gross pathology images, no 
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necrotic lesions were observed until 8h after CCl4 treatment (Figure 33). Initial necrotic 
lesions were observed at 18h in the wild type mice and already at 12h in the WISP1 knockout 
mice after treatment (black arrows). Clear dead cell areas, indicating the peak of liver 
damage, were detected at D1 in the wild type mice and already at 18h in the WISP1 
knockout mice. These observations suggested a time shift in the induction of liver damage in 
WISP1 knockout mice that is approximately 6h earlier compared to wild type mice. 
According to the previous concentration series, WISP1 knockout mice displayed an enlarged 
dead cell area, which is almost doubled in size at D1. Interestingly at 18h, the size of the 
affected area around the central vein is comparable in both wild type and WISP1 knockout 
mice.  
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Figure 33: Time-dependent H&E staining of WISP1 knockout and wild type mouse livers after administration 
of 460 mg/kg CCl4 for the indicated time points. Initial necrotic lesions were observed around the central veins 
(black arrows) in the wild type mice after 18h, leading to a full dead cell area after 24h of treatment. WISP1 
knockout mice showed initial affected areas already at 12h, followed by a full necrotic area at 18h after 
administration of CCl4. Representative images of three mice per condition, scale bars represent 100 µm.  
 
 This time-dependent analysis not only supports the previous results of the 
concentration-dependent analysis, but also revealed differences in the kinetics of developing 
acute liver damage after CCl4 in WISP1 knockout mice compared to their wild type 
3 RESULTS 
83 
littermates. Moreover, hepatotoxicity also appears to occur earlier in the WISP1 knockout 
mice. 
 
3.6.1 Molecular markers of cell death revealed earlier stage of liver damage in 
WISP1 knockout mice  
 As shown in time-dependent analysis after CCl4 administration, WISP1 knockout 
exhibited an already a clear necrotic area at 18h; whereas, wild type littermates showed 
dead cells only at the border of pericentral areas (Figure 33). In order to clarify the advanced 
stage of liver damage in WISP1 knockout mice, TUNEL assay and HMGB1 staining were 
performed. HMGB1 is a nuclear ubiquitously expressed protein in eukaryotes. Upon 
necrosis, it is passively released by cells and functions as a damage-associated molecular 
pattern (DAMP) [172, 173]. The terminal transferase uridyl nick end labelling (TUNEL) assay 
is used to detect DNA fragmentation, which is an indicator of apoptosis in cells. HMGB1 
staining displayed its translocation to the cytoplasm at 18h in wild type mice, illustrating the 
time at which the hepatocytes started to undergo cell death (Figure 34). At the same time 
point, WISP1 knockout mice exhibited no positive staining of nuclei or cytoplasm, indicating 
that all hepatocytes in the centrilobular region were already dead. TUNEL assay revealed few 
cells that were positively stained at the border of the centrilobular regions at 18h in wild 
type mice (Figure 35). Conversely, all hepatocytes in the WISP1 knockout mice were stained 
positive in the centrilobular region at the same time point. 
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Figure 34: HMGB1 staining in WISP1 knockout and wild type mice after administration of 460 mg/kg CCl4 for 
the indicated time points. At 30min, 2h and 8h all nuclei were stained positive, thus indicating no translocation 
of HMGB1 to the cytoplasm. Wild type mice revealed positive stained cytoplasm at the borders of the 
centrilobular regions after 18h (black arrow); whereas, WISP1 knockout mice showed no positively stained 
hepatocyte nuclei or cytoplasm. Representative images of three mice per condition, scale bars represent 100 
µm. 
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Figure 35: Terminal transferase uridyl nick end labelling (TUNEL) assay in WISP1 knockout and wild type mice 
after administration of 460 mg/kg CCl4 for the indicated time points. TUNEL positive staining (brown nuclei) 
was observed in the wild type mice at the border of centrilobular regions at 18h (black arrows). First single 
positive-stained hepatocytes were observed in the WISP1 knockout mice after 12h, followed by a completely 
positive-stained area at 18h. Representative images of three mice per condition, scale bars represent 100 µm. 
 
These data indicate an advanced stage of liver damage in the WISP1 knockout mice 
compared to wild type mice already at 18h after CCl4 administration. Both approaches 
showed full dead cell areas around the central veins in the WISP1 knockout mice at 18h after 
CCl4 administration; whereas, the wild type mice still displayed healthy hepatocytes within 
the centrilobular area. In conclusion, this approach not only showed an enhanced damage of 
the liver in WISP1 knockout mice, but also that the progress of liver damage occurred earlier 
in mice lacking WISP1.  
 
3.7 WISP1 knockout mice exhibit higher susceptibility to paracetamol-
induced liver damage 
 The initial results using CCl4 as a model compound to induce acute liver damage 
suggested a higher susceptibility of WISP1 knockout mice compared to wild type mice. In 
order to clarify if this phenotype is unique for CCl4, paracetamol was used as another 
hepatotoxic model. Therefore, wild type and WISP1 knockout mice were treated using a 
dose of 300 mg/kg APAP for 30min, 1h, 2h, 4h, 8h, 12h and D1. PBS was used as the vehicle 
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control. Wild type and WISP1 knockout mice exhibited the typical intense red color in the 
control condition of both the wild type and knockout mice, which started to become pale 1h 
and 2h after administration of APAP (Figure 36). Severe hemorrhage and characteristic white 
spots were visible in wild type and WISP1 knockout mice after 4h and 8h. An attenuated 
white spotted pattern was detected at 12h and D1 in the wild type mice compared to WISP1 
knockout mice. At the same time points, hemorrhage was still visible in the WISP1 knockout 
mice.  
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Figure 36: Time-dependent analysis of gross pathology appearance of WISP1 knockout and wild type mouse 
livers after administration of 300 mg/kg APAP for the indicated time points. Both wild type and WISP1 
knockout control livers show a smooth appearance and intense red coloration. Characteristic white spotted 
pattern was observed in the wild type and WISP1 knockout mice starting 1h after administration of APAP. After 
4h and 8h, severe hemorrhage was observed in both mice (white arrows). After 12h and at D1, characteristic 
white spotted pattern is attenuated in the wild type mice compared to the WISP1 knockout mice. Moreover, 
severe hemorrhage was detected only in the WISP1 knockout mice at later time points. Representative images 
of at least three mice per time point. 
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 To assess the pericentral dead cell area in wild type and WISP1 knockout mice after 
APAP administration, H&E staining was performed using paraffin embedded liver tissue 
(Figure 37). Consistent with gross pathology images, the first necrotic lesions were observed 
after 4h in wild type and WISP1 knockout mice. However, the area necrotic lesions in the 
WISP1 knockout mice were slightly enhanced compared to the wild type mice up to D1. The 
wild type mice exhibited severe hemorrhage at 4h and 8h after administration of APAP.  
 
 
3 RESULTS 
89 
 
Figure 37: Time-dependent H&E staining of WISP1 knockout and wild type livers after administration of 
300 mg/kg APAP for the indicated time points. Initial necrotic lesions were detected in the wild type mice 
after 4h of APAP administration (black arrows). Slightly enhanced necrotic lesions were observed in the WISP1 
knockout mice at 4h until D1 compared to the wild type mice. However, the wild type mice displayed severe 
hemorrhage at 4h and 8h after intoxication. Representative images of three mice per time point, scale bars 
represent 100 µm. 
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 By measuring alanine transaminase activity (ALT) in the plasma samples of wild type 
and WISP1 knockout mice, the extent of liver damage was assessed quantitatively. Elevated 
liver enzymes were detected starting at 4h after administration of APAP in wild type and 
WISP1 knockout mice (Figure 38). However, high variances between the biological replicates 
were observed in the wild type and WISP1 knockout mice at 8h, which made it challenging to 
determine differences between both mice. After 12h and D1, WISP1 knockout mice 
exhibited significantly enhanced liver enzymes compared to wild type mice.  
 
 
Figure 38: Time-dependent analysis of plasma transaminase activity after 300 mg/kg APAP in WISP1 
knockout and wild type mice for the indicated time points. Increased liver enzymes were observed in the wild 
type and WISP1 knockout mice starting at 4h after APAP administration. However, significantly enhanced ALT 
activity was detected at 12h and D1 in the WISP1 knockout mice. Data obtained from at least three mice per 
condition. Error bars indicate mean values ± S.E. *P<0.05 to wild type condition, unpaired t-test. 
 
3.8 WISP1 expression is induced after administration of CCl4 as well as 
after paracetamol in wild type mice 
 Previous results from quantitative RT-PCR (Chapter 3.1) revealed an induction of 
WISP1 expression in C57Bl/6N after CCl4 administration. However, wild type and WISP1 
knockout mice have a different genetic background (129S5/SvEvBrd * C57BL/6J, EMMA 
mouse repository EM:02344) compared to the mice used in previous experiments 
(C57Bl/6N). Therefore, in order to determine whether CCl4 or APAP treatment of wild type 
mice would also lead to an increase in WISP1 expression, RNA was isolated from CCl4 and 
APAP treated wild type and WISP1 knockout mice and transcribed into cDNA to measure 
WISP1 RNA. WISP1 expression increased after mild dose of CCl4 (460 mg/kg) at 8h, with the 
maximal induction of about 80-fold observed at 12h. On D1, the levels returned to the 
control levels in wild type mice (Figure 39). After administration of 300 mg/kg APAP, the 
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expression of WISP1 first decreased until 1h and increased at 8h after treatment with a 
maximal induction of about 2.5-fold at 12h. On D1, WISP1 levels decreased again to half of 
control levels. WISP1 expression was undetectable in the WISP1 knockout mice at all time 
points, confirming the successful deletion of WISP1. 
 
 
Figure 39: Time-dependent quantitative RT-PCR of WISP1 expression in wild type and WISP1 knockout mice 
after 460 mg/kg CCl4 and 300 mg/kg APAP for the indicated time points. WISP1 expression increased upon 
CCl4 administration with the maximal inductuion of about 80-fold at 12h. WISP1 RNA turned back to control 
levels at D1. After administration of APAP, WISP1 RNA decreased until 1h and further increased with the 
maximal induction of about 2-fold at 12h. Data represent mean of at least four biological replicates ± S.E. (-) No 
expression was detectable in the WISP1 knockout mice. 
 
 The results confirmed gene array data from the Bl6N mice and qRT-PCR of WISP1 
expression showing an induction after CCl4 administration (Figure 21). However, there was a 
time shift in the maximal induction of WISP1 expression after mild doses of CCl4 in the wild 
type mice. Interestingly, a decrease in RNA levels was observed at early time points after 
APAP administration followed by an increase in WISP1 expression upon the development of 
liver damage. However, the induction after APAP administration was much lower compared 
to the induction after administration of CCl4. 
 The next step was to clarify if WISP1 protein levels were also altered after the 
induction of liver damage. Therefore, plasma samples and liver tissue from 3 mice per time 
point were analyzed using Quantikine® ELISA Mouse/Rat WISP-1/CCN4 immunoassay. High 
basal levels of WISP1 protein were detected in the plasma samples, including an increase at 
2h and D1 after CCl4 (Figure 40). However, the increase in plasma concentrations was not as 
high as the increase in RNA levels; and, the peak in WISP1 expression (12h) did not match 
the peaks in plasma levels. In contrast, liver tissue samples had low levels of WISP1, with 
increased protein levels detectable at both early time points (30min, 2h) and later time 
points (18h, D1).  
 
3 RESULTS 
92 
 
Figure 40: Time-dependent analysis of WISP1 protein concentrations in plasma a) and liver tissue b) of wild 
type and WISP1 knockout mice after administration of 460 mg/kg CCl4. ELISA revealed high concentrations of 
WISP1 protein (about 1000 pg/ml) in the plasma which increased after 2h and D1 to about 1400 pg/ml. The 
concentrations in liver tissue samples increased at early time points after CCl4, turned back to control levels at 
8h and 12h and increased again at later time points (18h, D1). Data represent mean of at least three biological 
replicates ± S.E. (-) No protein concentrations were detectable in the WISP1 knockout mice. 
 
 Taken together, the qRT-PCR data suggested that WISP1 expression is induced upon 
CCl4 intoxication as well as after APAP administration. Compared to the maximal dose, using 
a low dose of CCl4 shifted the time when a maximal induction of WISP1 was observed to an 
earlier time point. However, previous results (maximal dose of CCl4) were performed using a 
different mouse strain (C57Bl/6N), which could explain the differences in the expression of 
WISP1, because WISP1 knockout and wild type mice have a different and mixed genetic 
background (129S5/SvEvBrd * C57BL/6J). 
 
3.9 Liver regeneration is not impaired by the absence of WISP1 
 In order to study whether liver regeneration is impaired by the absence of WISP1, 
wild type and WISP1 knockout mice were treated with either olive oil as the control vehicle, 
or with 460 mg/kg CCl4 intraperitoneally for D1, D2, D3 and D4. Gross pathology revealed 
that under control conditions, livers from both wild type and WISP1 knockout mice exhibited 
the characteristic dark red coloration of a healthy liver (Figure 41). After D1 of CCl4 
treatment, liver of the wild type mice showed the characteristic white spots (puncta), 
indicating localized areas of cell damage. This was more intensive in the WISP1 knockout 
mice at the same time point, reflecting an advanced stage of liver damage. On D4 of 
treatment, almost no white puncta were observed in the wild type mice, showing a 
successful recovery from liver injury. However, WISP1 knockout mice displayed an increased 
size of white puncta at D2 up to D4, when compared to wild type mice. 
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Figure 41: Time-dependent analysis of gross pathology appearance of WISP1 knockout mouse liver and wild 
type mouse liver after administration of 460 mg/kg CCl4 for the indicated time points. Wild type mice and 
WISP1 knockout mice showed a characteristic intense red color under control condition. At D1 up to D4, an 
increased size of white puncta was observed in the liver of WISP1 knockout mice compared to the liver of wild 
type mice. On D4, only slight white puncta were observed in wild type mice. Representative images of five mice 
per time point. 
 
Macroscopic alterations revealed enhanced liver damage in WISP1 knockout mice upon liver 
regeneration. In order to visualize the necrotic lesions microscopically, H&E staining was 
performed, using paraffin embedded liver sections of wild type mice and WISP1 knockout 
mice. The H&E staining showed enhanced pericentral necrosis in the livers of WISP1 
knockout mice at all the indicated time points compared to the livers of wild type mice 
(Figure 42). An enhanced immune cell infiltration was observed around the central veins in 
wild type mice on day 4 in contrast to the WISP1 knockout mice that still showed a small 
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necrotic lesion, which was associated with less infiltration of immune cells. Overall, these 
results suggest that the capacity to recover from liver injury is not impaired by the absence 
of WISP1. However, WISP1 knockout mice seem to require a longer time period to recover 
from liver damage.  
 
 
Figure 42: Time-dependent H&E staining of WISP1 knockout mice and wild type mice upon liver regeneration 
after administration of CCl4. H&E staining of livers from WISP1 knockout mice showed an increased size of the 
dead cell areas, when compared to wild type mice at the indicated time points. The necrotic lesions are not 
fully recovered at D4 in the WISP1 knockout mice; whereas, in the wild type mice only a strong immune cell 
infiltration was observed. Representative images of five mice per time point, scale bars represent 100 µm. 
 
 Dead cell areas of WISP1 knockout and wild type mice were quantified using image 
analysis software. The quantification revealed enlarged dead cell areas at all indicated time 
points in the WISP1 knockout mice (Figure 43). However, the dead cell areas in wild type 
mice, as well as in WISP1 knockout mice decreased with comparable kinetics starting from 
D2 to D4.  
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Figure 43: Time-dependent quantification of dead cell areas of WISP1 knockout mice and wild type mice 
after administration of 460 mg/kg CCl4 for the indicated time points. The quantification revealed enlarged 
dead cell areas in the WISP1 knockout mice upon liver regeneration. However, wild type and WISP1 knockout 
mice seemed to recover with comparable kinetics from liver injury. Data represent at least three mice per 
concentration. Error bars indicate mean ± S.E. ***P<0.001 to wild type condition, **P<0.01 to wild type 
condition, *P<0.05 to wild type condition, unpaired t-test. 
 
 Taken together, this experiment revealed that both the WISP1 knockout mice and 
wild type mice recover from acute liver injury after CCl4 administration with comparable 
kinetics. However, liver regeneration in the WISP1 knockout mice is delayed, when 
compared to wild type mice. One potential explanation is that the WISP1 knockout mice had 
twice the dead cell area after one day intoxication, and thus require a longer recovery period 
from acute liver injury. 
 
3.9.1 Proliferation is not altered during liver regeneration by the absence of 
WISP1  
 Previous observations revealed no difference in the capacity of WISP1 knockout and 
wild type mice to recover from acute liver injury. In order to examine whether proliferating 
cell nuclear antigen (PCNA) signaling and gene expression is altered during liver regeneration 
by the absence of WISP1, western blot analysis and qRT-PCR of liver homogenates were 
performed. 
 Proliferating cell nuclear antigen (PCNA) is a nuclear protein, which is involved in cell 
cycle progression, serving as a cofactor for DNA polymerase-δ [174]. Bhushan et al showed 
that most of the PCNA-positive stained cells can be observed during S-phase after 
administration of APAP at D2, indicating that PCNA is involved in DNA replication [86]. Thus, 
PCNA is used as a marker for proliferating cells [175]. 
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 Wild type and WISP1 knockout mice were injected intraperitoneally using 460 mg/kg 
CCl4 for D1, D2, D3 and D4. Olive oil was used as the control vehicle. Western blot analysis 
displayed activation of PCNA signaling in both wild type and WISP1 knockout mice starting at 
D2 until D4 (Figure 44). Quantification of signal volumes revealed no differences in the 
activation of PCNA in wild type mice compared to WISP1 knockout mice. 
 
 
Figure 44: Time-dependent western blot analysis of PCNA levels after administration of 460 mg/kg CCl4 
during liver regeneration. Results revealed no difference in PCNA levels in WISP1 knockout and wild type mice. 
a) Western blot, b) Quantification shows mean values of three independent biological replicates ± S.E. β-actin 
was used as loading control. 
 
 PCNA expression was increased upon liver regeneration to comparable levels in both 
wild type and WISP1 knockout mice (Figure 45). On D4, the expression of PCNA was slightly 
increased compared to wild type mice, most likely because proliferation is still needed in the 
WISP1 knockout mice, as the wound is not fully recovered. 
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Figure 45: Time-dependent quantitative RT-PCR of PCNA RNA after administration of 460 mg/kg CCl4 for the 
indicated time points. PCNA expression is increased to comparable levels in both wild type and WISP1 
knockout mice. However, at D4 expression was slightly higher in the WISP1 knockout mice. Data represent 
mean values of five biological replicates ± S.E. 
 
 In summary, these results suggest that proliferation was not impaired by the deletion 
of WISP1. On D4, WISP1 knockout mice seemed to have higher PCNA expression, because on 
D4 the wound is not fully regenerated in the WISP1 knockout mice compared to wild type 
mice.  
 
3.9.2 Cell cycle-dependent genes are slightly higher expressed when WISP1 is 
deleted  
 To study whether cell cycle dependent genes were altered by deletion of WISP1 
during liver regeneration, quantitative RT-PCR was performed. Therefore, RNA was isolated 
from wild type and WISP1 knockout mice and cell cycle-dependent RNA expression was 
quantified by quantitative RT-PCR. CycG2 is known to block cell cycle entry [176]; therefore, 
a comparable decrease in CycG2 expression was observed during liver regeneration in wild 
type and WISP1 knockout mice. Cytokines act as precursors to drive quiescent hepatocytes 
into the cell cycle (G0 to G1). Cell cycle progression is then driven by growth factors to 
override a restriction point in late G1-phase. Increased expression of cyclins, such as cyclin D, 
E and A, are associated with the passage from G1 to S phase [82, 116, 177, 178]. WISP1 
knockout and wild type mice showed similar expression pattern of CycD1, CycE2 and CycA2 
with increased induction on D2 and downregulation by D4 (Figure 46). Thereby, WISP1 
knockout mice displayed a slightly increased induction of cell cycle genes during liver 
regeneration, which could be due to a compensatory mechanism or to the fact that 
enhanced cell proliferation is needed in WISP1 knockout mice to overcome the enlarged 
dead cell areas. 
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Figure 46: Time-dependent quantitative RT-PCR of cell cycle-dependent genes CycG2, CycD1, CycE2, and 
CycA2 after administration of CCl4 for the indicated time points. CycG2 expression was downregulated to 
same extent in the wild type and WISP knockout mice. CycD1, CycE2 and CycA2 followed a similar expression 
pattern of an induction at D2 and a decrease during liver regeneration up to D4. Quantitative RT-PCR revealed 
slightly higher expression of cell cycle-dependent genes in WISP1 knockout mice during liver regeneration. Data 
represent mean values of five biological replicates ± S.E. 
 
 Taken together, these analyses revealed that cell cycle-dependent genes were not 
altered by the deletion of WISP1 upon liver regeneration. WISP1 knockout mice exhibited 
increased induction of cell cycle-dependent genes, which might be due to the fact that the 
wound is enlarged in these mice and enhanced proliferation is needed for recovery. 
Because liver regeneration was not impaired by the absence of WISP1, and a clear and 
robust protective phenotype was observed upon acute liver injury, the focus was to 
investigate WISP1 function upon acute liver injury.  
 
3.10 WISP1 knockout enhanced sensitivity is not caused by altered redox 
state or Cyp2e1 metabolism 
 The differential sensitivity of WISP1 knockout mice compared to wild type mice could 
be due to a basal reduction in antioxidant metabolites, such as GSH or an enhanced 
metabolic activation of CCl4 by Cyp2E1. Therefore, the next step was to examine GSH 
content in WISP1 knockout and wild type mice upon APAP and CCl4 administration, as well as 
the Cyp2E1 levels.  
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 Quantification of GSH levels were performed after administration of 300 mg/kg APAP 
or 460 mg/kg CCl4. Moreover, IHC staining was used to quantify Cyp2E1 areas around the 
central veins. Quantitative RT-PCR and western blotting were used to assess the expression 
of Cyp2E1 during acute liver damage caused by CCl4. 
 As seen in figure 27, GSH content did not differ in the control condition in wild type 
mice compared to WISP1 knockout mice. Moreover, depletion and recovery of GSH content 
was also comparable in the WISP1 knockout and wild type mice after treatment using 300 
mg/kg APAP (Figure 47 a). Depletion of GSH after administration of CCl4 was not as strong as 
in the APAP model (Figure 47 b). However, depletion and recovery of GSH was comparable 
in both the wild type and WISP1 knockout mice upon CCl4 administration. 
 
 
Figure 47: Time-dependent analysis of GSH content in wild type and WISP1 knockout mouse liver tissue after 
administration of a) 300 mg/kg APAP and b) 460 mg/kg CCl4. GSH content showed no significant difference in 
the wild type and WISP1 knockout mice after APAP administration. Data represent mean of at least three 
biological replicates ± S.E. 
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 The next step was to determine the Cyp2E1 positive area around the central veins in 
WISP1 knockout and wild type mice. Immunohistochemical staining of Cyp2E1 in control 
liver tissue (vehicle control) showed no difference between wild type and WISP1 knockout 
mice (Figure 48 a). Furthermore, the quantification revealed no significant difference in the 
size of Cyp2E1 stained positive area (Figure 48 b). Figure 48 c shows the result from qRT-PCR 
of Cyp2E1 in wild type and WISP1 knockout mice after administration of 460 mg/kg CCl4. 
Cyp2E1 expression was not significantly altered in the control condition, and the depletion of 
Cyp2E1 was comparable between wild type and WISP1 knockout mice.  
 
 
Figure 48: Analysis of Cyp2E1 expression showed no difference in wild type mice compared to WISP1 
knockout mice. a) Immunohistochemistry staining of Cyp2E1 in wild type and WISP1 knockout mice under 
control conditions at D1. Representative images of three mice per condition. Scale bars represent 100 µm. b) 
Quantification of Cyp2E1 positive stained area around the central veins. Results revealed no significant 
difference in the size of Cyp2E1 area in the wild type mice versus WISP1 knockout mice. Quantification was 
done using three biological replicates and five images were quantified from each biological replicate. Data 
represent mean ± S.E. c) Time-dependent quantitative RT-PCR of Cyp2E1 expression after administration of 
460 mg/kg CCl4 for the indicated time points. Cyp2E1 expression was decreased in both the wild type and 
WISP1 knockout mice in acute liver damage and no significant difference was observed. Data represent mean 
of at least five biological replicates ± S.E.  
 
 Finally, western blot analysis was used to determine protein levels of Cyp2E1 in liver 
homogenates after induction of liver damage by CCl4. This result indicated no significant 
difference in wild type and WISP1 knockout mice regarding Cyp2E1 protein levels in control 
conditions as well as during induction of liver damage (Figure 49 a, b).  
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Figure 49: Time-dependent analysis of Cyp2E1 protein levels in wild type and WISP1 knockout mice. a) 
Western blot analysis of Cyp2E1 levels in liver homogenates after induction of liver damage using 460 mg/kg 
CCl4. ß-actin was used as loading control. b) Quantification of western blot analysis. Western blot analysis and 
quantification of western blots revealed no difference in the protein levels of Cyp2E1 in wild type mice versus 
WISP1 knockout mice. Results are representative of three independent biological replicates per time point. 
Data are mean values ± S.E. β-actin was used as loading control. 
 
 In conclusion, these analyses revealed no differences regarding the redox state and 
metabolism of hepatotoxic substances in wild type and WISP1 knockout mice. Therefore, the 
hypothesis that altered metabolism or differences in redox state may be responsible for the 
enhanced liver damage in WISP1 knockout mice could be excluded.  
 
3.11 Gene expression of CCN family members revealed alterations by 
the absence of WISP1  
 CCN family members were reported to interact with cytokines, like TNFα, converting 
their proliferation-promoting effect into an apoptotic inducing potential [112]. Therefore, 
the next step was to investigate whether the expression of CCN family members is altered 
during liver injury by the deletion of WISP1 in knockout mice, which could influence the 
outcome of liver injury. RNA was isolated from CCl4 time series and qRT-PCR was performed 
for Cyr61 (CCN1), CTGF (CCN2) and Nov (CCN3). As seen in figure 50, Cyr61 was upregulated 
in all samples for all treated time points. However, the induction was higher in the WISP 
knockout mice at 2h and D1 compared to wild type mice. CTGF expression was increased at 
18h and D1 after CCl4 in both wild type and WISP1 knockout mice, but higher induction was 
observed in the WISP1 knockout mice. Nov expression only increased in the WISP1 knockout 
mice at all indicated time points.  
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Figure 50: Time-dependent quantitative RT-PCR of CCN family members after administration of 460 mg/kg 
CCl4 for the indicated time points. Cyr61 expression was induced at all time points. However, stronger 
induction was observed in the WISP1 knockout mice at 2h and D1. CTGF expression was induced in wild type 
and WISP1 knockout mice at 18h and D1, however, stronger induction was detected in the WISP1 knockout 
mice. Nov expression was induced only in the WISP1 knockout mice with the highest induction at 18h after CCl4 
treatment. Data represent mean of at least three biological replicates ± S.E. 
 
 This approach displayed that not only WISP1 is induced during acute liver damage, 
but also the CCN family members. Quantitative RT-PCR results revealed altered expression of 
CCN family members in the absence of WISP1. This led to the hypothesis that WISP1 
knockout mice tried to compensate for the loss of WISP1 by upregulating other CCN family 
members.  
 
3.12 Signal transduction analyses of WISP1 knockout and wild type mice 
during acute liver injury 
3.12.1 Deletion of WISP1 leads to stronger induction of stress signaling 
pathway JNK 
 MAPK associated signaling pathways are known to be activated upon various stimuli, 
such as ROS, growth factors, environmental stress or cytotoxic drugs. Activation of signaling 
cascade can trigger different cellular responses, including differentiation, migration and 
proliferation. However, apoptosis or inflammation could also be consequences of MAPK 
signaling [88, 179]. 
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 In order to study whether c-Jun N terminal kinases (JNKs) were altered upon CCl4 
administration in WISP1 knockout mice compared to wild type mice, western blot analysis 
was performed. Protein lysates were prepared using liver harvested from wild type and 
WISP1 knockout mice after administration of 460 mg/kg CCl4 for 30min, 2h, 8h, 18h and 24h. 
Figure 51 represents results from western blot analysis of JNK levels. Stronger JNK activation 
was observed in WISP1 knockout mice at 2h after administration of 460 mg/kg CCl4. 
 
 
Figure 51: Activation of JNK protein in wild type mice and WISP1 knockout mice upon CCl4 administration. a) 
Western blot analysis of JNK levels in wild type and WISP1 knockout mice after administration of 460 mg/kg 
CCl4. b) Quantification of western blot analysis from wild type mice versus WISP1 knockout mice. 
Phosphorylation of JNK was stronger induced at 2h in WISP1 knockout mice. β-actin was used as loading 
control. Results are representative of six independent biological replicates per time point. Data are mean 
values ± S.E.  
 
 Taken together, these results show that the deletion of WISP1 resulted in a higher 
activation of stress signaling in WISP1 knockout mice.  
 
3.12.1.1 Upstream regulator of JNK signaling, growth arrest and DNA damage-
inducible 45 beta (GADD45β) is not suppressed by the deletion of WISP1 
 Growth arrest and DNA damage-inducible 45 beta (GADD45β) was shown to inhibit 
JNK phosphorylation and thereby protecting against APAP-induced toxicity in mice [110, 
180]. In order to address the question whether GADD45β was involved in the protective 
phenotype of wild type mice, qRT-PCR was performed using RNA isolated from liver 
homogenates after CCl4 administration (Figure 52). GADD45β expression was increased at 2h 
and 18h after CCl4 administration. However, enhanced induction was observed at 2h and on 
D1 in WISP1 knockout mice.  
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Figure 52: Time -ependent quantitative RT-PCR of GADD45β in WISP1 knockout and wild type mice after 
460 mg/kg CCl4 for the indicated time points. GADD45β expression was observed to be increased in the WISP1 
knockout mice at 2h and D1 after administration of CCl4. Data represent mean of three independent biological 
replicates ± S.E. 
 
 Surprisingly, this result was contrary to our hypothesis, which proposed higher 
expression in the wild type mice leading to attenuated JNK signaling. Taken together, 
GADD45β was not the cause for lower JNK activation in the wild type mice.  
 
3.12.1.2 Stress-induced activating transcription factor 3 (ATF3) is not 
influenced by the absence of WISP1  
 ATF3 is known to be expressed at low levels under physiological conditions [181, 
182]. However, upon cellular growth or stress, such as exposure to CCl4 or APAP [183] the 
expression greatly increases, indicating ATF3 as a key regulator in cellular stress responses. 
ATF3 expression was linked to cell cycle progression, metabolism, as well as cell death [181-
183]. To examine whether ATF3 expression was altered upon genetic deletion of WISP1, 
quantitative RT-PCR was performed using RNA from wild type and WISP1 knockout mice 
treated with 460 mg/kg CCl4. Results showed a biphasic induction of ATF3 expression, which 
peaked at 2h and 12h after treatment (Figure 53). Levels of AFT3 RNA were comparable in 
both wild type and WISP1 knockout mice.  
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Figure 53: Time-dependent quantitative RT-PCR of ATF3 expression in wild type and WISP1 knockout mice 
after administration of 460 mg/kg CCl4 for the indicated time points. Results revealed a biphasic induction of 
ATF3 at 2h and 12h after CCl4 administration. However, no difference was detected in the wild type mice 
compared to WISP1 knockout mice. Data represent mean of six independent biological replicates ± S.E. 
 
 In summary, induction of AFT3 expression, an early response gene induced by cellular 
growth or stress, was not impaired by the absence of WISP1.  
 
3.12.2 Biphasic phosphorylation of ERK1/2 is attenuated in WISP1 knockout 
mice 
 In order to study whether extracellular-signal regulated kinase (ERK) was altered in 
WISP1 knockout mice compared to wild type mice, western blot analysis of liver tissue 
homogenates was performed after CCl4 administration (Figure 54). Biphasic activation of 
ERK1/2 was observed in the wild type mice at 30min until 2h, and at 18h after CCl4 
administration; whereas, in the WISP1 knockout mice ERK1/2 activation was observed only 
at 30 min and 2h.  
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Figure 54: Activation of ERK1/2 in wild type mice and WISP1 knockout mice upon CCl4 administration. a) 
Western blot analysis of p-ERK1/2 in liver homogenates of wild type and WISP1 knockout mice after 
administration of CCl4 for the indicated time points. b) Quantification of western blot analysis. Results show a 
biphasic phosphorylation of ERK1/2 in the wild type mice, which peaked at early time points (30 min and 2h) 
and at later time point (18h). The second phosphorylation of ERK1/2 was attenuated in the WISP1 knockout 
mice. Results are representative of six independent biological replicates per time point. Data are mean values ± 
S.E. β-actin was used as loading control 
 
 Analysis of ERK1/2 signaling revealed comparable activation levels at early time 
points in both wild type and WISP1 knockout mice. However, the second peak of activation 
at 18h was diminished in the WISP1 knockout mice. 
 
3.12.2.1 Absence of WISP1 does not influence the induction of early activated 
transcription factor c-Myc 
 ERK1/2 has been shown to phosphorylate numerous substrates as well as nuclear 
transcription regulators, such as c-Myc [93]. This transcription factor is known to be an early 
activated transcription factor associated with hepatocyte proliferation, cell growth and loss 
of differentiation [94-97]. In order to study whether the expression of c-Myc is altered upon 
the deletion of WISP1, RNA was quantified from the livers of wild type and WISP1 knockout 
mice treated with 460 mg/kg CCl4. Expression of c-Myc increased starting at 2h up to 18h 
treatment, before decreasing to control levels at D1 (Figure 55). However, the expression of 
c-Myc was slightly higher in the WISP1 knockout mice compared to wild type mice on D1. 
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Figure 55: Time-dependent quantitative RT-PCR of cMyc expression in wild type mice and WISP1 knockout 
mice after CCl4 administration for the indicated time points. cMyc expression was increased in both wild type 
and WISP1 knockout mice at 2h up to 18h. Slightly higher expression was detected in the WISP1 knockout mice 
on D1. Data represent mean of three independent biological replicates ± S.E. 
 
 Promotion of cell cycle progression is one of the key biological functions of c-Myc 
[97]. Therefore, the general lack in alteration of cMyc expression confirms previous findings 
(Chapter 3.9) showing no impairment of liver regeneration in the WISP1 knockout mice. 
 
3.12.3 Activation of Akt kinase, a cell survival mediator, is not altered by 
deletion of WISP1 in mouse liver 
 More than a decade ago, WISP1 was shown to decrease p53-mediated apoptosis by 
the activation of Akt kinase through inhibiting cytochrome C release and the up-regulation of 
anti-apoptotic Bcl-XL [106]. This led to the hypothesis that Akt kinase is involved in the 
protective phenotype of wild type mice. To investigate Akt signaling in wild type mice 
compared to WISP1 knockout mice, western blot analysis was performed using protein 
lysates from the livers of mice treated with CCl4. A time-dependent increase in the 
phosphorylation of Akt was observed in both wild type and WISP1 knockout mice starting at 
12h and lasting until D1. However, the activation was stronger at 18h in the WISP1 knockout 
mice (Figure 56). 
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Figure 56: Activation of Akt in wild type mice and WISP1 knockout mice. a) Western blot analysis of Akt 
levels after administration of 460 mg/kg CCl4 in wild type and WISP1 knockout mice. b) Quantification of 
western blot analysis. Phosphorylation was stronger induced in the WISP1 knockout mice at 18h. At D1, a 
similar phosphorylation was observed in both wild type and WISP1 knockout mice. Total Akt was used as a 
reference control. Results are representative of six independent biological replicates per time point. Data are 
mean values ± S.E. 
 
 Surprisingly, contrary to previous reports [106] and to our hypothesis, western blot 
analysis of WISP1 knockout mice showed slightly stronger activation of Akt kinase. This 
suggests that Akt kinase signaling was not mainly involved in the protective phenotype, 
which was observed in wild type mice.  
 
3.12.4 Deletion of WISP1 leads to the activation of p38 mitogen-activated 
protein kinase (p38) upon CCl4 administration 
 The previous results indicated alterations in extracellular signal-regulated kinase 
(ERK1/2). To examine if further MAPK signaling was impaired, p38 mitogen-activated protein 
kinase (p38) and c-Jun N-terminal kinase (JNK) were investigated. Therefore, western blot 
analysis was performed using liver tissue homogenates from wild type and WISP1 knockout 
mice treated with CCl4. Phosphorylation of p38 was stronger activated in the wild type mice 
under control condition compared to WISP1 knockout mice (Figure 57). At 12h, slightly 
enhanced activation of p38 was observed in the WISP1 knockout mice. 
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Figure 57: Activation of p38 in wild type mice and WISP1 knockout mice. a) Western blot analysis of p38 
levels in wild type and WISP1 knockout mice after 460 mg/kg CCl4. b) Quantification of western blot analysis. 
Activation of p38 was stronger induced in the wild type mice under control condition. At 12h, activation was 
enhanced in the WISP1 knockout mice compared to wild type mice. Total p38 was used as a reference control. 
Results are representative of six independent biological replicates per time point. Data are mean values ± S.E.  
 
3.12.5 Early mediator of necrotic cell death receptor interacting protein 
kinase (RIP3) is not altered in WISP1 knockout mice compared to wild type 
mice  
 Receptor interacting protein kinase (RIP3) was recently identified as an early 
mediator of APAP toxicity in mice, while modulating mitochondrial dysfunction and oxidative 
stress [51]. Western blot analysis was performed to examine whether RIP3 kinase is involved 
in the development of advanced liver damage in WISP1 knockout mice. The results revealed 
no difference in RIP3 protein levels in both WISP1 knockout and wild type mice (Figure 58).  
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Figure 58: RIP3 levels in wild type mice and WISP1 knockout mice. a) Western blot analysis of RIP3 levels 
after administration of 460 mg/kg CCl4 in wild type and WISP1 knockout mice. b) Quantification of western 
blot analysis. No difference was detectable in the wild type mice compared to WISP1 knockout mice. GAPDH 
was used as loading control. Results are representative of three independent biological replicates per time 
point. Data are mean values ± S.E.  
 
 In conclusion, the analysis revealed significant differences in the activation of 
signaling proteins in wild type and WISP1 knockout mice after induction of liver damage. 
Enhanced activation of MAPK-associated signaling may be responsible for the increased 
susceptibility of the WISP1 knockout mice to liver damage. However, stronger activation of 
the pro-survival PI3K/Akt signaling pathway was observed in WISP1 knockout mice. 
Furthermore, RIP3 seemed to be not involved in the progression of liver damage in wild type 
and WISP1 knockout mice.  
 
3.12.6 CCl4-induced ER-stress activation is not altered by the deletion of 
WISP1  
 The accumulation of misfolded proteins is known to activate three sensors in the ER 
lumen: IRE1α, PERK, and ATF6. The induction of IRE1α leads to the splicing of Xbp1 to a 
potent transcription factor, sXbp1, which controls genes involved in protein folding and 
quality control. However, prolonged or massive ER-stress is known to induce apoptosis via 
the upregulation of the transcription factor CHOP, which can induce the expression of pro- 
apoptotic genes, such as Bim and Erol1, and suppress the anti-apoptotic genes, such as Bcl-2 
[99]. Therefore, the involvement of ER stress was investigated in wild type and WISP1 
knockout mice. Results from the PCR analysis of Xbp1 splicing revealed no difference 
between wild type and WISP1 knockout mice (Figure 59).  
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Figure 59: PCR analysis of ER-stress marker Xbp1 after administration of 460 mg/kg CCl4 in wild type and 
WISP1 knockout mice. Splicing of Xbp1 was detected at 2h and 8h after CCl4 administration with no difference 
between wild type and WISP1 knockout mice. The results are representative for three mice per condition. 
 
 Moreover, the transcription factor CHOP was analyzed using quantitative RT-PCR. 
CHOP expression was induced at 2h and 8h after induction of liver damage in both the wild 
type and WISP1 knockout mice. However, no significant difference could be observed. 
 
 
Figure 60: Time-dependent quantitative RT-PCR of CHOP expression in WISP1 knockout and wild type mice 
after administration of 460 mg/kg CCl4 for the indicated time points. CHOP expression was not altered in wild 
type mice compared to WISP1 knockout mice after induction of liver damage. Data represent mean of three 
independent biological replicates ± S.E. 
 
 Taken together, these results showed that ER stress is involved in liver damage after 
CCl4; [99], however it may not be the reason for the enhanced susceptibility in WISP1 
knockout mice.  
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3.12.7 MAPK and inflammation-associated signaling pathways are not altered 
in WISP1 knockout and wild type mice after paracetamol administration 
 Previous results suggested alterations in MAPK associated signaling pathways after 
administration of CCl4 in wild type mice compared to WISP1 knockout mice. In order to 
clarify whether signaling pathways were also altered upon APAP administration, western 
blot analysis was performed. Therefore, wild type and WISP1 knockout mice were injected 
intraperitoneally using 300 mg/kg APAP for 30min, 2h, 4h, 8h, 12h and 24h. PBS was used as 
vehicle control for 24h. Western blot analysis showed a strong activation of JNK at 2h and 4h 
after APAP administration (Figure 61). The phosphorylation decreased at 8h and 12h, 
returning back to control levels at D1. However, quantifications of signal volumes revealed 
no differences in the activation of JNK in wild type mice compared to WISP1 knockout mice.  
 
 
Figure 61: Activation of JNK in wild type mice and WISP1 knockout mice upon APAP administration. a) 
Western blot analysis of JNK levels after administration of 300 mg/kg APAP in wild type and WISP1 knockout 
mice for the indicated time points. b) Quantification of western blot analysis. Phosphorylation of JNK was 
detected as early as 2h and decreased until 12h after APAP administration. β-actin was used as loading control. 
Results are representative of three independent biological replicates per time point. Data are mean values ± 
S.E.  
 
 Strong phosphorylation of ERK1/2 was observed at 2h up to 12h after APAP 
administration (Figure 62). Western blot quantification of three independent biological 
replicates did not reveal significant differences in wild type mice compared to WISP1 
knockout mice.  
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Figure 62: Activation of ERK1/2 in wild type mice and WISP1 knockout mice upon APAP administration. 
Western blot analysis of ERK1/2 levels after administration of 300 mg/kg APAP in wild type and WISP1 
knockout mice. b) Quantification of western blot analysis. Phosphorylation of ERK1/2 was observed at 2h up 
to D1 after APAP administration. However, no significant difference was observed in the wild type mice 
compared to WISP1 knockout mice. β-actin was used as loading control. Results are representative of three 
independent biological replicates per time point. Data are mean values ± S.E.  
 
 Taken together, these results demonstrated that the activation of MAPK associated 
signaling pathways was not significantly altered upon APAP administration in wild type mice 
compared to WISP1 knockout mice. These results led to the hypothesis that protective 
effects of WISP1 are not mediated through these signaling pathways after APAP 
administration.  
 
3.12.8 Activation of hepatoprotective signaling (STAT3) is enhanced in WISP1 
knockout mice compared to wild type mice 
 Previous results for MAPK associated signaling pathways revealed differences upon 
the deletion of WISP1 after administration of 460 mg/kg CCl4. Since these pathways are 
known to be induced by growth factors, cytokines or cellular stress, the hypothesis was that 
inflammation plays an important role when regarding WISP1 phenotype [88, 179].  
 The hepatoprotective signal transducer and activator of transcription 3 (STAT3) is 
known to be induced by pro-inflammatory interleukin 6 (IL6) [55]. In order to study the 
activation of STAT3 signaling in wild type and WISP1 knockout mice, western blot analysis 
was performed using liver homogenates after CCl4 administration. Analysis revealed an 
enhanced and prolonged STAT3 activation in the WISP1 knockout mice starting at 12h until 
D1 after induction of liver damage (Figure 63).  
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Figure 63: Activation of STAT3 in wild type mice and WISP1 knockout mice upon CCl4 administration. a) 
Western blot analysis of STAT3 levels after administration of 460 mg/kg CCl4 in wild type and WISP1 
knockout mice. b) Quantification of western blot analysis. Activation of STAT3 signaling was observed starting 
at 8h until 18h in the wild type mice. Furthermore the analysis showed a prolonged and enhanced activation of 
STAT3 in the WISP1 knockout mice starting at 12h until D1. Total STAT3 was used as reference control. Results 
are representative of six independent biological replicates per time point. Data are mean values ± S.E. 
 
 Interestingly, western blot analysis of STAT3 signaling revealed even stronger 
activation of the hepatoprotective signaling in WISP1 knockout mice, although those mice 
exhibited enhanced liver damage. Besides the hepatoprotective effect of STAT3, its 
activation is also linked to inflammation. This led to the hypothesis that WISP1 knockout 
mice may display a higher inflammatory state, since phosphorylation of STAT3 can be 
induced by pro-inflammatory cytokines, such as interleukin 6 (IL6) [55].  
 
3.12.9 Deletion of WISP1 does not alter inflammation-associated signaling 
upon APAP administration 
 Previous results suggested alterations regarding phosphorylation of STAT3 in WISP1 
knockout mice after administration of 460 mg/kg CCl4. In order to study the activation of 
STAT3 after administration of 300 mg/kg APAP, western blot analysis was performed. 
Protein lysates were prepared from wild type and WISP1 knockout mice treated for 30min, 
2h, 4h, 8h, 12h and 24h. Activation of STAT3 signaling was enhanced at 2h until 12h upon 
APAP administration (Figure 64). At 4h, western blot analysis showed a slightly stronger 
activation of STAT3 signaling in WISP1 knockout mice compared to wild type mice.  
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Figure 64: Activation of STAT3 in wild type mice and WISP1 knockout mice upon APAP administration. 
Western blot analysis of STAT3 levels after administration of 300 mg/kg APAP in wild type and WISP1 
knockout mice. b) Quantification of western blot analysis. Results revealed phosphorylation of STAT3 at 2h 
until 12h after APAP administration. Stronger activation of STAT3 was observed in WISP1 knockout mice at 
4h. Total STAT3 was used as loading control. Results are representative of three independent biological 
replicates per time point. Data are mean values ± S.E. 
 
 In conclusion, western blot analysis revealed slightly stronger activation of STAT3 
only at 4h in WISP1 knockout mice compared to wild type mice.  
 
3.13 Inflammation-associated genes are stronger induced by the 
absence of WISP1  
 Sterile inflammation is a well-known factor during various acute and chronic liver 
diseases [52, 53]. However, its contribution to liver regeneration versus enhancing liver 
injury is not well-known and still under debate [52, 184]. For example, inhibition of DAMP 
receptors or antagonism of TLRs during liver ischemia-reperfusion were shown to protect 
against hepatic ischemia-reperfusion injury [70, 71], suggesting a pro-damaging role of 
inflammation. In contrast, depletion of macrophages by clodronate liposomes led to 
enhanced liver damage after administration of APAP, suggesting a pro-regenerative role 
upon acute liver damage [185]. 
 First, in order to study cytokine expression upon CCl4-induced liver injury in wild type 
and WISP1 knockout mice, quantitative RT-PCR was performed. Results revealed an increase 
of TNFα, Il6, Lcn2 and IFNγ expression at 12h and 18h (Figure 65). Interestingly, the 
induction of TNF and IL-6 was stronger in WISP1 knockout mice at 12h and 18h after 
administration of CCl4, with a slight increase in IFNγ expression at 12h. 
 
3 RESULTS 
116 
 
Figure 65: Time-dependent quantitative RT-PCR of inflammatory cytokines TNFα, Il6, Lcn2 and IFNγ in wild 
type mice and WISP1 knockout mice for the indicated time points. Induction of cytokine expression was 
observed for all targets between 12h and D1. However, quantitative RT-PCR showed an enhanced expression of 
TNFα and Il6 after 12h and 18h in WISP1 knockout mice compared to wild type mice. At 12h, a slight increase in 
IFNγ expression was observed after CCl4 administration. Data represent mean of six independent biological 
replicates ± S.E. 
 
 These results suggest that the induction of inflammation upon CCl4 intoxication is 
enhanced in livers of WISP1 KO mice. 
 
3.13.1 Expression of neutrophil recruitment-associated chemokines are 
increased in WISP1 knockout mice 
 The next step was to investigate the expression of different chemokines since they 
are known to be involved in leukocytes chemoattraction to the site of injury. Moreover, low 
concentration levels of CXC chemokines, such as CXCL1-2, CXCl3 or CXCL5-8, were associated 
with proliferation and liver repair; whereas, high levels were related to hepatotoxicity, upon 
binding to their receptor CXCR2 [178]. The results show an induction in chemokines´ 
expression for all targets after the induction of liver damage in wild type and WISP1 
knockout mice (Figure 66). However, an enhanced expression in WISP1 knockout mice was 
observed for CCl3 and CCl4 at 12h, for CCl2 at 8h, for CCl5, Cxcl1 and Cxcl5 at 18h 
respectively.  
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Figure 66: Time-dependent quantitative RT-PCR of various chemokines after administration of 460 mg/kg 
CCl4 in wild type mice and WISP1 knockout mice for the indicated time points. Results revealed enhanced 
expression of CCl2, CCl3, CCl4, CCl5, Cxcl1 and Cxcl5 in WISP1 knockout mice compared to wild type mice at 8h 
up to 18h respectively. Data represent mean of six independent biological replicates ± S.E. 
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 In conclusion, the levels of almost all chemokines investigated were stronger induced 
in WISP1 knockout mice upon CCl4 intoxication, suggesting that deletion of WISP1 enhances 
the inflammatory response during acute liver injury. 
 
3.13.2 WISP1 knockout mice shows enhanced immune cell infiltration 
compared to wild type mice 
 Signal transduction and quantitative RT-PCR revealed a higher inflammatory response 
in WISP1 knockout mice after induction of liver damage using 460 mg/kg CCl4. In order to 
clarify if immune cell infiltration was altered upon deletion of WISP1, immunohistochemical 
staining was performed with antibodies targeting markers for all leukocytes (CD45), 
neutrophils (Ly6G) and Kupffer cells (F4/80). 
 Leukocytes (CD45 positive cells) were uniformly distributed in the control condition 
of both the wild type and WISP1 knockout mice (Figure 67). In the early time points after 
CCl4 administration (30min until 8h), there were no differences between the wild type and 
WISP1 knockout mice. At 18h and on D1, a strong immune cell infiltration was detected at 
the site of injury in both mice (black arrows indicate positively-stained leukocytes).  
 Immunohistochemical analysis (Figure 68) revealed just few positive neutrophils in 
the control condition and in the early time points after CCl4 administration (30min up to 8h). 
At 18h and D1, there was a strong neutrophil infiltration at the site of injury in both the 
WISP1 knockout as well as wild type mice (black arrows indicate positively stained 
neutrophils). 
 Figure 69 shows immunohistochemical analysis of Kupffer cells in wild type and 
WISP1 knockout mice. In the control conditions and at early time points after administration 
of CCl4 (30min until 8h), Kupffer cells were uniformly distributed in wild type and WISP1 
knockout mice. At 18h, there was an accumulation of Kupffer cells at the borders of the 
pericentral regions in wild type mice. WISP1 knockout mice exhibited enhanced Kupffer cell 
infiltration towards the pericentral dead cell area, as well as the periportal area. 
Furthermore, both wild type and WISP1 knockout mice showed attenuated Kupffer cell 
infiltration on D1 of treatment.  
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Figure 67: Immunohistochemical staining of leukocytes (CD45) in wild type and WISP1 knockout mice after 
administration of 460 mg/kg CCl4 for the indicated time points. Leukocytes were detected and found to be 
homogenously distributed in the control livers of wild type and WISP1 knockout mice (black arrows indicate 
positively stained brown leukocytes). Although, the signal in WISP1 knockout mice seemed to be less 
pronounced. At 18h and D1 after intoxication, leukocytes accumulated at the border of the pericentral area. 
Representative images of three biological replicates per time point, scale bars represent 100 µm. 
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Figure 68: Immunohistochemical staining of Neutrophils (Ly6G) in wild type mice and WISP1 knockout mice 
after administration of 460 mg/kg CCl4 for the indicated time points. Only few neutrophils were observed in 
the control tissue, as well as at 30min up to 8h after administration of CCl4. At 18h and D1, neutrophils 
infiltrated in the liver to the site of injury (black arrows indicate positively stained brown neutrophils). 
Representative images of three mice per time point, scale bars represent 100 µm. 
3 RESULTS 
121 
 
Figure 69: Immunohistochemical staining of Kupffer cells (F4/80) in wild type and WISP1 knockout mice after 
administration of 460 mg/kg CCl4 for the indicated time points. Homogenous distribution of Kupffer cells was 
observed in the control tissue, as well as at 30min up to 8h after administration of CCl4. At 18h, Kupffer cells 
infiltrate at the border of the pericentral area in wild type mice (black arrows indicate brown stained Kupffer 
cells). Infiltration was observed to be enhanced in the WISP1 knockout mice at 18h. Representative images of 
three mice per time point, scale bars represent 100µm. 
 
 Immunohistochemical analyses revealed strong immune cell infiltration upon CCl4 
administration in wild type and WISP1 knockout mice. In order to quantify the number of 
infiltrating leukocytes and neutrophils, 10 images were counted per biological replicate for 
positively-stained cells. Quantification of leukocytes revealed a reduced numbers in WISP1 
knockout mice in the control condition compared to wild type mice (Figure 70). However, 
more leukocytes were counted in WISP1 knockout mice at 18h after CCl4 administration. 
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There was also increased neutrophil infiltration in WISP1 knockout mice as early as 8h, 
compared to wild type counterparts, particularly at 8h and 18h after induction of liver injury.  
 
 
Figure 70: Time-dependent quantifications of immunohistochemical analysis of a) leukocytes and b) 
neutrophils. Results for CD45 revealed less leukocytes in WISP1 knockout mice in the control condition. 
However, at 18h more leukocytes were detected in the WISP1 knockout mice. More neutrophils were 
determined in WISP1 knockout mice already at 8h after CCl4 administration. At 18h, the number of neutrophils 
is doubled in WISP1 knockout mice compared to wild type mice. Data represent mean of 10 images counted 
per biological replicate, three biological replicates were used per time point ± S.E.  
 
 Taken together, these investigations indicated that there is a higher immune cell 
infiltration in WISP1 knockout mice upon CCl4 intoxication.  
 
3.14 WISP1 knockout hepatocytes reveal higher susceptibility to 
cytokine-induced cell death 
 The previous results revealed an enhanced inflammatory response in WISP1 
knockout mice after administration of 460 mg/kg CCl4. To gain insights into whether 
inflammation could be the cause for enhanced liver damage in WISP1 knockout mice, 
primary hepatocytes from wild type and WISP1 knockout mice were isolated and cultivated 
in collagen monolayer configuration. Hepatocytes were stimulated using TNFα and TGFβ in 
combination with actinomycin D to block transcription and DNA replication [186] in order to 
induce apoptosis. 
 Microscopically, no difference could be observed in WISP1 knockout hepatocytes 
regarding the morphology and viability in the control condition compared to wild type 
hepatocytes (Figure 71, 72). Upon stimulation with TNFα, apoptosis was observed in wild 
type and WISP1 knockout hepatocytes at already low concentrations. However, the WISP1 
knockout hepatoyctes revealed enhanced apoptosis starting from 5 ng/ml up to 10 ng/ml 
TNFα (indicated by red circles) compared to wild type hepatocytes.  
 TGFβ stimulation also caused an increase in apoptosis in both wild type and WISP1 
knockout hepatocytes in a concentration-dependent manner (Figure 72). Importantly, the 
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WISP1 knockout hepatocytes exhibited more apoptotic cells starting at concentrations of 
5 ng/ml up to 10 ng/ml of TGFβ (indicated by red circles).  
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Figure 71: Concentration-dependent in vitro stimulation of primary wild type and WISP1 knockout 
hepatocytes using TNFα for 8h. In vitro stimulation using different concentrations of TNFα revealed more dead 
cells at 5 ng/ml up to 10 ng/ml in the WISP1 knockout hepatocyte culture compared to wild type hepatocyte 
culture (indicated by red circles). Representative images of four independent biological replicates per 
concentration. Scale bars represent 20 µm.  
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Figure 72: Concentration-dependent in vitro stimulation of primary wild type and WISP1 knockout 
hepatocytes using TGFβ for 24h. In vitro stimulation using different concentrations of TGFβ revealed more 
dead cells at 5 ng/ml up to 10 ng/ml in the WISP1 knockout hepatocyte culture compared to wild type 
hepatocyte culture (indicated by red circles). Representative images of three independent biological replicates 
per concentration. Scale bars represent 20 µm.  
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 Microscopic assessment of apoptosis induction revealed enhanced susceptibility to 
TNFα as well as TGFβ stimulation in both the wild type and WISP1 knockout hepatocytes. For 
quantitative assessment, apoptotic cells of wild type and WISP1 knockout conditions were 
quantified. In this case, 5 images per concentration and biological replicate were counted. 
Quantification revealed a significant increase in apoptotic cells upon TNFα stimulation in the 
WISP1 knockout hepatocyte culture at all concentrations (Figure 73 a) compared to wild type 
conditions. Analyses of TGFβ stimulation (Figure 73 b) showed significantly enhanced 
apoptosis in the WISP1 knockout hepatocyte culture at just 7.5 ng/ml and 10 ng/ml.  
 
 
Figure 73: Concentration-dependent quantification of apoptotic cells after in vitro stimulation using a) TNFα 
and b) TGFβ. Stimulations using TNFα revealed a significant increase in the percentage of apoptotic cells at all 
concentrations in the WISP1 knockout hepatocyte culture. TGFβ stimulation showed a significant increase in 
the percentage of apoptotic cells at just 7.5 ng/ml and 10 ng/ml in the WISP1 knockout hepatocyte culture. 
Data represent mean of four (TNFα); and three (TGFβ) biological replicates ± S.E., five images were counted for 
each biological replicate, ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 to wild type condition, unpaired t-test. 
 
 Taken together, this investigation showed enhanced apoptosis upon TNFα and TGFβ 
stimulation in WISP1 knockout hepatocytes culture compared to wild type hepatocytes 
culture. However, TGFβ stimulation showed higher variances between the biological 
replicates than after stimulation with TNFα. These results supported the hypothesis that 
inflammation is involved in the development of enhanced liver damage in WISP1 knockout 
mice.  
 
3.14.1 Cleaved caspase 3 is stronger induced in WISP1 knockout hepatocytes 
upon stimulation with TNFα 
 In order to study the differential sensitivity to induction of apoptosis in wild type and 
WISP1 knockout hepatocytes, western blot analysis of cleaved caspase 3 was performed 
using protein lysates from WISP1 knockout and wild type hepatocytes. Cleaved caspase 3 
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was observed upon TNFα stimulation in a time-dependent manner in both wild type and 
WISP1 knockout hepatocytes (Figure 74). However, quantification of the western blot 
analysis revealed higher levels upon deletion of WISP1 in hepatocytes.  
 
 
Figure 74: Cleaved caspase 3 levels in wild type and WISP1 knockout hepatocytes upon TNFα stimulation. a) 
Western blot analysis of cleaved caspase 3 levels in wild type and WISP1 knockout hepatocytes after 
stimulation using TNFα for 8h for the indicated concentrations. b) Quantification of western blot analysis. 
Analysis shows a concentration-dependent increase in the cleaved caspase 3 levels in wild type and WISP1 
knockout hepatocytes. However, higher levels of cleaved caspase 3 were observed in WISP1 knockout 
hepatocytes compared to wild type hepatocytes. β-actin was used as loading control. Data represent mean of 
three independent biological replicates ± S.E.  
 
 In conclusion, this result confirmed the microscopic observation of enhanced 
apoptosis in WISP1 knockout hepatocytes upon TNFα stimulation.  
 
3.14.2 TGFβ stimulation displays no clear difference in cleaved caspase 3 
signaling  
 Since TGFβ stimulation revealed higher sensitivity of WISP1 knockout hepatocytes 
compared to wild type hepatocytes, protein expression analysis was performed to 
investigate the cleavage of caspase 3 as a marker of apoptosis. Protein lysates were 
prepared from primary wild type and WISP1 knockout hepatocytes after stimulation using 
different concentrations of TGFβ. Results revealed activation of cleaved caspase 3 in both 
WISP1 knockout and wild type hepatocytes (Figure 75). There were no differences in the 
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activation of cleaved caspase 3 signaling in wild type hepatocytes compared to WISP1 
knockout hepatocytes.  
 
Figure 75: Cleaved caspase 3 levels in wild type and WISP1 knockout hepatocytes upon TGFβ stimulation. a) 
Western blot analysis of cleaved caspase 3 levels in wild type and WISP1 knockout hepatocytes after 
stimulation using TGFβ for 24h for the indicated concentrations. b) Quantification of western blot analysis. 
Results revealed no difference in the activation of cleaved caspase 3 upon TGFβ stimulation in wild type and 
WISP1 knockout hepatocytes. β-actin was used as loading control. Data represent mean of three independent 
biological replicates ± S.E.  
 
 Taken together, it was shown that there is a comparable activation of cleaved 
caspase 3 upon TGFβ stimulation in wild type and WISP1 knockout mice. This is may be due 
to high variability between biological replicates which were already seen upon the 
quantification of apoptotic cells.  
 
3.15 WISP1 knockout hepatocytes are more susceptible to paracetamol 
toxicity in vitro 
 The previous analyses revealed enhanced susceptibility of WISP1 knockout mice upon 
300 mg/kg APAP administration. Hepatocytes which make up about 80 % of the liver mass 
[8], were shown to be the main source of WISP1 expression upon CCl4 administration in 
mice. Furthermore, pervious investigations by our group revealed that WISP1 is secreted by 
hepatocytes upon TGFβ stimulation in vitro (Campos, unpublished data). Therefore, the next 
step was to investigate wild type and WISP1 knockout cells upon stimulation using APAP in 
vitro in a collagen sandwich configuration. The first approach was to stimulate the cells using 
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a concentration range of 1 mM up to 10 mM directly after 3h of plating the cells, followed by 
24h of incubation. The second approach was to stimulate the hepatocytes on D1 in culture 
using the same concentrations for 24h incubation. Propidium iodide staining was performed 
directly after 24h of stimulation to visualize the dying hepatocytes.  
 Figure 76 shows results from propidium iodide staining of wild type and WISP1 
knockout hepatocytes after stimulation. Hepatocytes are stained positive for propidium 
iodide already at low (1 mM) concentrations of APAP. Cell death occurred in a 
concentration-dependent manner in wild type and WISP1 knockout hepatocytes. However, 
the deletion of WISP1 led to increased cell death upon APAP stimulation compared to wild 
type hepatocytes.  
 Stimulation on D1 in culture also led to cell death starting at 1 mM of APAP (Figure 
77). Increased concentration induced enhanced cell death in both wild type hepatocytes and 
WISP1 knockout. The toxic effect of APAP appeared to be more prominent in the WISP1 
knockout hepatocytes, where all hepatocytes were shown to be dead at 7.5mM and 10 mM 
of APAP stimulation.  
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Figure 76: Propidium iodide staining of wild type and WISP1 knockout hepatocytes after stimulation using 
various concentrations of APAP (3h after plating for 24h). Results show no alterations under control condition 
in both the wild type culture and WISP1 knockout culture. The number of dead cells increased in a 
concentration-dependent manner (nuclei were stained red upon cell death). Though, the WISP1 knockout 
hepatocytes showed an increased number of dead cells compared to wild type hepatocytes. Representative 
images of three biological replicates, magnification of 20X. 
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Figure 77: Propidium iodide staining of wild type and WISP1 knockout hepatocytes after stimulation using 
different concentrations of APAP (24h after plating for 24h). Propidium iodide staining revealed the first dead 
cells already at 1 mM of APAP. Cell death of hepatocytes (nuclei were stained red upon cell death) increased in 
a concentration-dependent manner in wild type and WISP1 knockout hepatocytes. Though, the deletion of 
WISP1 in hepatocytes led to an increased number of dead cells compared to wild type hepatocytes. 
Representative images of three biological replicates, magnification of 20X.  
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 In order to obtain quantitative measurements of cell death in wild type and WISP1 
knockout hepatocytes, propidium iodide staining was quantified. Stimulation after 3h in 
culture (for 24h) revealed a significant increase in the percentage of dead cells in the WISP1 
knockout culture at all the indicated concentrations compared to the wild type culture. 
Stimulation after 24h in culture (for 24h) also showed a significant increase in the 
percentage of dead cells at all concentrations in the WISP1 knockout culture compared to 
wild type culture. 
 
 
Figure 78: Quantification of dead cells after APAP stimulation a) Stimulation at 3h after plating for 24h. 
Quantification of dead cells revealed a significant increase in the percentage of dead cells in the WISP1 
knockout culture compared to the wild type culture. b) Stimulation at D1 in culture for 24h. Quantification 
detected a significant increase in the percentage of dead cells in the WISP1 knockout culture compared to the 
wild type culture. Data represent mean of three independent biological replicates ± S.E., 10 images were 
counted for each biological replicate, ****P<0.0001, **P<0.01, *P<0.05 to wild type condition, unpaired t-test. 
 
 Taken together, these results revealed a higher susceptibility of WISP1 knockout 
hepatocytes to APAP-induced cell death in vitro.  
 
3.16 Affymetrix gene array analysis of WISP1 knockout mice revealed 
alterations in gene expression compared to wild type mice 
 In order to study gene expression alterations in wild type and WISP1 knockout mice, 
a time resolved global gene expression profiling using Affymetrix microarrays was 
performed. For this purpose, wild type and WISP1 knockout mice received a single dose of 
460 mg/kg CCl4 or olive oil as control vehicle intraperitoneally. Liver tissue was collected 
after early (8h and 12h) and late time points (D1 and D3). For each time point, five wild type 
and five WISP1 knockout mice were used. Initially, expression levels after 8h, 12h, D1 and D3 
of wild type and WISP1 knockout mice were compared to their respective controls. The 
analysis detected 3,648 genes that were at least 2-fold deregulated in wild type and 4,617 
genes deregulated in WISP1 knockout mice, when compared to their corresponding control 
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group (pValue (FDR) < 0.05). The strongest up-regulated gene was the small proline-rich 
protein 1A (Sprr1a) with a 205-fold increase in expression at 12h in wild type mice and 231-
fold in WISP1 knockout mice (Figure 79). The strongest down-regulated gene was 
cytochrome P450, family 7, subfamily a, polypeptide 1 (Cyp7a1) with a 35-fold down-
regulation in wild type mice and 93-fold down-regulation in WISP1 knockout mice. 
Inflammation- and stress associated genes were among the strongest up-regulated genes, 
such as Hspa1a and 1b (heat shock protein 1a and 1b), member 2), Tnfrsf12a (tumor necrosis 
factor receptor superfamily, member 12a), Atf3 (activating transcription factor 3), Ifrd1 
(interferon-related developmental regulator 1), CD14 (CD14 antigen), Ier3 (immediate early 
response 3) and Ddit3 (DNA-damage inducible transcript 3). Likewise, metabolism-associated 
genes like Hsd3b5 (hydroxyl-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 5), Cyp2c37 (cytochrome P450, family 2, subfamily c, polypeptide 37), Cyp2c38 
(cytochrome P450, family 2, subfamily c, polypeptide 38) and Sult2a8 (sulfotransferase 
family 2A, dehydroepiandrosterone (DHEA) – preferring, member 8) were among the most 
down-regulated genes.  
 
 
Figure 79: Analysis of groups of similar regulated genes. The figure shows a snapshot of the results obtained 
for groups of similar regulated genes. Results show the fold change over wild type control or WISP1 knockout 
control respectively. Data are attached in the supplement 1.  
 
 Interestingly, gene array of wild type and WISP1 knockout mice did not reveal an up-
regulation of lipocalin 2 (Lcn2), which was one of the most up-regulated genes detected in 
previous gene array studies by our group [171]. However, typical gene expression patterns, 
such as the up-regulation of inflammation- and stress associated genes, and the down-
regulation of metabolism, were detected as previously reported by [171].  
 Principal component analysis indicated a good clustering of gene expression in wild 
type and WISP1 knockout control and after 8h of CCl4 administration (Figure 80). However, 
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at 12h, the WISP1 knockout samples clearly deviated from the corresponding wild type 
samples. At 24h and 72h, samples from wild type and WISP1 knockout mice clustered in a 
more diffuse way. This transcriptional regulatory network can be associated to 
corresponding biological features, already described by Campos [171], such as the activation 
of MAPK and ER-stress associated pathways (2h-8h) followed by an inflammation response 
on D1. These events are followed by the repression of metabolism-associated genes. Finally, 
regenerative processes take place, which are characterized by proliferating hepatocytes to 
restore tissue homeostasis (D2-D4). 
 
 
Figure 80: Principal component analysis of gene expression in wild type and WISP1 knockout livers after 
administration of 460 mg/kg CCl4. The graph represents the coordinates of the principal component 1 (PC1) 
and principal component 2 (PC2), which account for 54.5 % and 22.1 % of the deregulated genes in the 
transcriptional response after CCl4, respectively. The position of control and 8h samples revealed a robust and 
time-dependent clustering of 5 independent biological replicates per time point. However at 12h, WISP1 
knockout samples clustered clearly away from the corresponding wild type samples. At 24h and 72h, samples 
clustered in a more diffuse way, finally returning back to almost control conditions. 
 
 Taken together, the principal component analysis revealed a good clustering within 
the time-matched samples from both the wild type and WISP KO mice after CCl4 
administration. Importantly, at 12h WISP1 knockout samples clearly deviated from the wild 
type samples. Nonetheless, at the peak of liver damage (24h), samples clustered in a more 
diffuse way, thus showing no shift between wild type and WISP1 knockout mice. This was 
also observed for the regenerative process (72h) which seemed to be comparable in WISP1 
knockout and wild type mice. Further bioinformatics analyses were applied to identify the 
differences in transcriptional responses of wild type and WISP1 knockout mice.  
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3.16.1 Fuzzy C-Means clustering established 15 gene expression clusters  
 Fuzzy C-Means clustering allows pattern recognition in a large set of data [170], and 
was therefore used to analyze differentially expressed genes of WISP1 knockout and wild 
type mice. Here, the gene expression values from WISP1 knockout mice were used to 
calculate the differences in fold change relative to the wild type mice, according to the 
different time points measured. Subsequently, results were clustered using Fuzzy C means 
algorithm. Analysis revealed 15 main gene expression clusters, which consisted of a 
maximum of 21 genes (Figure 81).  
 
 
Figure 81: Fuzzy C-Mean clustering analysis of WISP1 knockout versus wild type mice identified 15 gene 
expression clusters. Fuzzy C-Mean clustering was used to analyze differential expressed genes in WISP1 
knockout mice. The analysis identified 15 main gene expression clusters, Fold = 1.5, p-value (FDR) < 0.05, data 
are attached in the supplement 2. 
 
3.16.2 Gene ontology and KEGG analyses revealed alterations in lipid 
metabolism in WISP1 knockout mice 
 Gene ontology (GO, http://www.geneontology.org/), an expert curated database 
assigning genes to various functional categories, was used to obtain biologically meaningful 
contexts from the gene list [187]. This database assigned genes to various functional 
categories [187] divided into three main categories: biological process (BP), molecular 
function (MF) and cellular component (CC). This method was applied to identify enriched 
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biological motifs within the time-dependent analysis. Therefore, data obtained from Fuzzy C-
Mean clustering were used.  
 Analysis of GO “biological process” revealed high enrichment of metabolism 
associated terms in cluster 1, such as “carboxylic metabolic process” (p = 3.62E-10), “oxoacid 
metabolic process” (p = 5.88E-10) and “small molecule metabolic process” (p = 5.78E-08) 
(Figure 82). Cluster 1 contained down-regulated genes for the 8h and D1 time points, 
indicating an intense loss in metabolic functions in both the WISP1 knockout and wild type 
mice after induction of liver damage. Moreover, cluster 2 and 12 depicted a high enrichment 
in lipid metabolic processes, such as “single-organism metabolic process” (p = 1.63E-08), 
“cellular lipid metabolic process” (p = 1.08E-09) and “organic substance metabolic process” 
(p = 1.13E-06) (Figure 62). These clusters showed an up-regulation of genes at 8h and D1, 
indicating a strong induction of lipid metabolism associated genes during the formation of 
acute liver damage.  
 
 
Figure 82: Analysis of GO “biological process” overrepresentation in a time-dependent gene clusters. The 
figure shows a snapshot of the results obtained from the overrepresentation of GO “biological processes”. The 
strongest overrepresentations of GO motifs were observed in cluster 1 containing down-regulated genes; 
clusters 2 and 12 containing up-regulated genes. Cluster 1 showed a high enrichment of GO terms associated 
with metabolism; clusters 2 and 12 were associated with lipid metabolism and oxidation-reduction processes, 
gray colored boxes indicate p-value˂10-5, data are attached in the supplement 3. 
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 Previous analysis of GO “biological process” showed a high enrichment of lipid 
metabolic processes in clusters 2 and 12. In line with this, analysis of GO “molecular 
function” revealed an enrichment of metabolism in up-regulated gene clusters (Figure 83). 
Among these genes clusters, GO terms such as “catalytic activity” (p = 2.90E-06) and 
“oxireductase activity” (p = 2.74E-06) were detected, suggesting that enzymes involved in 
these processes, like cytochrome P450 [188], are induced in these clusters.   
 
 
Figure 83: Analysis of GO “molecular function” overrepresentation in time-dependent gene clusters. The 
figure represents a snapshot of results obtained for overrepresentation of GO “molecular function”. According 
to previous analyses “biological process”, strong overrepresentations of GO motifs were observed in clusters 2 
and 12, containing up-regulated genes with GO terms such as enzyme activity, gray colored boxes indicate p-
value˂10-5, data are attached in the supplement 3. 
 
 Further analysis of GO “cellular component” confirmed previous results showing an 
up-regulation of lipid metabolic processes (Figure 84). Clusters 2 and 12 revealed an 
enrichment in GO terms, such as “membrane-bounded organelle” (p = 3.43E-07) and 
“cytoplasm” (p = 7.90E-06).  
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Figure 84: Analysis of GO “cell component” overrepresentation in the time-dependent gene clusters. The 
snapshot represents the results obtained for overrepresentation of GO “cell component”. The strongest 
overrepresentations of GO motifs were observed in clusters 2 and 12, showing a high enrichment of GO terms 
associated with membrane-bounded organelle and cytoplasm, gray colored boxes indicate p-value˂10-5, data 
are attached in the supplement 3. 
 
 However, to gain more precise information about altered pathways in this model, the 
Kyoto Encyclopedia of Genes and Genomes (KEGG http://www.genome.jp/kegg/) was used 
to identify biological motifs [189]. KEGG is a curated database that integrates current 
knowledge on molecular interactions, such as pathways, with databases such as GO [189]. 
Consistent with previous analysis, KEGG pathway enrichment in the gene clusters 2 and 12 
revealed strong overrepresentation of lipid and vitamin A metabolism associated pathways 
(Figure 85), like “PPAR signaling pathway” (p = 7.21E-06), “fatty acid degradation” (p = 5.43E-
09) and “retinol metabolism” (p = 9.23E-06). Moreover, metabolism-associated terms were 
detected in down-regulated gene cluster 1, including “metabolic pathways” (p = 8.38E-06). 
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Figure 85: Analysis of KEGG pathways overrepresentation in time-dependent gene clusters. This figure shows 
a snapshot of the results obtain for overrepresentation of KEGG pathways. Strongest overrepresentations of 
KEGG pathways were observed in clusters, which contain down-regulated genes (cluster 1) and up-regulated 
genes (clusters 2 and 12). Cluster 1 revealed a high enrichment of metabolic pathways, whereas clusters 2 and 
12 were highly associated to fatty acid metabolism, gray colored boxes indicate p-value˂10-5, data are attached 
in the supplement 3. 
 
 Taken together, GO and KEGG analyses revealed strong down-regulation of 
metabolism associated genes upon early time points of liver injury. Interestingly, the results 
showed strong up-regulation of lipid metabolism associated genes and pathways in WISP1 
knockout mice compared to wild type mice, which has never before been described. Hence, 
the results led to the hypothesis that the absence of WISP1 in the knockout mice altered 
lipid metabolism, potentially influencing the susceptibility to hepatotoxic substances.  
 
3.16.3 Absence of WISP1 leads to altered expression of metabolism-
associated genes 
 Since GO and KEGG analyses revealed alterations regarding metabolism, various 
genes were chosen to be confirmed by qRT-PCR. First, Cyp4a14 (cytochrome P450, family 4, 
subfamily a, polypeptide 14) and Cyp4a10 (cytochrome P450, family 4, subfamily a, 
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polypeptide 10) were investigated, since their upregulation was higher in the WISP1 
knockout mice compared to wild type mice (Figure 86). These cytochrome P450 enzymes are 
known to be involved in ω-hydroxylation of saturated and unsaturated fatty acids [190]. 
Furthermore, Fuzzy C-Mean clustering revealed a down-regulation of Serpina12 and 
Serpina1d already in the control condition and after CCl4 administration at all time points in 
the WISP1 knockout mice. These serine protease inhibitors are known to be involved in 
obesity and inflammation [191]. Finally, CIDEC was chosen as the gene array analysis 
revealed an up-regulation on D1, where enhanced susceptibility was detected in WISP1 
knockout mice upon induction of acute liver damage. Recently, CIDEC was reported to 
promote the formation of fat droplets and to be involved in the development of alcoholic 
steatohepatitis in mice and humans [192]. 
 
 
Figure 86: Analysis of Fuzzy C-Means clustering of WISP1 knockout mice versus wild type mice. Analysis 
revealed up-regulation (red color) of Cyp4a14, Cyp4a10 and CIDEC at 12h and D1 in the WISP1 knockout mice 
compared to wild type mice. Down-regulation (green color) was detected for Serpina12 and Serpina1d at all 
time points. Red color = fold change is greater two and pValue < 0.05, light red = fold change is greater two and 
pValue > 0.05, green = fold change is less minus two and pValue < 0.05, light green = fold change is less minus 
two and pValue > 0.05. Date are attached in the supplement 2.  
 
 Quantitative RT-PCR was performed using RNA from liver homogenates of wild type 
and WISP1 knockout mice after administration of 460 mg/kg CCl4 for 30min, 2h, 8h, 12h, 18h 
and D1. The results confirmed gene array data, showing a stronger induction of Cyp4A14 and 
Cyp4a10 in the WISP1 knockout mice at 18h and D1 compared to wild type mice (Figure 87).  
 
 
Figure 87: Time-dependent quantitative RT-PCR of Cyp4A14 and Cyp4A10 expression in wild type and WISP1 
knockout mice after administration of CCl4. Results revealed enhanced Cyp4A14 expression at 18h and D1 
after CCl4 administration. Cyp4A10 expression was stronger induced at 30 min, 18 h and D1 after CCl4 
administration. Data represent mean of six independent biological replicates ± S.E. 
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 Quantification of Serpina1d expression detected just a small decrease in control 
conditions and at 2h in WISP1 knockout mice, which did not completely reflect the data 
obtained from gene array (Figure 88). However, Serpina12 was strongly down-regulated at 
all time points in the WISP1 knockout mice compared to wild type mice. Finally, qRT-PCR 
analysis of CIDEC showed that its expression was upregulated in wild type and WISP1 
knockout mice after administration of CCl4, however on D1, the induction was higher in 
WISP1 knockout mice compared to wild type mice. 
 
 
Figure 88: Time-dependent quantitative RT-PCR of Serpina1d, Serpina12 and CIDEC expression in wild type 
and WISP1 knockout mice after administration of CCl4. Results showed a slight decrease in Serpina1d 
expression in WISP1 knockout mice under control conditions. However, up to D1 expression levels were 
comparable. Furthermore, analysis revealed a downregulation of Serpina12 at all time points in the WISP1 
knockout mice compared to wild type mice. CIDEC was induced upon CCl4 administration in both the wild type 
and WISP1 knockout mice. Enhanced expression levels were detected in the WISP1 knockout mice on D1 
compared to wild type mice. Data represent mean of six independent biological replicates ± S.E.  
 
 Taken together, quantitative RT-PCR confirmed the gene array data, showing an up-
regulation of Cyp4a14, Cyp4a10 and CIDEC at late time points after CCl4 administration. 
Moreover, down-regulation of Serpina12 in WISP1 knockout mice was also confirmed; 
however, there was only a slight decrease in Serpina1d as detected with qRT-PCR.  
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 In the past, hepatotoxic effects were mainly associated with altered metabolism or 
redox state. However, nowadays it is well known that hepatotoxic effects are triggered by 
various cellular and molecular mechanisms, such as induction of ER stress [99] or 
inflammation [55]. Previous gene array studies by our group revealed activation of MAPK 
signaling and ER stress, induction of inflammation, down-regulation of metabolism and 
finally regeneration [171] leading to a detailed description of fundamental biological 
features occurring upon drug-induced liver injury. In this study, WISP1 was identified as 
highest up-regulated gene among its protein family. In order to study the influence of WISP1 
upon drug-induced liver injury, a knockout mouse model was established. Two well-known 
and robust models to investigate hepatocellular injury and regeneration were chosen: CCl4 
and APAP. Surprisingly, genetic deletion of WISP1 led to enhanced susceptibility to CCl4 
administration as well as to APAP. CCl4-induced liver injury was associated with increased 
immune cell infiltration and increased expression of pro-inflammatory cytokines. Moreover, 
stress-associated signal transduction and inflammation-associated signaling pathways were 
stronger activated in WISP1 knockout mice compared to wild type mice upon CCl4 
administration. Interestingly, liver regeneration was not impaired by the absence of WISP1. 
Gene array analysis of WISP1 knockout and wild type mice revealed alterations regarding 
lipid metabolism, including strong up-regulation of cytochrome p450 enzymes in the WISP1 
knockout mice as well as up-regulation of CIDEC, which was reported to be involved in the 
development of alcoholic steatohepatitis. Taken together these results suggested that 
genetic deletion of WISP1 may alter the inflammatory response upon acute liver injury and 
potentially also lipid metabolism in the liver, which might influence the susceptibility to 
hepatotoxic-induced liver damage.  
 Upon previous gene array analysis, Wnt-induced secreted protein-1 (WISP1) was 
detected as one of the most up-regulated genes among the CCN family members. During my 
study I was able to validate WISP1 expression upon CCl4 administration by qRT-PCR in a time-
dependent manner, confirming a strong induction of WISP1 within the early injury phase (2h 
up to D1) in C57Bl/6N mice. CCN proteins were reported to be dynamically expressed upon 
various mitogenic signals as well as environmental alterations, such as inflammatory 
cytokines [130, 132]. Therefore, an up-regulation of WISP1 upon liver injury, whereby 
various cytokines and growth factors play an important role, is to be expected. Nonetheless, 
this is the first time that expression of WISP1 is considered to be connected with acute liver 
injury. While performing qRT-PCR analysis of different cell populations from liver tissue, it 
was observed that NPCs showed the highest WISP1 expression in control condition, whereas 
upon CCl4 administration, the induction of WISP1 was strongest in hepatocytes. To 
determine the overall contribution of WISP1 expression derived from NPCs compared to 
whole liver, it is important to consider that NPCs just make about 20 % of the liver cell mass 
compared to 80 % of hepatocytes. Furthermore, hepatocytes express up to four times more 
RNA mass than NPCs (Agata Widera´s dissertation [193]). Preliminary experiments from our 
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laboratory suggest that hepatocytes do not secrete WISP1 very effectively as shown by 
adeno-associated virus-derived overexpression of WISP1 (Daniela González´s dissertation, 
unpublished). Therefore, further experiments are necessary to determine the cell sources of 
WISP1 in liver tissue. Another difficulty in assessing the cell source of WISP1 in liver tissue is 
that histological analysis of WISP1 expression was not successful. This also makes it difficult 
to determine if there is a zonal localization and expression of WISP1. As reviewed in [132], 
CCN proteins were reported to be expressed upon various types of diseases such as cancer, 
liver fibrosis or osteoarthritis. While investigating WISP1 expression in a human liver disease 
cohort, containing patients suffering from fibrosis, cirrhosis or hepatocellular carcinoma, 
WISP1 expression was increased in cirrhosis and hepatocellular carcinoma patients’ samples. 
In line with this, CCN2 protein levels are known to be elevated in human patients suffering 
from liver fibrosis and correlate with the severity of systemic fibrosis [132]. Moreover, 
expression of CCN1 was found to be significantly higher in nodular HCC than the expression 
in solitary and small HCC, suggesting that CCN1 correlates with the recurrence and 
metastasis of HCC [134]. Taken together, these findings also highlight the importance and 
possible influence of WISP1 also in human liver diseases.  
 The implementation of a WISP1 knockout mice was an essential tool in my thesis. 
PCR and qRT-PCR analyses revealed successful validation of the absence of WISP1 in the 
knockout mice. Interestingly, WISP1 expression was determined in several tissues of which 
the strongest expression was detected in the lung, spleen and brain of wild type mice and 
lower expression was observed in the liver, intestine and muscles, which correlates with 
previous publications [128, 134]. Moreover, Königshoff et al reported that WISP1 is up-
regulated in patients suffering from idiopathic pulmonary fibrosis as well as in the mouse 
model of bleomycin-induced lung fibrosis. Depletion of WISP1 by a neutralizing antibody led 
to reduced bleomycin-induced lung fibrosis in mice [194]. This indicates that WISP1 might 
not only be important for the liver but also for the lung. However, the functions of WISP1 
can be diverse and seem to be highly organ- and cell type dependent.  
 However, contrary to other family members such as CCN1, CCN2 and CCN5, genetic 
deletion of WISP1 did not lead to embryonic or perinatal lethality, thus suggesting that 
WISP1 may not play an important role during development. Recently, another WISP1 
knockout mouse was reported to show defects in bone integrity, confirming no embryonic 
lethality of mice lacking WISP1 [195]. Analysis of bone tissue in our WISP1 knockout mice 
also showed similar bone defects (Ingo Seiler bachelor thesis, University Tübingen). 
Additionally, analyses of wild type and WISP1 knockout mouse livers did not reveal any 
difference regarding physiological or histological parameters. Further analyses regarding the 
redox state and metabolism associated gene Cyp2e1, which is important for drug 
metabolization [30], did not reveal any difference in WISP1 knockout mice compared to wild 
type mice in terms of control conditions. Therefore, WISP1 knockout mice were used to 
further study the role of WISP1 in acute liver injury. 
 A central result of my study was that genetic deletion of WISP1 led to enhanced 
susceptibility to hepatotoxic substances including CCl4 and APAP. When regarding 
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histological analyses of WISP1 knockout mouse livers after administration of CCl4, I was able 
to show that the dead cell areas were doubled in size compared to wild type mice. 
Furthermore, the first hepatic injury was observed after 12h of CCl4 administration and full 
dead cell area was detected after 18h in WISP1 knockout mice. However, wild type mice 
showed first dead cell area at 18h after CCl4 administration and full dead cell area was 
achieved on D1. This suggested that the genetic deletion of WISP1 did not only lead to 
enhanced susceptibility to hepatotoxic compounds, but also to a time-shift in developing 
liver damage. WISP1 was reported to promote cell survival via activation of Akt signaling 
[106] as well as upon TNFα mediated cardiomyocyte death [155]. Therefore, Akt signaling in 
wild type and WISP1 knockout mice was examined, leading to the conclusion that Akt 
signaling is not the main pathway involved as there was even a slightly stronger activation in 
the WISP1 knockout mice. However, during my study I was able to show for the first time 
that WISP1 may act as a pro-survival factor upon acute liver injury in vivo, induced by both 
CCl4 and APAP. This suggests that the protective role may not be  an unique mechanism 
induced by a special hepatotoxic compound but rather a general key mediator in response to 
hepatocellular stress. 
 In the past, hepatotoxicity was associated with an altered redox state [45] as well as 
alterations in metabolism [46, 47]. To test the hypothesis, that deletion of WISP1 may alter 
the redox state or metabolism in hepatocytes upon CCl4 administration, glutathione content 
as well as cytochrome p450 enzyme (Cyp2E1) were investigated. Interestingly, the absence 
of WISP did not alter the redox state or expression of Cyp2E1, suggesting that WISP1 
influences neither the redox state nor the metabolism of hepatotoxic compounds, which 
could be a cause for enhanced susceptibility to hepatotoxic compounds.  
 In the current study, increased WISP1 expression was detected upon a maximal dose 
of CCl4 in C57Bl/6N mice. Using a lower dose of CCl4 in wild type mice confirmed the up-
regulation of WISP1 expression. However, the expression of WISP1 in wild type mice was 
shown to be more strongly induced and maximal induction was detected earlier. These 
effects could be due to the fact that wild type mice have a different genetic background 
(129S5/SvEvBrd * C57BL/6J) compared to C57Bl/6N, which were used for initial experiments. 
Moreover, dose-dependent effects could also be an explanation for the detected 
differences. Interestingly, WISP1 protein levels were detected at high concentrations in the 
plasma of wild type mice. This is consistent with the fact that CCN proteins are secreted 
extracellular matrix proteins [132]. However, liver tissue homogenates revealed only low 
levels of WISP1 protein compared to plasma samples. Interestingly, WISP1 protein 
concentrations showed a biphasic behavior in liver tissue upon exposure to CCl4, with peaks 
at early time points (30min) and D1 after CCl4 administration. This could be due to the fact, 
that CCN proteins are known to be dynamically expressed upon various mitogenic signals 
and environmental disorders [130, 132]. Furthermore, Sedlaczek et al also showed a biphasic 
increase at 6h and 72h of CCN2 upon CCl4 administration in rat livers [196]. Jun et al 
investigated the role of CCN1 upon wound healing, thereby showing similar biphasic pattern 
of mRNA expression and protein levels, suggesting a distinct function during inflammation 
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and maturation phase of wound healing [197]. Moreover, the expression of CCN proteins is 
known to be down-regulated during adulthood [132], which could explain the low levels of 
WISP1 upon control conditions.  
 CCN proteins were reported to be dynamically expressed upon mitogenic signals as 
well as environmental stress [130, 132]. Therefore, the first increase of WISP1 protein 
secretion could be due to cellular stress and the second increase could be induced through 
cytokine production leading to the initiation of liver regeneration to restore tissue 
homeostasis. CCl4 administration was reported to induce cellular stress, as shown by the 
induction of stress-associated pathways at early time points such as JNK [198]. Moreover, at 
D1 sterile inflammation, which is initiated by DAMPs released during CCl4-induced liver 
damage, caused secretion of cytokines and growth factors leading to the activation of a 
regeneration program [8, 116, 199]. Therefore, the conditions for two types of regulatory 
mechanisms of WISP1 secretion upon CCl4 intoxication are consistent with the molecular 
events observed in this investigation, namely early stress signaling and subsequent 
regenerative responses. Nonetheless, it remains unclear, if high basal levels of WISP1 are 
enough to exert a protective phenotype or if the induction of WISP1 expression is needed to 
generate this effect.  
 Liver regeneration, which is perhaps the best studied aspect of liver injury [14], 
includes the secretion of cytokines and growth factors such as TGFβ, IL-6 or HGF [8, 116, 
199] followed by the expression of proliferation markers, such as PCNA, and cyclins, such as 
cyclin D, E or A [200]. The current study revealed no difference in the ability to recover from 
drug-induced liver injury in wild type mice compared to WISP1 knockout mice, since the 
regeneration process was comparable in both sets of mice. However, WISP1 knockout mice 
displayed an enhanced and prolonged activation of proliferation, which could be due to the 
fact that the enhanced dead cell area in WISP1 knockout mice needed longer to be fully 
recovered. Taken together, the absence of WISP1 seemed to have no influence on liver 
regeneration. A similar effect was observed upon investigation of TGFβ signaling with regard 
to the control of liver regeneration. Oe et al showed that mice containing a conditional 
disruption of TGFβ type II receptor exhibited an enhanced proliferative response in the liver, 
however, the termination of liver regeneration was not altered. The authors suggested that 
increased signaling by activin A may act as a compensatory mechanism to regulate liver 
regeneration when TGFβ signaling is blocked [201]. Therefore, it remains to be determined 
whether similar compensatory effects may influence liver regeneration in mice lacking 
WISP1. 
 A central aspect of this study was to investigate signal transduction pathways, such as 
mitogen-activated protein kinase (MAPK) signaling after CCl4 administration. Especially 
stress-activated protein kinases, such as JNK, were shown to play an important role during 
drug-induced liver injury [7, 48, 49, 85]. For example, Gunawan et al reported that usage of 
JNK inhibitor reduced liver damage upon APAP administration. Moreover, knockout mice for 
JNK1 and JNK2 were also protected upon APAP-induced liver injury [84]. Furthermore, 
Nakagawa et al showed that the genetic deletion of ASK1, which is an activating kinase for 
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JNK, led to attenuated liver injury upon APAP administration [202]. Interestingly, the JNK 
inhibitor SP600125 was not effective against CCl4-induced liver injury [84]. Investigating 
signal transduction in the current study, revealed an enhanced activation of stress-
associated signaling (JNK) in WISP1 knockout mice upon the administration of CCl4. Also, the 
second peak of ERK activation (on day 1) was not observed in mice lacking WISP1. Additional 
signaling pathways, or their downstream targets, showed no significant differences in wild 
type and WISP1 knockout mice, including p38, c-myc or ATF3 expression. Furthermore, ER 
stress, which is associated with the induction of cell death via CHOP [101, 102], was shown 
to be non-differentially activated in the wild type mice compared to WISP1 knockout mice. 
Moreover, studying RIP3 activation, which has recently been described as an early mediator 
of APAP toxicity [51], did not show any difference in wild type mice compared to WISP1 
knockout mice. Taken together, one hint which could explain the advenced liver damage is 
the enhanced JNK activation. Since GADD45β was reported to inhibit JNK phosphorylation 
leading to reduced APAP toxicity in mice [110, 180], the hypothesis was that attenuated JNK 
phosphorylation is connected to increased GADD45β expression. Surprisingly, GADD45β 
expression was even higher in WISP1 knockout mice, leading to the conclusion that 
GADD45β is not the cause for reduced JNK activity in wild type mice. For this reason, further 
investigations are needed to examine whether JNK is really the cause or just a consequence 
of increased cellular stress upon genetic deletion of WISP1. Therefore, the usage of JNK 
inhibitors in vivo, such as SP600125, or in vitro approaches using siRNA to knockdown JNK 
activity in hepatocytes should lead to a reduced hepatotoxicity in the WISP1 knockout mice, 
provided that JNK caused enhanced susceptibility in mice lacking WISP1.  
 The investigation of expression of CCN family members upon CCl4 administration 
revealed increased expression of the family members upon genetic deletion of WISP1. Since 
CCN family members were reported to have overlapping functions because of their structure 
similarities [132, 195], it can be speculated that expression of other CCN family members 
could be induced to compensate for the lack of WISP1. CCN proteins, including CCN1 and 
CCN2, were reported to induce ROS production in fibroblasts [112]. However, despite their 
similar structure, they can mediate opposing functions, for example CCN1 was reported to 
reduce liver fibrosis [143], whereas CCN2 was shown to promote fibrosis [147]. Moreover, 
CCN1 was shown to act in synergistically with TNFα and FasL, leading to the production of 
ROS as well as to a robust activation of JNK, further leading to TNFα-induced apoptosis [112, 
146]. Thus, one potential mechanism is that increased CCN1 expression in the WISP1 
knockout mice lead to an enhanced JNK activation and further contributing to enhanced cell 
death. To examine this hypothesis in vivo studies using an antibody against CCN1 or siRNA to 
knockdown CCN1 expression could be helpful. Beyond that, the treatment of wild type mice 
using CCN1 in combination with CCl4 should lead to enhanced liver damage compared to 
wild type mice treated only with CCl4.  
 The current study revealed not only enhanced susceptibility to CCl4-induced liver 
damage, but also to APAP-induced hepatotoxicity. Signal transduction upon CCl4-induced 
liver injury revealed alterations in JNK, ERK1/2 and STAT3 signaling. Therefore, the 
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investigation of these pathways after APAP administration was another central approach in 
my study. However, none of these pathways showed any significant difference in activation 
comparing wild type mice to WISP1 knockout mice. As reported by Gunawan et al, JNK 
signaling was involved in APAP-induced toxicity validated by the usage of the JNK inhibitor 
SP600125, yet the JNK inhibitor was not effective with regard to CCl4-induced liver damage 
nor upon Concanavalin A hepatotoxicity [84]. Moreover, regarding ER stress, Uzi et al 
confirmed a reduction in liver damage when using CHOP knockout mice upon APAP 
administration [103]. On the contrary, Campos et al detected no difference in the protection 
against CCl4-induced liver damage by using similar CHOP knockout and wild type mice [99]. 
Taken together, this suggests that signaling and molecular mechanisms can be different 
concerning various models. Therefore, enhanced susceptibility may be mediated through 
different pathways upon APAP administration in the WISP1 knockout mice.  
 Investigating the Wnt/β-catenin pathway could be useful since WISP1 is a target of 
the Wnt/β-catenin pathway. It is an important pathway controlling the liver zonation [30, 
128, 154], which is relevant for drug metabolism. In the past, most studies investigated 
CCN1-3 proteins, focusing on their receptors and binding partners. Just recently, Stephens et 
al investigated interactions of WISP1 with integrin receptors by using truncated versions of 
WISP1 [203]. They found that WISP1 mediated adhesion of epithelial cells, as well as CXCL3 
secretion and activation of β-catenin, mainly through the C-terminal domain of the protein. 
However, the results did not reflect an all or nothing situation, suggesting that WISP1 may 
act through various domains. Moreover, the interaction of WISP1 was reported to depend 
on different receptors with regard to two different cell lines [203]. Therefore, it would be 
interesting to study the interaction of truncated versions of WISP1 with various receptors on 
hepatocytes and NPCs in vitro. This might be further beneficial with regard to the 
identification of potential mechanisms of WISP1 in these cells. Furthermore, it might also 
help to gain more information regarding the mechanism of WISP1 in vivo. 
 Sterile inflammation is a well-known aspect during drug-induced liver injury [25, 54]. 
Upon hepatotoxic compound exposure, DAMPs are release and cause production of pro-
inflammatory cytokines and chemokines by binding to TLRs on macrophages leading to 
further recruitment of neutrophils and circulating monocytes [53, 64]. The role of leukocytes 
in hepatotoxic liver injury is not fully understood. Accumulation of neutrophils can cause 
further cell death by the release of ROS and proteases. However, both neutrophils and 
macrophages can also contribute to wound healing by phagocytosis of cell debris [61, 65, 
66]. Although sterile inflammation is well-described feature of DILI, its contribution to the 
progress of liver injury is still controversial. Liu et al reported that the depletion of 
neutrophils using anti-Gr-1 antibody led to reduced liver injury upon APAP administration 
[67]. Contrary to the proposed pro-damaging role of inflammation, deleption of Kupffer cells 
by clodronate liposomes led to enhanced hepatic injury [73]. Moreover, genetic deletion of 
STAT3 in myeloid cells attenuated liver damage, accompanied by enhanced inflammation 
which was detected by an increased number of infiltrating immune cells as well as increased 
cytokine production [55]. During my study I was able to show that the genetic deletion of 
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WISP1 was associated with enhanced liver damage and a stronger inflammatory response. 
The enhanced inflammatory response was characterized by stronger activation of 
hepatoprotective STAT3 signaling, as well as an increased expression of pro-inflammatory 
cytokines. Furthermore, an increased number of infiltrating immune cells was detected upon 
CCl4 administration in WISP1 knockout mice. However, it remains unclear whether increased 
inflammatory response is a cause or a consequence of the enhanced hepatic injury, since 
enhanced inflammation was observed at same time that the first hepatotoxic events were 
observed in WISP1 knockout mice. The implementation of additional in vivo models focusing 
on liver inflammation (hepatitis), such as Concanavalin A or D-galactosamine in combination 
with LPS or TNFα, could be useful for further investigations in the future.  
 The implementation of in vitro studies using primary mouse hepatocytes 
compromised various advantages and disadvantages. For example, isolated and cultivated 
hepatocytes represent a rather inflammatory liver than a healthy or control liver, as 
reported by Godoy et al [204]. This is due to alterations in the gene expression patterns and 
the transcriptional regulatory networks in hepatocytes, which can also influence the 
expression and mode of action of WISP1. However, since in vivo studies include complex 
mechanisms and interactions of various cell types in the liver as well as infiltrating immune 
cells [64], it is rather difficult to examine the role of WISP1 on hepatocytes alone. 
Furthermore, hepatocytes make up about 80% of the liver mass [8] and WISP1 expression 
was mainly derived by hepatocytes upon CCl4 administration as shown in my study. In vivo 
experiments also revealed an enhanced inflammation in WISP1 knockout mice, which was 
consistent with an advanced liver damage and an increased WISP1 expression upon CCl4 
administration. To examine whether hepatocytes themselves are more susceptible to 
cytokine or APAP stimulation, in vitro studies using WISP1 knockout hepatocytes and wild 
type hepatocytes were implemented. Primary hepatocytes are the most relevant in vitro tool 
to determine liver functions including drug toxicity, metabolism or transport [205-207]. 
Stimulation of hepatocytes using TNFα or TGFβ in combination with actinomycin D, revealed 
an enhanced susceptibility of WISP1 knockout hepatocytes, which was associated with an 
enhanced caspase 3 activation. This suggests that the genetic deletion of WISP1 in 
hepatocytes makes them more susceptible to cell death, which was also confirmed by 
stimulation using APAP. So it is likely that WISP1 in hepatocytes is needed to develop the 
protective phenotype in vitro as well as in vivo. In fact, further investigations regarding the 
effect on NPCs are needed, since high expression of WISP1 was found in the NPCs upon 
control conditions. Moreover, deeper insights on the molecular events leading to enhanced 
susceptibility in hepatocytes are needed. Therefore, stimulation of knockout hepatocytes in 
vitro using WISP1 protein or adenoviruses to restore WISP1 expression, could be useful to 
test whether the hepatocytes could be rescued. Furthermore, the usage of truncated 
versions of WISP1 could be beneficial to get a deeper insight in the mechanism of the 
protective effect.  
 A central aspect of the current study was the usage of gene array analysis combined 
with qRT-PCR analyses in the wild type and WISP1 knockout mice upon CCl4 administration. 
4 DISCUSSION 
150 
The analyses revealed a strong up-regulation of cytochrome P450 enzymes and a down-
regulation of serine protease inhibitors, which were associated to inflammation and obesity 
[191], at all time points. Cytochrome P450 gene 4 family (CYP4) is known to metabolize 
medium (C10-C16) saturated, unsaturated and branched chain fatty acids by ω-oxidation, 
which becomes important during increased influx of fatty acids or in cases where the 
mitochondrial oxidation system is insufficient for metabolizing fatty acids. Therefore, strong 
up-regulation of CYP4A genes should prevent from excessive increase of fatty acids, which 
can cause lipid toxicity and initiates fatty liver inflammation (steatohepatitis) [190, 208, 209]. 
Moreover, analysis of KEGG pathways revealed up-regulation of fatty acid degradation and 
PPAR signaling, which is involved in the induction of CYP4A enzymes and regulation of lipid 
and glucose homeostasis [210, 211]. Furthermore, Murahovschi et al reported that WISP1 
might link obesity to inflammation and insulin resistance [162]. Taken together, the results 
of my study suggest that genetic deletion of WISP1 may alter lipid metabolism in 
hepatocytes which could be a mediator for enhanced toxicity, since there is a connection 
between obesity and an increased risk of hepatotoxicity [212, 213]. Moreover, the 
accumulation of fatty acids can cause lipid toxicity in the liver [208]. Further investigations 
regarding altered pathways,, such as PPAR signaling, need to be addressed to explain and 
clarify potential effects of WISP1 during lipid metabolism. For example, in vitro stimulation 
of wild type and WISP1 knockout hepatocytes using oleic acid could reveal alterations in the 
uptake and metabolism of free fatty acids, as well as alterations in the signal transduction. 
 Finally, cell death-inducing DFF45-like effector C (CIDEC), which is reported to be 
localized in the cytoplasm and to be involved in promoting the formation of fat droplets 
[214], is up-regulated in WISP1 knockout mice on D1. CIDEC was shown to participate in the 
development of metabolic disorders as well as in the regulation of cell apoptosis [214-217]. 
Recently, Xu et al suggested that CIDEC promotes the development of alcoholic 
steatohepatitis in mice and humans, by acting synergistically with ethanol to induce ROS 
production leading to hepatocellular death [192]. Therefore, it is likely that CIDEC may 
contribute to the development of liver injury in the WISP1 knockout mice. However, further 
investigations are needed to clarify this hypothesis. 
 Taken together, the present study revealed a yet unknown role of WISP1 as a 
protective mediator upon acute liver injury. The genetic deletion of WISP1 led to an 
enhanced stress-associated and pro-inflammatory signaling. Enhanced inflammation was 
confirmed by an increased expression of pro-inflammatory cytokines as well as enhanced 
immune cell infiltration. However, it still remains unclear whether inflammation is the 
consequence of enhanced liver damage, or if inflammation might cause hepatotoxic effects. 
Finally, gene array analysis revealed an altered lipid metabolism in the WISP1 knockout mice, 
which could also contribute to the development of liver injury. Further investigations are 
needed to clarify the potential mechanism of WISP1 upon lipid metabolism and toxicity. 
Although potential binding partners and receptors need to be investigated along with the 
precise mechanism through which WISP1 is mediating its pro-survival role, it seems as if in 
future WISP1 might be a promising target for therapeutical interventions, since also the 
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human liver disease patients’ samples revealed an increased WISP1 expression. Lastly, this 
study highlighted the importance of the transcriptional network and uncovered a yet 
unknown important mediator upon the development of acute liver damage. This might 
further help to acquire a deeper insight in the mechanisms and the progress of 
hepatotoxicity. Further studies regarding the role of WISP1 in chronic diseases, such as 
fibrosis or cancer could unveil even further important influences of WISP1. 
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